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GENERAL CONSIDERATIONS 
Fungi have emerged as a major cause of human disease, particularly among 
immunocompromised patients and patients with serious underlying medical conditions [1], 
which has led to increased research in this area. Invasive candidosis now is widely recognized as 
an important public health problem, with considerable morbidity, mortality, and associated 
health care costs [2].  
Candida species represent the fourth most common group of isolates from bloodstream 
infections in the United States; recent reports also suggest an increase of candidaemia in Europe 
[2-5]. 
C. parapsilosis was first isolated from the stools of a patient with diarrhea in Puerto Rico in 
1928 [6, 7]. The species was named Monilia parapsilosis to distinguish it from the more common 
isolate, Monilia psilosis, known today as C. albicans. In 1932, Monilia parapsilosis was renamed 
Candida parapsilosis. 
C. parapsilosis cells display an oval, round, or cylindrical shape. The colonies, on Sabouraud 
dextrose agar, are white, creamy, shiny, and smooth or wrinkly. C. parapsilosis can exist in either 
a yeast shape or pseudohyphal form. C. parapsilosis is typically a commensal of the human skin, 
but is also a disease agent. Over the past decade, the incidence and clinical relevance of               
C. parapsilosis has increased. It is of special concern among critically ill neonates [8-10]. 
Lodderomyces elongisporus was previously believed to be the teleomorph of                           
C. parapsilosis due to similarities between: (1) GC nuclear content; (2) conserved rRNA portions 
and (3) behavior in biochemical tests and substrate assimilation [11, 12]. Nowadays, they are 
considered distinct species, although very closely related [13-15]. This is an example of a 
masquerading species, becoming molecular identification and genotyping more needed in 
clinical practice. It is quite possible that there are a number of new yeast species in clinical 
material that cannot be distinguished phenotypically from a more common species; implications 
could arise due to distinct antifungal susceptibility patterns. 
Given the continued emergence of C. parapsilosis, comprehensive studies regarding its 
epidemiology, virulence traits, clinical manifestations, genetics, and antimicrobial susceptibility 
are needed. 
 
EPIDEMIOLOGY 
At present, C. parapsilosis stands out as the second most common yeast species isolated 
from patients with bloodstream infections in Latin America and Asia [16, 17], but it is also 
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commonly found in European surveys [1, 17, 18]. Similar results were found in Portugal, 
according to a prospective, observational study of bloodstream fungal infections [19].                   
C. parapsilosis outranks C. albicans in some European [20], Asian [21, 22], and South American 
[23] hospitals. 
In comparison to other Candida species, C. parapsilosis has a more ubiquitous distribution 
in nature. C. parapsilosis is not an obligate human pathogen, having been isolated from 
nonhuman sources [7] such as domestic animals, insects, soil, and marine environments [24].          
C. parapsilosis is also a normal human commensal, and it is one most frequent fungal isolate 
from the subungueal space of human hands, as is the case with the hands of health care 
workers. Such finding suggests its role as a potential reservoir and route for nosocomial 
transmission [25, 26].  
The latest study concerning Candida bloodstream infections in 79 medical centers 
worldwide by Pfaller et al. [2] reported that 17.1% of infections were caused by C. parapsilosis, 
after C. albicans (48.4%) and C. glabrata (18.2%). Moreover, the study distinguished the 
infections in community-onset and nosocomial bloodstream infections; C. parapsilosis was more 
common among nosocomial episodes. 
  
RISK FACTORS 
Invasive disease caused by C. parapsilosis can occur without prior colonization and is 
frequently transmitted horizontally via contaminated external sources such as medical devices 
or fluids, the hands of health care workers, prosthetic devices, and central venous catheters. The 
increase in the frequency of C. parapsilosis infections has been attributed to a variety of risk 
factors, including the organism selective growth capability in hyperalimentation solutions and its 
affinity for intravascular devices and indwelling prosthetic materials. Immunocompromised 
individuals such as AIDS and surgical patients, particularly those submitting to surgery of the 
gastrointestinal tract, are at high risk for infection with C. parapsilosis. Additionally, patients 
requiring prolonged use of a central venous catheter or indwelling devices are at increased risk 
for infection with C. parapsilosis. The population at greatest risk for nosocomial infection with     
C. parapsilosis is that of extremely low-birth-weight neonates. Colonization of the skin or 
gastrointestinal tract is frequently the first step in the pathogenesis of invasive candidal disease, 
and neonates are especially prone to disease given their compromised skin integrity, increased 
susceptibility to gastrointestinal tract infection, the long-term needed for central venous 
catheters, and prolonged endotracheal intubation [8, 27]. An observational study addressing the 
epidemiology of invasive fungal infections among infants admitted to Neonatal Intensive Care 
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Units (NICUs) of one Italian region showed that C. parapsilosis was the most common isolated 
species (61,9%); the main potential risk factors were related to a central venous catheter placed, 
length of stay superior to 7 days and total parenteral nutrition for more than 5 days [28]. A study 
about the occurrence of Candida spp. during a three-year period in two NICUs, in Hungary, 
reported the following species distribution: C. albicans (73%), C. parapsilosis (24%) and                
C. glabrata (3%). The study also concludes that the mortality rate for C. parapsilosis was higher 
than for C. albicans [29]. A study regarding Candida spp. distribution among bloodstream 
infections by patient age revealed that C. parapsilosis was most common among the 0-19 year 
age group [30]. 
The hands of health care workers are major vectors for the exogenous acquisition of            
C. parapsilosis. As a normal commensal of human skin, C. parapsilosis represents a major threat 
to patients interacting with colonized health care workers, particularly when breaches in 
standard hand-washing protocols occur. Although the percentages vary among studies, multiple 
reports described C. parapsilosis as the yeast organism most commonly isolated from health 
care workers hands [31, 32]. Molecular typing methods have illustrated the link between hand 
carriage of C. parapsilosis and the horizontal transmission and outbreak of nosocomial infections 
by C. parapsilosis [33]. For example, C. parapsilosis genotyping results in 3 fungaemia outbreaks 
in NICUs in the southeastern United States, supplied clear evidence of horizontal transmission in 
2 outbreaks; in the third outbreak, the bloodstream isolates corresponded to 2 distinct 
genotypes circulating in the unit; one genotype was shared by one infected patient and the 
hands of a healthcare worker [34]. In an investigation of a cluster of C. parapsilosis infections 
involving six patients in a Brazilian cancer ward, C. parapsilosis was recovered from the hands of 
three health care workers; two of such isolates were molecularly identical to the outbreak strain 
[25].  
 
CLINICAL MANIFESTATIONS 
C. parapsilosis is responsible for a broad variety of clinical manifestations that generally 
occur in individuals with impaired immune system, neutropenia, or burns and in patients 
admitted to neonatal or surgical intensive care units. C. parapsilosis causes invasive disease 
(fungaemia) worldwide. Several studies addressing fungaemia reported this species [18, 19, 21-
23, 35-47]. C. parapsilosis fungaemia can lead to the seeding of tissues and multiple organs, 
resulting in deep-seated infections [48], and results in mortality rate ranging from 4% [49] to 
approximately 45% [3, 45, 46]. Candida species account for 94.1% of fungal endocarditis cases, 
many of which develop following cardiac surgery [50]; C. parapsilosis is associated with 17% of 
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the identified cases, making it the second most common species after C. albicans [51]; overall, 
mortality ranges from 41.7% [52] to 65% [7]. Fungal peritonitis results in serious morbidity and 
in a mortality rate of up to 44% [53]. The major predisposing factor for fungal peritonitis is 
treatment of previous bacterial peritonitis with antibiotics, which presumably promotes fungal 
overgrowth [54]. Although C. albicans is credited as the most common Candida species causing 
peritonitis, numerous papers have reported that C. parapsilosis is the predominant species 
associated with such disease [53, 55-57]. C. parapsilosis is associated with invasive ocular 
diseases such as endophthalmitis (particularly postoperative infection) and keratiti [58-60]. 
Otomycosis is a relatively uncommon infection causing otitis media or externa. However when it 
occurs,  C. parapsilosis is the first or second most common isolate [61, 62]. C. parapsilosis was 
seldom mentioned as an agent causing pathological lesions of the nails, but it has gained 
increasing recognition as the most common etiological agent causing Candida onychomycosis 
[63, 64]. C. parapsilosis is an infrequent agent of fungal meningitis [65-68] or fungal arthritis [7]. 
Vaginal candidosis is the second most common genital infections in fertile age women in the 
United States and Europe, after bacterial vaginosis [69], and C. albicans is associated with 85% to 
95% of such cases. Surprisingly, 30% of recurrent vulvovaginal candidosis cases are caused by 
non-C. albicans species like C. parapsilosis [70]. Therefore, proper identification of the Candida 
species should be undertaken in patients with recurrent or complex vulvovaginitis before 
initiation of shortcourse antifungal treatment, which may be less effective against                    
non-C. albicans species [71-73]. It is noteworthy that although C. parapsilosis is infrequently 
isolated from vaginal cultures, it nevertheless may be isolated from asymptomatic women [72, 
73]. Among Candida species,  C. parapsilosis is not a frequent agent of urinary tract infection 
[74]. 
 
GENETICS 
The increasing clinic relevance of C. parapsilosis promoted a deeper analysis into its 
genome. The sequencing of the entire genome was carried out by Sanger Institute 
(http://www.sanger.ac.uk/sequencing/Candida/parapsilosis/). Recently it was reported the 
genome sequences of six Candida species (including C. parapsilosis) and compared these and 
related pathogens and non-pathogens [75]. C. parapsilosis is a diploid pathogen with an 
estimated genome size of 13.1 megabases and 5733 open reading frames; the genome is 
organized in 8 chromosomes. 
Genetic and/or genomic heterogeneity is known to occur among C. parapsilosis isolates 
[13, 76, 77]. The high level of genetic variation was shown by several techniques. On the basis of 
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randomly amplified polymorphic DNA (RAPD) analysis [78], multilocus enzyme electrophoresis 
[13], analysis of the internal transcribed spacer sequences of DNA encoding ribosomes [13], DNA 
relatedness analysis [79], morphotyping [80], analysis of mitochondrial DNA sequence 
differences [81], DNA topoisomerase II gene sequence analysis [82], and analysis with an 
oligonucleotide probe used for fingerprinting of C. parapsilosis isolates [83], it was found that      
C. parapsilosis forms a complex composed of three genetically distinct groups (groups I, II, and 
III). Although genetically heterogeneous, these groups are phenotypically indistinguishable. In 
2005, Tavanti et al. [84] proposed the replacement of the existing designations of C. parapsilosis 
group II and group III by C. orthopsilosis and C. metapsilosis, respectively, and the retention of 
the designation C. parapsilosis for the former group I isolates. In order to distinguish between 
the three species, Tavanti et al. [84] proposed the analysis of the restriction polymorphism of 
the SADH gene, which encodes a secondary alcohol desidrogenase and which is common to all 
three species. Strains from each group are found in samples from human patients; clinical 
isolates are predominantly of group I. However, there is substantial genetic variation even within 
group I isolates. This variation is associated with several molecular determinants of virulence, 
such as the ability of the fungus to colonize distinct hosts and niches (i.e., humans or animals 
and skin, blood, or sputum), the appearance of specific phenotypes (i.e., antibiotic resistance), 
and the ability to generate biofilm [76, 85]. The separation of the previous groups I, II, and III 
into species leads clinical publications to distinguish between them. Recent studies have shown 
that some clinical isolates formerly identified as C. parapsilosis in fact correspond to isolates of 
the closely related species C. orthopsilosis and C. metapsilosis [13, 84, 86, 87] which account for 
about 10% of the total number of former C. parapsilosis isolates [87]. As more data regarding 
the different species are collected, further differences between these species will likely 
accumulate. These two new species may inhabit important niches in certain patient populations, 
thus stressing the need for continued surveillance in each country to monitor the prevalence and 
distribution of these three species. 
Interestingly, C. parapsilosis lacks nucleotide sequence diversity [84]. The frequency of 
mutation in C. albicans is about 1/140 bp in examined coding regions [88, 89]. In contrast, 
studies involving C. parapsilosis only found two polymorphic nucleotide sites among 7.5 kbp 
sequences [84] and only four mutations among more than 36 kbp [90]. The lack of nucleotide 
sequence diversity suggests that C. parapsilosis is highly clonal and has only recently, within the 
past one million years, emerged as a species. 
Indeed, molecular methods used to distinguished C. parapsilosis strains only evidence a 
very few types.  Different techniques are applied in molecular differentiation studies, especially 
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in outbreak situations: RAPD analysis [33, 86, 91], restriction fragment length polymorphism 
(RFLP) analysis [33], sequence analysis of the intergenic transcribed spacer gene [86, 91], 
microsatellite analysis [92, 93], electrophoretic karyotyping [94], and southern blot assay [34] 
among others. Different methods provide different results, a fact that underscores the 
importance of combining multiple typing methods, of testing several control isolates, and the 
need to correlate the results with careful epidemiological assessment. 
 
VIRULENCE ATTRIBUTES 
C. parapsilosis pathogenicity has been attributed to several intrinsic attributes, including 
promoted adhesion to medical devices and/or host cells, biofilm formation, and secretion of 
hydrolytic enzymes.  
Adhesion is likely a critical step in yeast pathogenesis. This property might be expected for 
C. parapsilosis; following its acquisition from an exogenous source, its subsequently adheres to 
medical indwelling devices, and finally invades the host. However, several studies addressing 
intraspecies variation in adherence found no relationship between invasiveness and adherence 
[95-97]. In fact, Panagoda et al. [97] described that superficial C. parapsilosis isolates displayed 
51.5% greater avidity for buccal epithelial cells than systemic isolates; nonetheless the result was 
not considered statistically significant. The first large-scale study comparing adhesion of                      
C. albicans and C. parapsilosis (12 and 24 isolates, respectively) documented a 20.6% greater 
avidity of C. parapsilosis for buccal epithelial cells and a 143.7% greater adhesion to acrylic 
material, although the differences between the first values were not significant due to the large 
range of C. parapsilosis adhesion values (23.50 to 154.30 per 50 buccal epithelial cells) [97]. The 
large number of adherent C. parapsilosis cells reported in this study may result from 
coadherence among yeast cells causing aggregates at epithelial surfaces, a trait more often 
observed for this species than for  C. albicans. Conversely, other studies reported an 80% to 95% 
higher adhesion of C. albicans to buccal epithelial cells comparing to C. parapsilosis [98, 99].  
Clinical isolates of C. albicans form biofilm [100], which may be an important fact for 
sustaining infection. Biofilm formation may be especially important for  C. parapsilosis, since 
medical indwelling devices appear to be the predominant route of infection [25, 101]. The 
biofilm-forming potential was cited as a reason why patients with C. parapsilosis-infected 
catheters should have the device promptly removed [102]. C. parapsilosis biofilms can occur on 
diverse medical indwelling devices, including central and peripheral venous catheters, 
hemodialysis and peritoneal dialysis catheters, intracardiac prosthetic devices, and prosthetic 
joints [103]. As a commensal of human skin, the organism can come into contact with medical 
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devices during its insertion or during its management, particularly in health care settings where 
lapses in proper hand hygiene may occur. It is noteworthy that C. parapsilosis isolates with 
increased biofilm ability have been associated with outbreaks. According to Kuhn et al. [95] 
biofilm formation is an important component of a strain`s ability to cause an infections 
outbreak. Biofilm formation confers significant resistance to antifungal therapy by limiting the 
penetration of substances through the matrix and by protecting cells from the host immune 
responses. Biofilm-forming C. parapsilosis isolates have been associated with significantly higher 
mortality rates in patients at an Italian university hospital compared to clinical isolates incapable 
to develop biofilm (71.4% versus 28%, respectively) [104]. The capacities of different                     
C. parapsilosis isolates to cause disease in various tissues may be influenced by its respective 
ability to form biofilm. Studies appointed that C. parapsilosis blood isolates are capable of 
forming more biofilm, compared to isolates from other body sites [105, 106]. Two recent studies 
documenting the generation of C. parapsilosis homozygous lipase knockout mutants found that 
the mutants have a decreased ability to form biofilm [107, 108].  
Phenotypic switching occurs in C. parapsilosis; four phenotypes are described for                  
C. parapsilosis: smooth, concentric, crepe and crater [83].  Cells from crepe and concentric 
phenotypes are almost entirely pseudohyphal, whilst cells from smooth and crater phenotypes 
are mostly yeast-like [109]. Hypha development from yeast cells is critical for adherence, an 
essential first step in microbial colonization, which is in turn a key event in the initiation of the 
pathogenic process [110, 111]. In response to attachment to a surface, fungal cells produce 
biofilm, that contributes to the infectious process and antibiotic resistance [112]. In C. albicans 
the generation of biofilm is associated with the dimorphic switch from yeast to hyphal growth. 
The structure of the formed biofilm involves two distinct layers: a thin, basal yeast layer and a 
thicker, less compact hyphal layer [113]. In contrast, C. parapsilosis strains produce 
quantitatively less and structurally a less complex biofilm than C. albicans [100, 114]. However 
certain pseudohyphal C. parapsilosis phenotypes generate more biofilm and are more agar 
invasive than strains remaining predominantly in the yeast form [109]. 
Fungal secreted enzymes may play a relevant role in its pathogenesis. Phospholipases, 
lipases and proteases are three of the best-characterized of such enzymes. Although the role of 
phospholipase B, lipases and secreted aspartyl proteases (SAPs) are well studied in C. albicans 
[115, 116], the relationship between C. parapsilosis virulence and these enzymes remains 
unclear. SAPs facilitate invasion and colonization of the host tissues by disrupting host mucosal 
membranes and degrading important immunological and structural defense proteins [117, 118]. 
The function of phospholipases during infection is not yet well understood, although it is 
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believed that they are involved in the disruption of host membranes [115, 119]. The putative 
roles of microbial extracellular lipases include the digestion of lipids for nutrient acquisition, 
adhesion to host cells and tissues, synergistic interaction with other enzymes, unspecific 
hydrolysis due to additional phospholipolytic activities, initiation of inflammatory processes by 
impairing immune cell functions, and self-defense mediated by lysing competing microflora 
[120, 121]. Regarding C. parapsilosis, no correlation was found between phospholipase activity 
and the site of isolation or with other virulence attributes, in isolates from an outbreak [95]. The 
same study [95] did not support the concept that SAPs expression is a critical virulence attribute 
for C. parapsilosis. De Bernardis et al. [96] found an inverse relationship between SAPs 
expression and invasiveness since, C. parapsilosis cutaneous isolates had higher SPAs activity 
than blood isolates.  However, Gacser et al. [122] showed that lipase inhibitors significantly 
reduce tissue damage during C. parapsilosis infections of reconstituted human tissues.  
Regarding the other related species, C. metapsilosis and C. orthopsilosis, several studies 
characterized their virulence attributes [122-126]. C. metapsilosis was the less virulent member 
of the C. parapsilosis groups based on the interaction with immune cells [126]. A study 
addressing the effects of the three species upon reconstituted human oral epithelial and 
epidermal tissues concluded that C. orthopsilosis caused damage similar to C. parapsilosis 
isolates, whereas C. metapsilosis was the less virulent [122]. Concerning biofilm formation, the 
available results contradict; whilst de Toro et al. [124] described that C. orthopsilosis and                       
C. metapsilosis are not able to form biofilm, Lattif et al. [123] described that all species are able 
to form biofilm.  
 
SUSCEPTIBILITY 
Several classes of antimycotic drugs with different modes of action and target spectra are 
at present available to treat clinical fungal infections, including C. parapsilosis infections [127]. 
The base analog flucytosine, which is taken up into the cell by a specific transporter and then 
converted into 5-fluoro-uridine monophosphate by the sequential action of the enzymes 
cytosine deaminase and uracil phosphoribosyltransferase, causes the production of aberrant 
RNA and also inhibits DNA synthesis. The polyenes, the most important member of which is 
amphotericin B (AMB), bind to ergosterol, the major sterol in the fungal cell membrane, and 
form pores, thereby causing membrane damage. The azoles impair sterol biosynthesis by 
inhibiting sterol 14α-demethylase, which results in ergosterol depletion and accumulation of 
toxic methylated sterols. Finally, the echinocandins impair cell wall synthesis by inhibiting β-1,3-
glucan synthase. 
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Fungi can become resistant to the described antifungal drugs by specific mechanisms. 
Mutations that cause defects in the uptake of flucytosine or in its intracellular conversion are a 
frequent cause of resistance to this drug [128-130]. A decrease in the membrane ergosterol 
content can lead to reduced polyene susceptibility [131-133]. Three distinct mechanisms have 
been so far described regarding azole resistance: (1) failure to accumulate the drug 
intracellularly, which may be caused by the lack of drug penetration due to changes in 
membrane lipids and sterols [134] or by active efflux of drugs resulting particularly from 
overexpression of genes CDR1, CDR2 and MDR1 [135-138]; (2) increased production of the azole 
target enzyme [139-141]; (3) point mutations in genes coding for the target enzyme, the ERG 
genes, thus reducing azole target affinity [142]. The overexpression of efflux proteins and the 
associated increased activity is considered to be the most relevant mechanism of azole 
resistance, conferring cross-resistance to several azoles. Two types of efflux pumps, localized in 
the cytoplasmatic membrane, that transport antifungal drugs are known: the ATP-binding 
cassette transporters, which use ATP as the energy source to drive transport, and the major 
facilitators, which are energized by the proton gradient across the cell membrane [143]. 
Mutations in the FKS1  and FKS2 genes, encoding a subunit of the β-1,3-glucan synthase 
complex, result in resistance to echinocandin drugs [144]; such mutations confer resistance to all 
clinically used echinocandins. Recently, the compensatory increase in the production of chitin, 
the second structural cell wall polysaccharide, has been proposed as a mechanism causing 
reduced efficacy of echinocandins [145, 146]. 
C. parapsilosis is not considered particularly prone to the development of antifungal 
resistance [36, 95, 147, 148]. However, recent reports suggest that its decreased susceptibility to 
azoles and to echinocandins might become a cause for clinical concern [147-151]. The 
emergence of C. parapsilosis strains that have decreased susceptibility to fluconazole (FLC) and 
that may be transmitted throughout the hospital environment has been related to the extensive 
use of fluconazole in combination with suboptimal hand hygiene and central venous catheter 
care in a population of seriously ill patients [18]. Few studies have yet addressed the antifungal 
susceptibility profile of C. parapsilosis [7, 18, 147] and to our knowledge none has addressed the 
inherent resistance mechanisms.  
There is currently no consensus about the treatment of invasive C. parapsilosis disease, 
although the therapeutic approach typically involves the removal of any foreign body and the 
administration of systemic antifungal. Historically, amphotericin B has been the most frequently 
used antifungal [38, 152, 153]. The main issue with conventional amphotericin B therapy is the 
drug’s poor aqueous solubility and toxicity [154]. Fluconazole is the most frequently 
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administered alternative to amphotericin B. However, clinical resistance in C. parapsilosis has 
been reported [104, 151]. Interestingly, the long-term use of fluconazole to control                       
C. parapsilosis bloodstream infections in a Finland NICU eventually led to the emergence of a 
fluconazole-resistant strain that was responsible for cross-infections over a 12-year period [151]. 
However, other studies addressing fluconazole prophylaxis have not identified fluconazole-
resistant strains [155-157]. In vitro resistance to itraconazole (ITC) has been described [38, 158]. 
Minimal inhibitory concentration (MIC) values of voriconazole (VRC) are lower than of older 
azoles [35, 38, 40, 159, 160]. In vitro resistance to voriconazole is rare, with early reports 
showing 100% susceptibility [161]. Overall, C. parapsilosis isolates are also susceptible to 
posaconazole (PSC), the newer triazole [162]. 
Regarding echinocandins, the newest class of antifungal agents, MIC values are higher for     
C. parapsilosis than those for other Candida species [38, 152, 163, 164]. Although the basis for 
echinocandin resistance is not yet clearly understood, structural differences in the components 
of the cell wall, a reduced affinity for the glucan synthase protein complex due to mutations in 
FKS genes, or a difference in its regulatory network may be involved [164]. Despite elevated 
echinocandin MIC levels, several studies reported  in vitro and in vivo activity against                     
C. parapsilosis [95, 165-169], particularly in clinical episodes involving isolates resistant to 
amphotericin B, to fluconazole, or to both compounds [170]. Echinocandins can fail during 
treatment of C. parapsilosis bloodstream infections, in which the echinocandins MIC values are 
low [149]. Also, breakthrough infections by C. parapsilosis have occurred in individuals 
administered echinocandins for other indications [171]. At concentrations above the breakpoint 
for echinocandins, these drugs can paradoxically promote the in vitro growth of some isolates of 
C. parapsilosis and other Candida species [172]. Additionally, recent epidemiological studies 
have found an association between increasing caspofungin usage and an increased incidence of 
C. parapsilosis bloodstream infections [173].  
The latest available study concerning the antifungal resistance pattern of Candida 
bloodstream isolates [174] only identified 14 resistant C. parapsilosis isolates (among a total of 
232 isolates) to fluconazole. All isolates were susceptible to voriconazole, posaconazole, 
anidulafungin (ANF), caspofungin (CSF) and micafungin (MCF); the study incorporated 2085 
bloodstream infections isolates of Candida spp. from 79 medical centers throughout the world 
between January 2008 and December 2009. 
Few studies addressed the antifungal susceptibility profiles of the distinct C. parapsilosis 
groups. Chen et al. [175] demonstrated that most isolates within C. parapsilosis groups were 
susceptible to flucytosine, azoles, amphotericin B and echinocandins; however,  C. metapsilosis 
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isolates related to significantly higher MIC values of both fluconazole and voriconazole 
comparing to C. parapsilosis sensu stricto and C. orthopsilosis. On the other hand, C. metapsilosis 
isolates related to significantly lower MIC values of caspofungin than C. parapsilosis sensu stricto 
and C. orthopsilosis. Micafungin MIC values were also significantly higher for C. parapsilosis 
sensu stricto isolates than for C. orthopsilosis and C. metapsilosis. Usually, C. metapsilosis is 
described as the less susceptible species to fluconazole [87, 148]. Diekema et al. [176] found that 
all the isolates of the less common species within the C. parapsilosis groups were susceptible to 
voriconazole, posaconazole, anidulafungin, caspofungin, and micafungin. Similar results were 
described in other studies [87, 177]. Additionally, a surveillance study in Spain revealed that the 
new species were highly susceptible to all the antifungals (amphotericin B, flucytosine, azoles 
and echinocandins) in particular to echinocandin compounds (MIC values were two- to threefold 
lower) and amphotericin B, comparing with C. parapsilosis. These differences were especially 
notable for anidulafungin [178]. 
A large amount of data demonstrates the resistance of Candida biofilms to antimycotic 
drugs [179]. Despite its less complex structure, C. parapsilosis biofilm is similarly resistant to       
C. albicans biofilm to antifungals such as amphotericin B and azole compounds [106, 180]. 
However, therapeutic levels of echinocandins can inhibit metabolic activities of C. parapsilosis 
biofilms [152, 180, 181]; lipid formulations of amphotericin B were shown to have activity 
against C. parapsilosis biofilm [152]. 
While the endogenous reservoir remains the most important mechanism for acquisition of 
candidaemia, patient-to-patient spread by indirect transmission and the nosocomial acquisition 
of Candida species from environmental sources is being increasingly suspected [182]. The role of 
the hospital environment as a potential reservoir for Candida species was suggested by 
prospective epidemiological studies. In these studies, Candida isolates had been recovered from 
inanimate surfaces prior to the acquisition of the same strains by patients [183]. Although the 
primary reservoir of C. parapsilosis in the hospital setting is yet unknown, carriage on the skin of 
healthy individuals, particularly on the hands of health care workers, has since long been 
recognized [25, 184]. Prophylatic measures are necessary to control the nosocomial microbial 
population and to reduce the incidence of hospital infections. Few studies have addressed the in 
vitro activity of antiseptics and detergents against Candida spp.. The degree of in vitro inhibition 
of growth varied according to Candida species [185]. Traoré et al. [186] showed that products 
with sufficient potency to exhibit tuberculicidal proprieties produced substantial reductions in 
the titre of C. albicans, although some showed a lesser reduction in titre of C. parapsilosis, which 
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may reflect differences in cell hydrophobicity between Candida species. These findings highlight 
the need for particular care in selecting a suitable surrogate for desinfectant testing assays.  
 
FINAL REMARKS 
The emergence of C. parapsilosis as the leading non-C. albicans Candida species poses a 
major threat for the future since, unfortunately, the incidence of C. parapsilosis infections may 
continue to rise. Advances in health care will allow for higher survival rates among neonates 
admitted at NICUs, and the increased use of immunomodulatory medications for diverse 
indications will place more people at risk of infection with C. parapsilosis. This pathogen has a 
high affinity for parenteral nutrition, frequently colonizes the hands of health care workers, and 
forms biofilm on prosthetic surfaces, central venous catheters and medical indwelling devices. 
Its recognition as a major cause of numerous diseases across the globe, particularly among 
neonates and its survival hospital environments, merits additional compressive research efforts 
concerning its epidemiology, genetics, and antimicrobial susceptibility.  
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The main goal of this work was to achieve a better understanding of the genesis of 
nosocomial infection by Candida parapsilosis. A special emphasis was directed to the following 
topics: 
1. Assessment of the incidence and distribution of C. parapsilosis groups (including       
C. metapsilosis and C. orthopsilosis) in a large university hospital. 
 
2. C. parapsilosis genotyping, in order to establish a relationship regarding the identity 
and similarity of different isolates (including clinical and environmental isolates). 
 
3. Definition of the antifungal susceptibility patterns to azoles, amphotericin B and 
echinocandins by C. parapsilosis, C. metapsilosis and C. orthopsilosis in a large 
university hospital. 
 
4. Assessment and characterization of the potential for in vitro induction of resistance 
by distinct azole antifungals among C. parapsilosis isolates. 
 
5. Elucidation about the native and induced (in vitro and in vivo) antifungal drug 
resistance mechanisms developed by C. parapsilosis to azoles and echinocandins. 
 
6. Assessment of the activity of several chemical germicides and physical agents 
against C. parapsilosis (clinical and environmental isolates). 
 
7. Monitoring of the expression of virulence attributes by distinct C. parapsilosis strains 
(susceptible versus resistant). 
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STRAINS  
 
The study included clinical and environmental Candida parapsilosis strains. In some 
experiments strains from the American Type Culture Collection (ATCC) and other Candida 
species were included. 
Until testing, all strains were stored in Brain-Heart broth (Difco Laboratories, Sparks, MD) 
with 5% glycerol at 70ºC. For each experiment, each strain was subcultured twice on Sabouraud 
agar medium (Difco Laboratories) at 35ºC for 48 h.  
 
CLINICAL C. PARAPSILOSIS STRAINS 
All the clinical C. parapsilosis strains used were obtained from patients admitted at 
different care units from Hospital S. João, Porto, Portugal, namely from oncologic, burn, 
transplant, infectious and pediatric departments, among others. The strains were isolated from 
different body sites, like blood, urine, respiratory tract, bile fluid, mucosal surfaces, spinal fluid, 
peritoneal fluid, among others and also from central venous catheters. 
The clinical strains used also included strains deposited at the collection of the 
Microbiology Department, Faculty of Medicine, University of Porto that was constructed 
throughout the years.  
The set of clinical strains shows considerable diversity since the isolates were obtained at 
different dates and from different patients and anatomic sites.  
All isolates were biochemically identified as C. parapsilosis by Vitek 2 YBC identification 
cards (bioMérieux, Paris, France). 
 
ENVIRONMENTAL C. PARAPSILOSIS STRAINS 
The environmental group of strains included strains isolated from the air of care units of 
Hospital S. João and from food given to patients admitted at the same hospital.  
Air samples were collected in different critical care units. Samples were obtained by air 
filtration with a MAS-100 Eco instrument (Merck Eurolab, Switzerland). The instrument was 
placed in the center of the room, one meter above the floor. Five hundred liters of air was 
filtered; the agar medium used was Dichloran Glycerol 18 (Difco Laboratories). The air particles 
were deposited at the agar surface of a 90 mm Petri plate. Afterwards, plates were incubated at 
30ºC during 48 h for assessment of fungal growth. 
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Food samples were obtained according to Portuguese guidelines for yeasts and moulds 
counting in food [187, 188]. A sample from a daily meal of patients was evaluated; fungi were 
recovered in the Cooke Rose Bengal agar medium (Difco Laboratories). 
All the isolates were biochemically identified as C. parapsilosis by the use of Vitek 2 YBC 
identification cards. 
 
CONTROL STRAINS 
The Reference strains ATCC 22019, ATCC 96139, and ATCC 96144, from the American Type 
Culture Collection, were used as controls for C. parapsilosis, C. orthopsilosis, and                           
C. metapsilosis, respectively. 
The Reference strains Staphylococcus aureus ATCC 25923 and Staphylococcus epidermidis 
ATCC 14990 were used as positive and negative controls for coagulase expression.  
In some experiments, specific Candida species had been used as controls (mentioned in the 
appropriate section). Two C. albicans strains (kind gift from Dr. Ted White, Seattle, WA, USA) 
with well characterized antifungal resistance mechanisms were used: C. albicans strain 95-68, 
with overexpression of CDR1 and CDR2 genes (ATP-dependent efflux pumps), and C. albicans 
strain   2-76, showing low levels of resistance genes expression. C. albicans wild type strain 
SC5314 and the chitinase deleted strain Δchs3 with low chitin content (kind gift from Dr. Carol 
Munro, Aberdeen, United Kingdom), were used as controls for chitin content determination 
assays. 
 
OTHER MICROBIAL STRAINS 
Regarding the assessment of hydrogen peroxide dry-mist system efficacy (Susceptibility to 
Physical and Chemical Agents section) other bacteria and fungi were used. The Reference strains 
S. aureus ATCC 25279, Acinetobacter baumannii ATCC 25393, Escherichia coli ATCC 32218, 
Pseudomonas aeruginosa ATCC 27853, Enterococcus faecalis ATCC 2912, C. albicans ATCC 
90028, C. parapsilosis ATCC 22019, C. krusei ATCC 6258, Aspergillus fumigatus ATCC 204305 and 
Penicillium marneffei ATCC 18224 and one clinical isolate (from Hospital S. João patients) of each 
of the mentioned species were used; in addition, three clinical isolates and ATCC 27294 type 
strain of Mycobacterium tuberculosis were also included in this study.  
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Additional yeasts strains were used in chitin studies (Virulence Attributes section), namely, 
C. glabrata (6 strains), C. krusei (4 strains), C. tropicalis (4 strains), C. albicans (3 strains) and 
Cryptococcus neoformans (1 strain). All these strains had been isolated from patients admitted 
at Hospital S. João and from different body sites. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
MATERIAL AND METHODS 
 
 
46 
 
MOLECULAR DISTINCTION BETWEEN C. PARAPSILOSIS, C. ORTHOPSILOSIS AND                         
C. METAPSILOSIS 
 
In order to distinguish between C. parapsilosis, C. orthopsilosis and C. metapsilosis, Tavanti 
et al. [84] proposed the analysis of the restriction polymorphism of the SADH gene, which 
encodes a secondary alcohol desidrogenase and is common to all three species. The restriction 
profile obtained is singular by species.  
Type strains ATCC 22019, ATCC 96139, and ATCC 96144 were used as controls for                    
C. parapsilosis, C. orthopsilosis, and C. metapsilosis, respectively. 
 
DNA EXTRACTION 
Yeast genomic DNA was extracted as described by Hoffman and Winston [189], with some 
adaptations. Briefly, yeast cells grown overnight in YEPD broth (1% yeast extract, 2% peptone, 
2% glucose) at 30°C with agitation were harvested, washed with water and lysed by vortexing 
for 10 min with 0.3 g of glass beads (diameter 0.45 to 0.52 mm; Sigma, St. Louis, MO), 200 l of 
lysis buffer (100 mM Tris-HCl, pH 8.0, 2% Triton X-100, 1% sodium dodecyl sulfate, 1 mM EDTA), 
and 200 l of phenol-chloroform-isoamyl alcohol 25:24:1 (Sigma). After vortexing the mixture, 
200 l of TE (1 mM EDTA, 10 mM Tris-HCl, pH 8.0) was added to the lysate; the mixture was 
microcentrifuged at 20,000 g for 10 min and the aqueous phase was transferred to a new vial. 
DNA was precipitated following the addition of 1 ml of ethanol and afterwards was treated with 
RNase (10 mg.ml-1; Sigma) for 1 h at 37°C; the DNA was reprecipitated and resuspended in 100 l 
of TE. 
The concentration, quality, and integrity levels of DNA samples were evaluated with a 
BioPhotometer (Eppendorf, Madrid, Spain). 
 
SADH GENE AMPLIFICATION 
Amplification of the SADH gene was performed by Polimerase Chain Reaction (PCR) with 
the primers SADH-F and SADH-R (Table 1, page number 74) as previously described by Tavanti et 
al. [84]. The amplification conditions were as follows: a first denaturation cycle of 2 min at 94°C, 
followed by 35 cycles at 94°C for 30 s (denaturation step), 50°C for 30 s (annealing step), and 
72°C for 30 s (elongation step) and an extension final step of 10 min at 72°C. PCRs were 
performed in a Realplex Mastercycler instrument (Eppendorf). 
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SADH GENE RESTRICTION 
The amplified SADH genes was digested with the BanI enzyme (New England Biolabs, 
Hitchin, United Kingdom) in a 40 µl volume containing 20 µl of the PCR product and 40 U of BanI. 
The digestion products were separated on a 2% agarose gel containing ethidium bromide 
(Sigma) 0.5 mg.ml-1; the running buffer was TAE (40 mM Tris acetate [pH 8.0], 1 mM EDTA) and a 
100-bp DNA ladder (Invitrogen, Barcelona, Spain) was used as a molecular size marker. DNA 
fragments were visualized in an UVITEC instrument (Cambridge, United Kingdom) and strains 
distinguished between   C. parapsilosis, C. orthopsilosis and C. metapsilosis.  
Amplified fragments of the C. orthopsilosis strains were sequenced (as described in 
Antifungal Resistance Mechanisms section) to exclude the hypothesis that a point mutation 
exists in the restriction site of C. parapsilosis.  
After this procedure C. parapsilosis strains were named C. parapsilosis sensu stricto.  The 
following experiments were all based upon C. parapsilosis sensu stricto strains. 
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GENOTYPING OF C. PARAPSILOSIS STRAINS 
 
RANDOM AMPLIFIED POLYMORPHIC DNA ANALYSIS 
The technique performed allows concluding about genetic similarity between strains from 
the species C. parapsilosis. Genotyping was performed following random amplified polymorphic 
DNA (RAPD) analysis method, based upon randomly amplification of unknown sequences of 
genomic DNA using a specific primer. All C. parapsilosis isolates (clinical and environmental) 
were screened by RAPD test with the primer RPO2 (Table 1, page number 74) [14]. Genomic 
DNA was extracted was described above (Molecular Distinction between C. parapsilosis,              
C. orthopsilosis and C. metapsilosis section). Reaction volumes of 50 µl contained 100 ng of 
genomic DNA, 1.5 U of Taq polymerase (Fermentas, Maryland, USA), 5 µl of 10x magnesium-free 
buffer, 3 µl of 25 mM MgCl2, a 200 µM concentration of deoxynucleoside triphosphates, and a 
10 µM concentration of the primer. The amplification conditions were as follows: a first 
denaturation cycle of 2 min at 94°C, followed by 35 cycles at 94°C for 1 min (denaturation step), 
36°C for 1 min (annealing step), and 72°C for 75 s (elongation step) and an extension final step of 
10 min at 72°C. PCRs were performed in a Realplex Mastercycler instrument. Amplified DNA 
products were separated by electrophoresis in a 2% agarose gel containing ethidium bromide 
(0.5 mg.ml-1); the running buffer was TAE (1 mM EDTA, 40 mM Tris acetate, pH 8.0) and a 100-bp 
DNA ladder was used as a molecular size marker. DNA fragments were visualized with an UVITEC 
instrument.  
 
MITOCHONDRIAL DNA RESTRICITON ENDONUCLEASE ANALYSIS 
The mitochondrial DNA restriction endonuclease (mtDNA RE) analysis is another 
convenient and powerful tool that allows valid comparisons between isolates of the same 
species. This technology was applied to all C. parapsilosis isolates (clinical and environmental). 
For each sample, a reaction mixture was prepared containing 1x HinfI enzyme reaction buffer 
(Metabion, Planegg, Germany), 1 µg.µL-1 RNase, 0.5 U.µL-1 HinfI restriction enzyme (Metabion), 
approximately 25-30 µg of total DNA and DNAse-RNAse free water up to 20 µL final volume; 
reaction tubes were incubated overnight at 37ºC. Restriction was ended upon HinfI inactivation 
by incubating for 20 min at 80ºC. DNA fragments were separated by electrophoresis in a 1% 
agarose gel containing ethidium bromide (0.5 mg.ml-1); the running buffer was TAE  and a 1-kbp 
DNA ladder (Invitrogen) was used as a molecular size marker. DNA fragments were visualized 
with an UVITEC instrument. 
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ANTIFUNGAL SUSCEPTIBILITY TESTING 
 
ANTIFUNGALS 
Antifungal drugs used in this study were obtained from the respective manufacturer as 
standard and pure powders.  Four azoles (fluconazole-FLC, voriconazole-VRC, itraconazole-ITC 
and posaconazole-PSC), three echinocandins (caspofungin-CSF, anidulafungin-ANF and 
micafungin-MCF) and amphotericin B (AMB) were used. Fluconazole, voriconazole and 
anidulafungin were obtained from Pfizer (Groton, CT, USA); itraconazole was obtained from 
Janssen-Cilag (Titusville, NJ, USA); posaconazole was obtained from Schering-Plough (Kenilworth, 
NJ, USA); caspofungin was obtained from Merck (Rahway, NJ, USA); micafungin was obtained 
from Astellas Pharma (Tokyo, Japan); and amphotericin B was obtained from Bristol-Myers 
Squibb (New York, NY, USA). 
The solvent of fluconazole, caspofungin and micafungin was sterile distilled water; for 
voriconazole, itraconazole, posaconazole, anidulafungin and amphotericin B was dimethyl 
sulfoxide (DMSO; Merck). For all antifungals, successive dilutions to a final concentration of 6400 
µg.ml-1 were prepared in Roswell Park Memorial Institute 1640 medium (RPMI 1640; Sigma) 
buffered to pH 7.0 with 0.165 M Morpholine Propanesulfonic Acid Buffer (MOPS; Sigma) and 
stored at -70ºC until use. 
Itraconazole was used only for susceptibility evaluation of isolates from in vivo cases (In 
Vivo Induction of Antifungal Resistance section). Micafungin, the new antifungal from the 
echinocandin class, was used for susceptibility evaluation of in vitro induced echinocandin 
nonsusceptible strain (In Vitro Induction of Antifungal Resistance section), as well as for strains 
used in FKS1 gene sequencing (Antifungal Resistance Mechanisms section) and chitin assessment 
(Virulence Attributes section) studies.  
 
SUSCEPTIBILITY TESTING 
The minimal inhibitory concentration (MIC) of each antifungal drug was determined 
according to the M27-A3 protocol and the M27-S3 supplement of the Clinical and Laboratory 
Standards Institute [CLSI, [190, 191]]. The MIC values were registered after 24 h of incubation 
with echinocandins, and after 48 h with azoles and amphotericin B. MIC value was the lowest 
concentration at which a visual reduction of growth of approximately 50% was registered for 
azoles and echinocandins. Regarding amphotericin B, MIC value was the lowest concentration at 
which no discernible growth was observed. The susceptibility breakpoints were those 
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established by CLSI. For fluconazole, the MIC for susceptibility (S) was ≤8 µg.ml-1, the MIC for 
susceptible-dose dependent (S-DD) was 16 to 32 µg.ml-1, and the MIC for resistance (R) was     
≥64 µg.ml-1; for voriconazole, the MIC for S was ≤1 µg.ml-1 , the MIC for S-DD was 2 µg.ml-1, and 
the MIC for R was ≥4 µg.ml-1; for itraconazole, the MIC for S was ≤0.125 µg.ml-1 , the MIC for       
S-DD was 0.25-0.5 µg.ml-1, and the MIC for R was ≥1 µg.ml-1. For posaconazole and amphotericin 
B, strains inhibited by ≤1 µg.ml-1 of each antifungal were considered to be S. For the 
echinocandins, susceptibility was considered for a MIC ≤2 µg.ml-1. Additionally, standard MIC50 
and MIC90 values were calculated for echinocandins, which are the MIC values at which 50% 
and 90% of the isolates were inhibited, respectively. 
The C. parapsilosis ATCC 22019 type strain was used for quality control of antifungal 
susceptibility testing, according to the same CLSI protocol. 
 
PARADOXICAL EFFECT 
During chitin assessment studies, the existence of a paradoxical growth phenomenon in the 
presence of high caspofungin levels was checked for C. parapsilosis strains. In this case, a range 
of concentrations ranging from 0.03 to 256 µg.ml-1 was tested (rather than 0.015 to 8 µg.ml-1) 
and MIC was determined using prominent inhibition, corresponding to 50% as an end point. The 
paradoxical effect was defined as a progressive increase in cell growth occurring at least two 
drug dilutions above the MIC after 48 h of incubation [172]. 
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IN VITRO INDUCTION OF ANTIFUNGAL RESISTANCE 
 
Induction studies with two different antifungal classes were performed: azoles and 
echinocandins. All experiments started by incubating a randomly selected colony from a 
susceptible C. parapsilosis strain in 10 ml of RPMI 1640 overnight in a rotating drum at 150 rpm, 
35ºC. Next day, an aliquot of this culture, containing 106 cells, was transferred to different vials, 
each containing 10 ml of culture medium without or with an antifungal drug at specific 
concentration and reincubated as described.  
Each day, during the assay, an aliquot (1 ml) from each subculture was mixed with 0.5 ml of 
50% glycerol and frozen at -70ºC for later testing.  
 
INDUCTION OF AZOLE RESISTANCE 
Azole resistance was induced with three different antifungals: fluconazole, voriconazole 
and posaconazole. Four blood culture isolates of C. parapsilosis (BC014, BC011, BC190 and 
BC237) and one C. parapsilosis ATCC strain were used in this study. 
The susceptibility profile to fluconazole, voriconazole, posaconazole, amphotericin B and 
caspofungin was monitored during the assay.  
Two different approaches were followed: 
i) Incubation for 30 days with constant concentrations of fluconazole (16 μg.ml- 1), 
voriconazole (2 μg.ml-1) or posaconazole (1 μg.ml-1); these concentrations are 
described as corresponding to therapeutic blood levels obtained during antifungal 
treatment [192]. Strain BC014 was used in microarray assays (Antifungal Resistance 
Mechanisms section); the strains obtained after incubation with fluconazole, 
voriconazole and posaconazole were named BC014RFLC, BC014RVRC and BC014RPSC 
respectively and the initially susceptible strain was named BC014S. 
 
ii) Incubation with fluconazole, voriconazole and posaconazole twice the concentration 
of the MIC value, for 15 days, and afterwards four times the concentration until the 
30th day. 
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INDUCTION OF ECHINOCANDINS RESISTANCE 
One C. parapsilosis susceptible strain (blood culture isolate BC041) was incubated with 
anidulafungin at constant concentration of 2 μg.ml-1, during 30 days; this concentration is 
described as corresponding to therapeutic blood level obtained during antifungal treatment 
[193]. The initial susceptible strain was named BC014S and the nonsusceptible final strain was 
named BC041NS. The susceptibility profile to fluconazole, amphotericin B, caspofungin, 
anidulafungin and micafungin was monitored during the assay.  
 
ASSESSMENT OF THE STABILITY OF THE ANTIFUNGAL RESISTANCE PHENOTYPE 
The stability of the resistance phenotypes obtained following in vitro induction assays was 
assessed by subculturing the resistant strains in 10 ml of RPMI 1640 medium overnight in a 
rotating drum at 150 rpm, 35ºC, without any antifungal drug for a total of 30 days. Daily, an 
aliquot containing 106 cells of the previous day`s culture was inoculated into 10 ml of fresh 
medium while another aliquot was taken and mixed with 0.5 ml of 50% glycerol and frozen        
at -70ºC. After thawing, the MIC values for antifungals were re-determined for each of the frozen 
isolates. 
 
POPULATION ANALYSIS 
After in vitro induction assays and in order to determine whether the induced resistance in 
C. parapsilosis isolates was associated with selection of a resistant subpopulation, analysis of 
resistance within the cellular population was performed both with susceptible and induced 
resistant strains. Population analysis would allow assessing whether it existed or not a 
homogeneous population (containing only susceptible cells or a mixture between susceptible 
and resistant cells) both in the resistant induced strains and in the initial susceptible strain. This 
could exclude the selection by induction of an initial resistant clone that already existed in initial 
susceptible population.  
This assay was performed as described previously by Marr et al. [194]. A single colony of 
the initially susceptible strain and one of each of the final resistant strains were cultured 
overnight in YEPD broth at 35ºC; a suspension containing 103 cells was prepared in 1 ml of RPMI 
1640 and 50 µl were plated in Sabouraud agar medium without and with fluconazole (1, 4, 16 
and 64 mg.ml-1), voriconazole (0.125, 0.5, 2 and 8 mg.ml-1) and posaconazole (0.25, 1, 4 and 16 
mg.ml-1) for azole resistant strains and without and with anidulafungin (0.5, 1, 2 and  4 mg.ml-1) 
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for echinocandin resistant strain. Growth was quantified after 48 h of incubation at 35ºC. The 
number of colonies growing in the presence of the drug at each concentration, relatively to the 
number growing in its absence was calculated and plotted.  
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IN VIVO INDUCTION OF ANTIFUNGAL RESISTANCE 
 
During the time study three in vivo episodes of C. parapsilosis bloodstream infection were 
studied. All the episodes involved patients admitted at different care units of Hospital S. João. 
Previous therapy with fluconazole and decreased azole susceptibility during the treatment were 
findings common to these cases.  
From each patient, C. parapsilosis isolates were recovered from blood before, during 
and/or after the treatment with fluconazole. All isolates were initially identified as C. parapsilosis 
using Vitek 2 YBC identification cards. They were also identified molecularly as C. parapsilosis 
sensu stricto and not the related species C. orthopsilosis or C. metapsilosis by a DNA-based test 
(Molecular Distinction between C. parapsilosis, C. metapsilosis and C. orthopsilosis section). 
Molecular typing was performed for all isolates collected from the same patient (Genotyping of 
C. parapsilosis Strains section). MIC values of different azoles were determined for all isolates 
(Antifungal Susceptibility Testing section); stability of the in vivo acquired susceptibility 
phenotype was assessed as described above (In Vitro Induction of Antifungal Resistance section) 
and the resistant mechanism developed was explored (Antifungal Resistance Mechanisms 
section). Moreover, microarray technique was applied in order to compare gene expression 
profile of the initial and the final strains from patient A. 
 
CASE REPORT A 
A 26-year-old male patient was admitted in October 2007 with a diagnosis of congestive 
heart failure. In addition to chronic kidney failure, under hemodialisis, he had Crohn`s disease. 
Neutrophil count and glucose blood level were normal; leukocyte count, hemoglobin, albumin 
and protein blood levels were below normal. A thoracic surgical procedure was performed to 
the patient. Renal support was provided. After surgical procedure, bacteria were isolated from 
blood. He was started a cephalosporin and aminoglycoside, ending the infection. In January 
2008, the patient developed fever and antifungal prophylaxis was initiated with lipossomal 
amphotericin B, 80 mg intravenous/day. The first blood culture positive for C. parapsilosis 
(isolate BCA1) was obtained three days later after initiation of the antifungal therapy. Following 
four days, amphotericin B was replaced by oral therapy with fluconazole 400 mg/day.  Two other 
C. parapsilosis isolates were recovered from blood, after fifteen days (isolate BCA2) and 
seventeen days (isolate BCA3) away following the first positive blood culture. C. parapsilosis was 
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not detected in cultures of other biological products. He died in April 2008; death was associated 
with candidaemia.  
 
CASE REPORT B 
A 68-year-old male patient was admitted in January 2008 with a diagnosis of duodenal 
stenosis, being submitted to a gastrojejunostomy. Neutrophil count and glucose blood level 
were normal; leukocyte count, hemoglobin, albumin and protein blood levels were below 
normal. During hospital admission, he developed a nosocomial pneumonia and bacteremia and 
received treatment with several antibiotics, like vancomycin, ciprofloxacin, linezolid, amikacin, 
imipinem and amoxicillin + clavulanic acid. Since admission the patient was placed a central 
venous catheter. The first isolation of C. parapsilosis (isolate BCB1) was in April; he was started six 
days later intravenous fluconazole (400 mg/day), during eight days. The second (BCB2) and the 
third (BCB3) C. parapsilosis isolates were obtained after three days and on the last day of 
fluconazole therapy respectively. Then the therapy was changed to intravenous lipossomal 
amphotericin B (80 mg/day). C. parapsilosis was also found in the central venous catheter.  He 
died in June; death was considered to be candidaemia-related. 
 
CASE REPORT C 
A 70-year-old male patient was admitted in January 2008 with a diagnosis of colon cancer, 
anemia and pneumonia. Glucose blood level was normal; leukocyte count, hemoglobin, albumin 
and protein blood levels were below the normal. He was submitted to a colostomy and 
ileostomy. Since admission the patient was placed a central venous catheter. Bacteria were 
recovered from the catheter, urine, blood, respiratory tract and cutaneous exsudate; therapy 
with azithromycin, ciprofloxacin, vancomycin, imipinem, ceftriaxone, tazobactam and piperacillin 
was administered. C. parapsilosis (isolate BCC1) was recovered for the first time in July; he was 
immediately started with fluconazole 400 mg/day for twelve days. Three, five and nine days 
after from the first isolation of C. parapsilosis other three isolates were obtained (isolates BCC2, 
BCC3 and BCC4). C. parapsilosis were also recovered from others specimens, like urine, bile fluid 
and cutaneous exsudate. In urine and cutaneous exsudate, C. albicans was concomitant with     
C. parapsilosis. Death occurred within 10 days and was associated with candidaemia.  
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ANTIFUNGAL RESISTANCE MECHANISMS 
 
Different experimental approaches were followed in order to elucidate about resistance 
mechanisms expressed by C. parapsilosis to different antifungals. Phenotypic and genotypic 
studies were undertaken with resistant strains obtained from in vitro induction studies, from the 
in vivo cases and with other available resistant clinical strains.  
 
EVALUATION OF EFFLUX ACTIVITY 
Two different approaches were considered for evaluation of the efflux activity of resistant 
C. parapsilosis strains. Strains obtained after induction of susceptible strains (BC014, BC011, 
BC190 and BC237; In Vitro Induction of Antifungal Resistance section) with different azoles and 
isolate BCA3 from the in vivo case (In Vivo Induction of Antifungal Resistance section) were 
studied. 
 
EFFLUX PUMPS BLOCKERS 
Several compounds were described as being able to block efflux pumps from the yeast 
cell membrane. The blocker prevents the antifungal to be expelled, allowing its inhibitory 
effect. There is a synergic effect between the antifungal and the blocker. To highlight this 
effect, susceptibility testing in the presence of the efflux blocker was evaluated. Two 
methodologies were undertaken: 
i) Verapamil (Sigma) 100 µM and ibuprofen (Sigma) 100 mg.l-1 were used as efflux 
pumps blockers of ATP-binding cassette efflux pumps according to Pina-Vaz et al. 
[195]. Stock solutions were prepared in sterile distilled water and then added to 
yeast cell suspensions. Susceptibility to azoles (fluconazole, voriconazole and 
posaconazole) was evaluated in the presence of these two blockers, at constant 
concentrations, according to the M27-A3 protocol from CLSI for antifungal 
susceptibility testing of yeasts [190, 191]. C. albicans strain 95-68, with 
overexpression of CDR1 and CDR2 genes (ATP-dependent efflux pumps), and         
C. albicans strain 2-76, showing low level of resistance gene expression, were 
used as controls. 
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ii) Agar disk diffusion assay was performed with tacrolimus (FK506), another efflux 
blocker, according to Marchetti et al. [196]. Strains were incubated overnight in 
YEPD broth at 37ºC, 150 rpm. The inoculum of 106 cells.ml-1 was prepared in 
sterile distilled water. The yeast suspensions were spread onto YEPD agar 
medium containing fluconazole at a supra-MIC value (128 µg.ml-1), and without 
fluconazole. Blank paper disks, 6mm (Becton Dickinson, NJ, USA), were 
impregnated with an FK506 solution in serial concentrations (10-fold dilutions 
ranging from 0.1 to 100 mg.ml-1) and with DMSO and allowed to dry for 2 h. For 
each tested strain, the disks were applied in the inoculated agar plates (after 
previous assessment of FK506 nontoxicity upon yeast cells). A plate containing 
only fluconazole (no FK506 disk) was used as a control for cell viability in the 
presence of fluconazole supra-MIC values. The agar plates were incubated at 
37ºC, and the results were evaluated after 24 h and 48 h. C. albicans strain 95-
68, with overexpression of CDR1 and CDR2 genes (ATP-dependent efflux pumps) 
was used as control. 
 
 EFFLUX PUMPS FLUORESCENCE SUBSTRATE 
 Flow cytometric analysis using Rhodamine 6G (Rh-6G; Sigma), a specific substrate of 
efflux pumps, was performed as described previously [197, 198] to compare initial 
susceptible strain with induced resistant final strains. 
Briefly, yeast cells were grown to logarithmic phase in 5 ml of YEPD broth at 35ºC, 150 
rpm. Labeling of cells was conducted in 1 ml of YEPD broth, containing 107 cells and 10 mM 
Rh-6G for 30 min at 35ºC, after which the reaction was stopped by placing the tubes on ice. 
The mixture was then diluted 40-fold with cold sterile 0.1 M  phosphate-buffered saline 
(PBS; Sigma) at pH 7.0 and analysed in a FACSCalibur flow-cytometer equipped with a 15 
mW 488 nm argon laser. From each yeast suspension, 30.000-50.000 cells were analysed; 
cell fluorescence was determined at FL1 fluorescence channel (515 nm). All experiments 
were performed in duplicate. 
The final strains were also assayed with and without verapamil. Before labeling the 
yeast cells, they were incubated with verapamil (100 μM) for 90 min [199]. 
 C. albicans strain 95-68, with overexpression of CDR1 and CDR2 genes, was used as 
control and tested for efflux pump activity in the presence of  verapamil.  
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GENE SEQUENCING 
Genes involved in antifungal resistance were amplified and then sequenced for assessment 
of point mutations. 
  
  GENE AMPLIFICATION 
 
  ERG11 GENE 
Genomic DNA from one azole susceptible C. parapsilosis strain (BCA1) and one 
azole resistant C. parapsilosis strain (BCA3) from an in vivo induction case (In Vivo 
Induction of Antifungal Resistance section) was extracted as described previously 
(Molecular Distinction between C. parapsilosis, C. orthopsilosis and C. metapsilosis 
section). Afterwards, DNA sequence analysis of the ERG11 gene was performed.  The 
primers used were ERG11-F1 and ERG11-R1 (Table 1, page number 74). A 1470 bp 
fragment was amplified.  The amplification conditions were as follows: a first 
denaturation cycle of 2 min at 98ºC, followed by 40 cycles at 98ºC for 10 s 
(denaturation step), 64ºC for 30 s (annealing step), and 72ºC for 30 s (elongation step) 
and an extension final step of  7 min at 72ºC. PCRs were performed on the Realplex 
Mastercycler instrument.  
 
TRANSCRIPTION FACTOR GENES 
The transcription factors MRR1, UPC2 and NDT80 from the susceptible strain 
(BC014S) and resistant strains (MRR1 for BC014RFLC and BC014RVRC, UPC2 and NDT80 
for BC014RPSC) from the in vitro induction assay were amplified. Genomic DNA was 
extracted as described previously (Molecular Distinction between C. parapsilosis,          
C. orthopsilosis and C. metapsilosis section). The primers used were MRR1-F1 and 
MRR1-R1 for MRR1 gene, NDT80-F1 and NDT80-R1 for NDT80 gene, and UPC2-F1 and 
UPC2-R1 for UPC2 gene (Table 1, page number 74). The amplification conditions were 
as follows: a first denaturation cycle of 2 min at 94ºC, followed by 30 cycles at 94ºC for 
30 s (denaturation step), 60ºC for MRR1, 58ºC for UPC2 or 62ºC for NDT80 for 30 s 
(elongation step), and 72ºC for 50 s (elongation step) and an extension final step of 7 
min at 72ºC. PCRs were performed on the Realplex Mastercycler instrument.  
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HOT SPOT 1 REGION OF FKS1 GENE 
C. parapsilosis strains [six echinocandin nonsusceptible clinical strains (BC011, 
BC017, BC022, BC043, BC101 and BC132), and the initial echinocandin susceptible 
strain (BC041S) and the final echinocandin nonsusceptible strain (BC041NS) from the in 
vitro induction assay (In Vitro Induction of Antifungal Resistance section)] were 
studied. Genomic DNA was extracted as described previously (Molecular Distinction 
between C. parapsilosis, C. orthopsilosis and C. metapsilosis section) and DNA 
sequence analysis of the hot spot 1 (HS1) region of FKS1 gene was performed.  The 
primers used were FKS1HS1-F and FKS1HS1-R (Table 1, page number 74). A 796 bp 
portion of FKS1 was amplified.  The amplification conditions were as follows: a first 
denaturation cycle of 2 min at 96ºC, followed by  40 cycles at 96ºC for 30 s 
(denaturation step), 69,6ºC for  30 s (annealing step), and 72ºC for 30 s (elongation 
step) and an extension final step of 10 min at 72ºC. PCRs were performed on the 
Realplex Mastercycler instrument. 
 
 SEQUENCING OF AMPLIFIED PRODUCTS 
PCR products amplified were treated with ExoSAP-IT (USB Corporation, OH, USA) and 
used as template for the sequencing reactions, performed with the Big Dye Terminator 
Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Warrigton, United Kingdom). The 
DNA products were purified with Sephadex G-50 Fine (GE Healthcare Europe GmbH, 
Freiburg, Germany) and sequenced in an ABI PRISM 3130 Genetic Analyzer (Applied 
Biosystems). The results were analyzed with the Sequencing Analysis 5.2 software from 
Applied Biosystems. 
 
ALIGN SEQUENCES 
 The coding sequence of the susceptible strain (BCA1) ERG11 gene was aligned with that 
obtained for the resistant strain (BCA3). 
The coding sequences of the susceptible strain (BC014S) MRR1, UPC2 and NDT80 genes 
were aligned with those obtained for the resistant strains (BC014RFLC, BC014RVRC or 
BC014RPSC). 
  The coding sequences of the clinical strains (BC011, BC017, BC022, BC043, BC101 and 
BC132) HS1 region of FKS1 gene were aligned with the C. parapsilosis sequence obtained 
MATERIAL AND METHODS 
 
 
60 
 
from Broad Institute (http://www.broadinstitute.org/). Regarding the induced 
nonsusceptible strain (BC041NS), the sequence was aligned with that obtained from the 
susceptible initial strain (BC041S). 
The software used was the MUSCLE software [200]. Alignments were analyzed in BioEdit 
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html). 
 
 MICROARRAY ASSAYS (1) 
In order to compare gene expression profile between different C. parapsilosis strains 
(susceptible versus resistant), microarray technology was applied. The microarray platform 
provides the global constitutive changes in gene expression, which can shed some light on genes 
that might explain resistant profiles. All laboratory and data analysis work was performed in 
School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, 
Dublin, Ireland, in collaboration with Professor Geraldine Butler. 
This technology was applied on susceptible strain (BC014S) and resistant strains (BC014RFLC, 
BC014RVRC and BC014RPSC) obtained from the in vitro induction assay (In Vitro Induction of 
Antifungal Resistance section). It was also performed with BCA1 and BCA3 strains from the in vivo 
induction case (In Vivo Induction of Antifungal Resistance section). 
 
  RNA EXTRACTION 
A 50 ml C. parapsilosis suspension with an OD600nm of 0.2 was obtained after dilution of 
an overnight culture in YEPD broth at 35ºC, 150 rpm. The suspension was incubated in the 
same conditions until an OD600nm of approximately 1. After centrifugation, the pellet was 
used for RNA extraction using a RiboPure Yeast Kit (Ambion, Austin, TX, USA) according to 
the manufacturer’s instructions.  
The concentration, quality, and integrity levels of RNA samples were determined with 
an Agilent 2100 Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA), according to the 
manufacturer’s instructions. Only samples yielding 28S/18S rRNA ratios between 1.6 and 
2.2 and showing absence of degradation were used in subsequent analysis. 
 
MICROARRAY PLATFORM 
All the experiments were carried out using C. parapsilosis microarrays manufactured by 
Agilent Technologies. The microarray platform is described on the NCBI Gene Expression 
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Omnibus Database (GEO) with the ID GPL13192. The oligonucleotides were designed with 
eArray from Agilent Technologies using an in-house annotation of 5,834 putative open 
reading frame. Each gene is represented by two sets of probes, both spotted in duplicate. 
Probes are randomly distributed. Four copies of each array were printed on a single slide 
(4x44k), and hybridized individually [201]. 
 
PROBE PREPARATION AND MICROARRAY HIBRIDIZATION 
Twenty-four micrograms of total RNA were first incubated with 200 pmol of anchored 
oligonucleotide deoxyribosylthymine (Invitrogen, Carlsbad, California, USA) for 10 min at 
70°C. First-strand buffer (1x; Invitrogen); 1.5 mM dATP, dTTP, and dGTP; 25 μM dCTP; 10 
mM dithiothreitol; 2 μl Superscript II reverse transcriptase (Invitrogen); and 37.5 μM Cy3-
dCTP or 37.5 μM Cy5- dCTP (GE Healthcare Europe GmbH) were mixed in a final volume of 
40 μl. The mixture was incubated at 42°C for 2 h. An additional 1 μl of Superscript II was 
added to the mixture, and incubation continued for 1 h at 42°C. Residual RNA was degraded 
with 1 μl of RNase A (QIAGEN, Hilden, Germany) at 50 μg.ml-1 and 1 μl of RNase H 
(Invitrogen) at  0.05 unit.μl-1, for 30 min at 37°C. The labeled cDNAs were purified using a 
QIAquick PCR purification kit (QIAGEN), according to the manufacturer’s instructions; then, 
labeled cDNAs were pooled in 45 μl of hybridization buffer (supplied with microarray). This 
mixture was denatured at 95°C for 2 min, immediately cooled with ice, applied to the DNA 
microarray and covered with a 24-mm X 60-mm coverslip. Slides were placed in a 
hybridization chamber (Corning Incorporated, Palo Alto, CA, USA) and incubated at 42°C for 
approximately 16 h. Slides were washed twice with oligo aCGH wash buffer 1, oligo aCGH 
wash buffer 2 and with stabilization and drying solution from Agilent.  The microarray 
analysis of the resistant induced strains was performed in distinct experiments; 
comparisons were made with the initial susceptible strain. In each experiment, four 
biological replicates (including two dye swaps) were prepared. 
 
DATA ANALYSIS 
The microarrays were scanned with a GenePix 4000B scanner (Molecular Devices, 
Sunnyvale, CA, USA) at 10 μm resolution. Data were acquired with the GenePix Pro 5.0 
software (Molecular Devices), and low-quality spots were automatically flagged. In addition, 
saturated spots or spots without background corrected intensities greater than 20 in the 
Cy3 or the Cy5 channel were flagged. In each experiment, four biological replicates were 
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performed. In order to estimate and adjust any probe-specific dye effect, two arrays were 
dye-swapped in each experiment. Data was analyzed using the LIMMA package [202] from 
the Bioconductor Project (http://bioconductor.org). Three datasets were preprocessed 
using Loess normalization and no background correction, as suggested by Zahurak et al. 
[203]. Duplicate probes within each array were considered as technical replicates. This 
assumption allows taking full advantage of the platform design, by analyzing the within-
array replicate spots using a pooled correlation method. Quality controls were performed in 
order to assess the good quality of the arrays and to verify any presence of chromosomal-
bias expression [204]. 
  
GENE ONTOLOGY ANALYSIS 
A total of 5,091 C. parapsilosis orthologs of C. albicans genes (87.3% of C. albicans 
genome) were extracted from the Candida Gene Order Browser [205]. Gene ontology 
enrichment analysis was performed using the web tool GoTermFinder, available on the 
website of the Candida Genome Database 
(http://www.candidagenome.org/cgibin/GO/goTermFinder). 
 
CLUSTERING ANALYSIS 
The datasets were preprocessed using the LIMMA package from the Bioconductor 
Project. Loess normalization was used to normalize the ratio of the intensities between the 
two channels for each array separately (within-array normalization), followed by quantile 
normalization to normalize the ratio of the intensities to be compared across arrays. 
Hierarchical clustering was performed on the normalized datasets using euclidean distance 
and complete linkage [206]. Clustering approaches to identify gene expression patterns 
from DNA microarray data were performed [206]. 
 
MICROARRAY DATA ACESSION NUMBER 
Raw microarray data for BC014S strain and BC014RFLC, BC014RVRC and BC014RPSC  
strains and the description of the array have been deposited in the Gene Expression 
Omnibus Database, under the accession number GSE27409 (superseries). The link is 
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE27409. The same did not happen 
for BCA1 and BCA3 strains due to its low quality. 
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GENE EXPRESSION BY REAL-TIME QUANTITATIVE POLYMERASE CHAIN REACTION 
In order to quantify the expression level of certain genes involved in azole resistance 
mechanisms, real-time quantitative polymerase chain reaction (RT-qPCR) was performed using 
the susceptible strain (BC014S) and resistant induced strains  (BC014RFLC,  BC014RVRC, BC014RPSC) 
from in vitro studies and the susceptible strain (BCA1) and the resistant strain (BCA3) from the in 
vivo induction case. Moreover, this technique was applied after microarrays data analysis in 
order to confirm its findings.  
 
cDNA SYNTHESIS 
First-strand cDNA was synthesized from 100 ng of total RNA in a 20 μl reaction volume 
using a SuperScript III Reverse Transcriptase kit (Invitrogen) according to the 
manufacturer´s instructions.  RNA was extracted as described previously.  
 
GENES 
For BC014RFLC strain, expression level of ERG11, GRP2, ALD5, MDR1, MRR1 and RPL82 
genes were determined. For BC014RVRC strain, expression level of GRP2, ALD5, ERG11, 
MDR1 and MRR1 genes were determined. For BC014RVRC strain, expression level of ERG11, 
RPL82, ERG6, UPC2, SOD4 and NDT80 genes were determined. For BCA3 strain, expression 
level of ERG11, ERG6, NDT80 and UPC2 genes were determined.  
The oligonucleotides used were designed using Oligo Explorer program 
(http://www.genelink.com/) and are listed in Table 1 (page number 74). 
 
POLIMERASE CHAIN REACTION 
For each RT-qPCR five replicates for each strain were integrated. The amplification 
conditions were as follows: a first denaturation cycle of 1 min at 95ºC, followed by 35 cycles 
at 95ºC for 15 s (denaturation step), 60ºC for 30 s (annealing step), and 60ºC for 30 s, and an 
extension final step of 5 min at 60ºC. PCRs were performed using PerfeCTa SYBR Green Fast 
Mix (Quanta Biosciences, Gaithersburg, MD, USA) on the Realplex Mastercycler instrument. 
The signal obtained for each gene was normalized with the TUB4 signal. 
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SUSCEPTIBILITY TO PHYSICAL AND CHEMICAL AGENTS 
 
Eight C. parapsilosis clinical strains and eight environmental strains were exposed to 
physical and chemical agents. Regarding chemical agents, either pure compounds or commercial 
solutions commonly used as disinfectants were tested.  Moreover, a new product, a hydrogen 
peroxide dry-mist system for hospital disinfection, was tested against C. parapsilosis strains and 
other microorganisms. 
 
SUSCEPTIBILITY TO PHYSICAL AGENTS 
C. parapsilosis strains were exposed to different physical agents in order to determine the 
inhibitory effect in cell growth. Exposition occurred at different times to obtain a kinetic of the 
effect. At the end of the treatment with the physical agent, 50 µl of serial dilutions (10-1 till 10-6) 
of the different suspensions were platted on Sabouraud agar medium. Plates were incubated for 
76 h at 37ºC and CFUs counted afterwards.  
 
HEATING AT 60ºC 
Glass vials containing 5 ml of cell suspensions in 0.1 M PBS adjusted to 106 cells.ml-1 
were incubated in a hot bath at 60ºC for 0, 5, 15, 30 and 45 min. To ensure the metabolic 
stability of cells after the treatment, vials were immersed in ice for 30 min.  
 
MICROWAVE IRRADIATION 
Microwave irradiation was performed by exposing 60 ml of  cell suspensions  in PBS 
adjusted to 106 cells.ml-1 in glass vials for 0, 20, 40, 60 and 90 seconds to 2540 MHz, at 
maximum power (800 W) in a microwave (Crown, Japan). After treatment, vials were 
immersed in ice for 30 min.  
 
ULTRAVIOLET IRRADIATION 
Glass vials containing 1 ml of cell suspensions in 0.1 M PBS adjusted to 106 cells.ml-1 
were exposed to ultraviolet irradiation for 1, 2, 3, 5 and 10 min at 8 mW.cm-2, 312 nm in the 
UVITEC instrument.  
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SUSCEPTIBILITY TO CHEMICAL AGENTS  
 
 CHEMICAL AGENTS 
 
PURE COMPOUNDS 
Chemicals were tested following the CLSI protocol for antifungal susceptibility 
testing [190, 191]. Chlorhexidine (Sigma; 0.004-2%), ethanol (Merck; 0.08-40%), 
sodium hypochlorite (Merck; 0.04-20%), hydrogen peroxide (Merck; 0.002-1%), 
potassium permanganate (Sigma; 0.0008-0.4%) and acid boric (Sigma; 0.002-1%) were 
studied. Serial dilutions of the initial solutions were prepared with RPMI 1640 medium. 
 
COMMERCIAL SOLUTIONS 
The commercial solutions of chemical agents as they are used in clinic practice 
were tested by time-kill assay. The solutions were: Handscrub (chlorhexidine 0.4%; 
Paracelsia, Porto, Portugal), Aniosgel 85 NPC (ethanol 70%; ANIOS, Hellemmes-Lille, 
France), Solution Dakin (0.5% sodium hypochlorite; Proclinica, Odivelas, Portugal), 
Hydrogen Peroxide (3%; Labesfal, Amadora, Portugal), Potassium Permanganate 
(0.01%; Uniphar, Dublin, Irland) and Acid Boric (3%; Fecofar, Lisboa, Portugal). 
 
MIC AND MLC VALUES DETERMINATION 
The MIC and the minimal lethal concentration (MLC) values of chemical agents (pure 
compounds) were determined according to the M27-A3 protocol and the M27-S3 
supplement from CLSI for antifungal susceptibility testing of yeasts [190, 191]. The value 
was established by visual reading at 24 and 48 h. MIC value was the lowest concentration at 
which a visual reduction in growth of approximately 50% was registered. After reading MIC 
value, 20 µl of each suspension were platted on Sabouraud agar medium and incubated at 
30ºC for 48 h. MLC value was the lowest concentration at which a growth of 10 or less 
colonies was registered.  
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TIME-KILL ASSAY 
One ml of a 106 yeast cell suspension of each C. parapsilosis strain was exposed to each 
commercial solution for 1, 5, 10, 15 and 30 min at room temperature. Afterwards, the 
chemical was removed, the cells resuspended in sterile distilled water, serially diluted and 
50 µl of each dilution platted on YEPD agar medium. Plates were incubated at 30ºC for 5 
days and growth assessed by CFUs counting. Growth inhibition kinetic was determined 
comparing the test plates with control plate (not exposed to chemicals). 
 
EVIDENCE OF CELL MEMBRANE LESION BY FLOW CYTOMETRY 
The goal of this task was to evaluate the lesion of the membrane caused by each agent. 
Cytometric evaluations after staining with the fluorescence probe propidium iodide (PI) were 
performed. As shown previously, PI is a fluorescence probe that only stains nucleic acids of cells 
with serious cytoplasmic membrane damage, i.e., dead cells [207]. 
A final concentration of 106 cells.ml-1 of one C. parapsilosis strain was incubated with RPMI 
1640 medium containing the chemical agent or was exposed to the physical agent. After the 
incubation time, cells were washed and resuspended in 0.1 M PBS with  PI 1 µg.ml-1 for 30 min at 
room temperature. Yeast suspensions were analyzed in a FACSCalibur flow-cytometer equipped 
with a 15 mW 488 nm argon laser. From each suspension a 30.000-50.000 cells were analysed; 
cell fluorescence was determined at FL3 fluorescence channel (650 nm). All experiments were 
performed in triplicate. 
 
CHEMICAL AGENTS 
Cell suspensions were exposed to commercial solutions for 1, 5, 10, 15 and 30 min at 
room temperature. After incubation, cells were washed and stained with PI.  
 
PHYSICAL AGENTS 
Cell suspensions were exposure to heating at 60ºC for 45 min, microwave irradiation 
for 90 s and ultraviolet irradiation for 10 min. Afterwards yeast cells were washed and 
staining with PI.  
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HYDROGEN PEROXIDE DRY-MIST SYSTEM 
GlosairTM 400® system (ASP, Irvine, CA, USA) is a programmable dry-mist generator which 
combines with the disinfectant solution GlosairTM 400® Cartridge, diffusing hydrogen peroxide 
and silver cations as small size particles (approximately 10 µm in diameter). These droplets 
circulate freely in the air as a dry aerosol. The GlosairTM 400® Cartridge is composed by hydrogen 
peroxide 5%, phosphoric acid <50 ppm, silver cations <50 ppm, gum arabica <1 ppm and bi-
osmotic water 95%. Diffusion times are calculated according to the room size in order to reach 
the concentrations mentioned.  
 
 IN VITRO ANTIMICROBIAL ACTIVITY 
Type strain C. parapsilosis ATCC 22019 and one clinical isolate (BC014) were included in 
this study. Yeast suspensions containing approximately 106 cells.ml-1 were prepared in 0.1 M 
PBS. Serial dilutions from 106 cells.ml-1 to 101 cells.ml-1 were prepared and 100 µl from each 
suspension spread on BH agar medium. The plates were then left open in a laboratory room 
in different positions and heights, and exposed to one single cycle of dry-mist 
decontamination. Afterwards, the plates were removed and incubated at 25ºC for 5 days. 
CFUs were quantified and compared to control plates (not exposed to decontamination but 
incubated in similar conditions). The reduction in growth was calculated. All experiments 
were performed in duplicate. 
The Reference strains S. aureus ATCC 25279, Acinetobacter baumannii ATCC 25393, 
Escherichia coli ATCC 32218, Pseudomonas aeruginosa ATCC 27853, Enterococcus faecalis 
ATCC 2912, C. ATCC 90028, C. parapsilosis ATCC 22019, C. krusei ATCC 6258, Aspergillus 
fumigatus ATCC 204305 and Penicillium marneffei ATCC 18224 and one clinical isolate of 
each of the mentioned species were also included in this study (manuscript VII in 
Publications section).  
 
DETERMINATION OF MIC VALUES 
The determination of MIC value of the disinfectant solution was performed according 
to the M27-A3 protocol and the M27-S3 supplement from CLSI for antifungal susceptibility 
testing of yeasts [190, 191] regarding C. parapsilosis ATCC 22019 type strain. The MIC values 
were established by visual reading at 48 h of incubation; MIC value was the lowest 
concentration at which a visual drastical reduction in growth (≥ 90%) was registered. The 
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disinfectant solution was successively diluted (1:2) in RPMI 1640 medium; ten 
concentrations were tested, ranging from 5% to 0.01% of hydrogen peroxide and <50 ppm 
to <0.1 ppm silver cations. 
MIC values regarding the ATCC type strains of the other species mentioned above were 
also calculated according to the respective protocol for susceptibility testing. Activity 
against three clinical isolates and ATCC 27294 type strain of M. tuberculosis was evaluated 
according to the standard procedures of the BD BACTEC MGIT 960 (Becton Dickinson, 
Franklin Lakes, NJ, USA) using Mycobacteria Growth Indicator Tubes (MGIT) (manuscript VII 
in Publications section).  
 
EVIDENCE OF CELL MEMBRANE LESION BY FLOW CYTOMETRY 
 A final concentration of 106 cells.ml-1 of C. parapsilosis was prepared in 1 ml of 
disinfectant solution. After 5 min of incubation at room temperature, cells were washed 
and re-suspended in 0.1 M PBS with propidium iodide (PI) at final concentration of                
1 µg.ml-1. Yeast suspensions were analyzed in a FACSCalibur flow-cytometer equipped with 
a 15 mW 488 nm argon laser. From each suspension a 30.000-50.000 cells were analysed; 
cell fluorescence was determined at FL3 fluorescence channel (650 nm). All experiments 
were performed in triplicate. Intact and damaged cells were photographed under an optical 
microscope (AxiosKop 40, Zeiss) with camera system AxionCam MRc5 Zeiss (AxionVision 
Release 4.6.3. SP1 program). 
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VIRULENCE ATTRIBUTES 
 
 In order to study the correlation between drug resistance and virulence attributes, we 
compared susceptible and resistant C. parapsilosis strains. The first nine topics involved the  
azole susceptible (BC014S) versus resistant strain (BC014RPSC); the last two were performed with 
echinocandin susceptible strains (BC041S strain and BC002, BC021, BC034 clinical isolates) 
versus nonsusceptible strains (BC041NS strain and BC011, BC017, BC022 clinical isolates). 
BC014RPSC and BC014NS were obtained from in vitro induction studies (In Vitro Induction of 
Antifungal Resistance section). 
 
GROWTH KINETIC 
For the determination of growth curves, C. parapsilosis cell suspensions (from a smooth 
colony) in 100 ml YEPD broth with an initial OD600nm of 0.1 were incubated at 37ºC under 
agitation for 48 h; growth was assessed by measuring optical density along time, up to 48 h. 
 
ANALYSIS OF PHENOTYPIC SWITCHING 
C. parapsilosis cell suspensions obtained after overnight growth, of cells from a smooth 
colony, at 30ºC, 150 rpm, in YEPD broth were prepared in the same medium, to a final 
concentration of 103 cells.ml-1. Approximately 50 µl were plated onto YEPD agar medium (ten 
plates per strain) and incubated at 30ºC for 96 h; the presence of distinct colony phenotypes was 
checked visually. Colonies were photographed under a stereoscopic binocular microscope (520-
LAB1, Quirumed, Valencia, Spain) with AxionCam MRc5 Zeiss (AxionVision Release 4.6.3. SP1 
program) camera system. Cells from each colony were resuspended in sterile distilled water and 
photographed under an optical microscope (AxiosKop 40, Zeiss, Barcelona, Spain) with 
AxionCam MRc5 Zeiss camera system. 
To assess the switching frequencies of colonies, cells were removed from individual 
colonies, suspended in water, counted and plated at approximately 100 cells (CFUs) per plate 
(ten plates of YEPD agar medium). These plates were incubated for 72 h at 30ºC and the 
different colonies morphologies were counted and classified. 
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AGAR INVASION 
C. parapsilosis suspensions obtained after overnight growth, of cells from a smooth colony, 
at 30ºC, 150 rpm, in YEPD broth were serially diluted to 103 cells.ml-1. Approximately 50 µl were 
plated onto YEPD agar medium and incubated at 30ºC for 96 h. Different colonies were 
photographed under a stereoscopic binocular microscope with AxionCam MRc5 Zeiss camera 
system. Those on the surface were removed by washing under running water. The cells 
remaining under the agar were then photographed. 
 
PSEUDOHYPHAL DEVELOPMENT 
C. parapsilosis cells (from a smooth colony) were grown in RPMI 1640 medium with 10% 
fetal calf serum (Invitrogen) for 24 h at 37ºC; pseudohyphal development was checked and 
photographed under an optical microscope with AxionCam MRc5 Zeiss camera system. 
   
ADHERENCE ASSAY 
Adherence ability of C. parapsilosis cells (from a smooth colony) was evaluated using two 
different methods: the classic method  and a new method developed by Silva-Dias et al. [208] 
based upon a flow cytometric assay. 
 
CLASSIC METHOD 
C. parapsilosis cells were grown at 30ºC to stationary phase in Sabouraud broth, 
washed thice with ice-cold deionized water and adjusted to 2x106 cells.ml-1 in sterile 0.1 M 
PBS). A stock solution of blue, unmodified polystyrene microspheres was prepared by 
mixing 6 µl of a 10% solids suspension (Molecular Probes, Invitrogen) in 2 ml of 0.1 M PBS, 
resulting in a concentration of 9x108 microspheres.ml-1. Equal volumes (100 µl) of yeast cells 
and microsphere suspensions were placed in acid-washed glass test tubes and equilibrated 
at room temperature (final concentrations, 106 cells.ml-1 and 4.5x108 microspheres.ml-1). 
The mixture was vigorously vortexed for 30 s and the percentage of yeast cells with three or 
more attached microspheres was assessed by microscopy (300 cells per sample). The assay 
was performed in triplicate. 
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FLOW CYTOMETRIC ASSAY 
A mixture of green fluorescent polystyrene beads (1x105 beads.ml-1) (Molecular Probes, 
Invitrogen) and C. parapsilosis cells (106 cells.ml-1) in 0.1 M PBS was analyzed in a 
FACSCalibur flow-cytometer equipped with a 15 mW 488 nm argon laser.  From each yeast 
suspension, 30.000-50.000 cells were analysed; cell fluorescence was determined at FL3 
fluorescence channel (650 nm). All experiments were performed in triplicate. The numerical 
results were expressed as a percentage of cells associated with microspheres population. 
 
BIOFILM FORMATION  
Biofilm formation was assessed in 12-well tissue culture plates by incubation of 1 ml of a 
106 cells.ml-1 C. parapsilosis cells suspension (from a smooth colony) in RPMI for 24 h and  48 h 
at 37°C.  After biofilm formation, the medium was aspirated, and nonadherent cells were 
removed by thoroughly washing the biofilms three times with sterile 0.1 M PBS. The biofilm 
formation capacity was evaluated by: i) a 2,3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenyl 
amino) carbonyl]- 2H-tetrazolium hydroxide assay (XTT; Sigma) which measures the metabolic 
activity [209] and ii) a crystal violet assay (CV) which measures the biomass formation [210]. XTT 
was dissolved in sterile 0.1 M PBS at 0.5 g.l-1. The solution was sterilized by filtration through a 
0.22 µm pore size filter. Prior to each assay, the XTT solution was thawed and supplemented 
with menadione (10 mM stock dissolved in acetone; final concentration 1 µM; Sigma), an aliquot 
of 1 ml of the XTT-menadione solution was added per well, and the plates were incubated in the 
solution at 37°C for 2 h. A sample (500 µl) was then transferred from each well into a fresh       
12-well plate (to eliminate interference of cells with colorimetric readings), and the colorimetric 
change resulting from XTT reduction was measured at 490 nm.  The assays were performed in 
triplicate. For fixation of the biofilms, 100 μl 99% methanol was added (15 min), after which 
supernatants were removed and the plates were air-dried. Then, 100 μl of a 0.02 % CV solution 
was added to all wells. After 20 min, the excess CV was removed by washing the plates under 
running tap water. Finally, bound CV was released by adding 150 μl of 33% acetic acid (Sigma). 
The absorbance was measured at 590 nm.  
 
COAGULASE ACTIVITY 
Coagulase production was assessed by the formation of a clot that could not be 
resuspended by gentle shaking after inoculation each strain [controls and C. parapsilosis strains 
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(smooth colony)] in 500 µl of EDTA-rabbit plasma and incubation for 4 h (or 24 h if no clot was 
formed), at 35ºC. 
 Type strains S.aureus ATCC 25923 and S.epidermidis ATCC 14990 were used as positive and 
negative controls. 
 
CATALASE ACTIVITY 
 C. parapsilosis suspensions (from a smooth colony) adjusted to 106 cells.ml-1 were exposed 
to hydrogen peroxide solution at concentration of 25 mM. After 1 h of incubation at 30ºC, yeast 
cells were washed, ressuspended in sterile distilled water and serially diluted. Approximately 50 
µl were plated onto YEPD agar medium and incubated at 30ºC for 72 h; afterwards CFUs were 
counted and the results compared with plates sampled with suspensions not exposed to 
hydrogen peroxide. Assays were performed in triplicate.  
 
 MICROARRAY ASSAYS (2) 
To get an insight whether there is an effective relation between drug resistance and 
virulence attributes for C. parapsilosis, we compared large-scale gene expression profile of 
susceptible and resistant strains (smooth phenotypes) using microarray analysis, as described 
previously (Antifungal Resistance Mechanisms section). 
 
 CELL WALL CHITIN CONTENT 
 
CALCOFLUOR WHITE RESISTANCE 
Calcofluor white (CFW; Sigma) was incorporated into YEPD agar plates at 50 µg.ml-1.    
C. parapsilosis cells were grown to late log phase in YEPD broth and serially diluted to a final 
concentration ranging from 106 to 102 cells.ml-1 in fresh YEPD broth. YEPD agar plates were 
inoculated with 5 µl drops of each cell suspension and incubated for 72 h at 30ºC.  
 
FLOW CYTOMETRIC ASSAY 
Chitin content was measured using by a new method developed by Costa-de-Oliveira 
et al.  (manuscript VIII in Publications section) based on flow cytometric analysis.  
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CFW binds to chitin and cellulose from cell wall of yeasts. Since it is a fluorescent 
probe, it is possible to correlate the mean of intensity of fluorescence emitted by cells with 
the amount of chitin. A cytometric protocol was developed in order to measure cell wall 
chitin content and distinguish chitin content among different cell populations.     
C. parapsilosis cells were grown in YEPD broth at 35ºC under agitation until late log 
phase. A 106 cells.ml-1 suspension in sterile distilled water was stained with CFW 2.5 µg.ml-1, 
a specific chitin dye (excitation at 365 nm and emission at 430 nm), for 15 min at room 
temperature, in the dark. Yeast cells were washed by centrifugation and the blue 
fluorescence (Pacific blue channel) was quantified in a BD FACSCanto II flow cytometer 
(Becton Dickinson, Madrid, Spain). BD FACSCanto II system consists of an excitation source 
with up to three lasers: blue (488-nm, air-cooled, 20-mW solid state), red (633-nm, 17-mW 
HeNe), and violet (405-nm, 30-mW solid state). The mean intensity of fluorescence, from 
three independent experiments, emitted from stained (positive population) and non-
stained (autofluorescence - negative population) yeast cell populations were analyzed and 
processed with FACSDiva software. For each experiment a staining index (SI) was calculated 
as follows: [mean positive population – mean negative population)/ 2 x standard deviation 
of the negative population; [211]).  
C. albicans cells SC5314 [212] and Δchs3, a chitinase deleted strain with low chitin 
content [213], were used as controls for chitin content determination assays. Other yeasts 
were used: 6 strains of C. glabrata, 4 strains of C. krusei, 4 strains of C. tropicalis, 3 strains of 
C. albicans and 1 strain of Cryptococcus neoformans (manuscript VIII in Publications 
section).  
 
EPIFLUORESCENCE MICROSCOPY  
In order to confirm the results obtained from flow cytometry, C. parapsilosis cells were 
examined under epifluorescence microscopy. Yeast cells were grown and prepared as 
described for flow cytometric assays and stained with CFW 25 µg.ml-1 for 15 min. Upon 
staining, 30 µl of the cell suspension were placed on a slide and overlapped with vectashield 
fluorescence mounting media (Vector Laboratories, Peterborough, UK). The stained 
suspensions were observed under an epifluorescence microscopy (400X) imager Z Apotome 
(Zeiss).  
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Table 1. Sequences of primers. 
 
Primer name Primer sequence 
ALD5-F 5`-ACTTACAAACAACCAACGGG-3` 
ALD5-R 5`-ATCTTCCTCCAATGCTTCA-3` 
ERG6-F 5`-GAAACAAAGAGATTGAGCGACT-3` 
ERG6-R 5`-GAAAGAAGAACCCCAGCC-3` 
ERG11-F1 5`-ATTTGGTTTACTTGTGTTTGCTCC-3` 
ERG11-R1 5`-ATTTCTGCTGGGTGTTGAGGTA-3` 
ERG11-F2 5`-GGTTTACTTGTGTTTGCTCCT-3` 
ERG11-R2 5`-GTCCATAAGATACGGCTGAAC-3` 
FKS1HS1-F 5`-AATGGGCTGGTGCTCAACAT-3` 
FKS1HS1-R 5`-CATCAAGTTCCATCTGAAATTGAAGG-3` 
GRP2-F 5`-GTTGTATTCATCAGTGGAGCC-3` 
GRP2-R 5`-GACCAGCAGACTTGAGCA-3` 
MDR1-F 5`-TTCGTGATAGTTTTGGTGGTAG-3` 
MDR1-R 5`-TGAACCTGGAGTGAATCTTGT-3` 
MRR1-F1 5`-CCCTTTCTTCCGCAGATTTC-3` 
MRR1-R1 5`-CGTTGTAAAGATGGCGTGGT-3` 
MRR1-F2 5`-ACAATGGTCTGAGCAATGAA-3` 
MRR1-R2 5`-GGCAATACTGGTGATGGAA-3` 
NDT80-F1 5`-TCTCGTGCCCGATATCTTTG-3` 
NDT80-R1 5`-TCTCGCATACACAGTCTCTC-3` 
NDT80-F2 5`-CTCTGGTGGTGCTAATGATG -3` 
NDT80-R2 5`-ATGTTGTTGAGGGAGTGAAGA-3` 
RPL82-F 5`-TTGCTTCTGCTGATGAGG-3` 
RPL82-R 5`-CCATAATACCACCACCCC-3` 
RPO2 5`-GCGATCCCCA-3` 
SADH-F 5`-GTTGATGCTGTTGGATTGT-3` 
SADH-R 5`-CAATGCCAAATCTCCCAA-3` 
SOD4-F 5`-TCAGGAAGACACGGTAAGATT-3` 
SOD4-R 5`-GCAAAGTGGATAACAATGGA-3` 
TUB4-F 5`-TGTATTCCACAATGATGCCT-3` 
TUB4-R 5`-TGCCTTGAAACGAAGTAG-3` 
UPC2-F1 5`-TTTGCCGGTAAACCATCC-3` 
UPC2-R1 5`-TTTCCTCCACCCCTATTGTAG-3` 
UPC2-F2 5`-ATTGGAGTGTGGGTATCTTCAT-3` 
UPC2-R2 5`-CCTTCGCCTTCTTCAGTTC-3` 
 
 
 75 
 
 
 
 
 
RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 76 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
77 
 
INCIDENCE AND DISTRIBUTION OF C. PARAPSILOSIS, C. ORTHOPSILOSIS AND                             
C. METAPSILOSIS 
 
Details regarding the 175 C. parapsilosis isolates are depicted in Table 1. Amplification of 
SADH gene fragment was performed using the genomic DNA of all isolates as template. Isolates 
displaying a fragment with a size other than 716 bp were excluded from this study. Six strains 
(3.4%), corresponding to 4 blood and 2 mucosal isolates, were not confirmed to belong to            
C. parapsilosis group (e.g. Fig. 1a, lane 3). For C. parapsilosis group a fragment of SADH gene 
(716 bp) was amplified by PCR (e.g. Fig. 1a, lane 1,2,4,5 and 6). According to the BanI restriction 
pattern of the above fragment, isolates were molecularly discriminated as C. parapsilosis sensu 
stricto, C. orthopsilosis and C. metapsilosis (Fig. 1b): C. parapsilosis sensu stricto has one BanI 
restriction site, at position 196; C. orthopsilosis has none; and C. metapsilosis has three BanI 
restriction sites (at positions 96, 469, and 529). The SADH fragments of the previously identified 
C. orthopsilosis isolates were sequenced (data not shown); all four sequenced isolates 
correspond in fact to C. orthopsilosis. Therefore, misidentification due to possible point mutation 
in C. parapsilosis sensu stricto was excluded. 
The incidence and distribution of the three species is detailed in Table 1; 160 isolates 
(91.4%) were identified as C. parapsilosis sensu stricto, 4 (2.3%) as C. orthopsilosis and 5 (2.9%) 
as C. metapsilosis; six isolates corresponded to other Candida species.  C. orthopsilosis and          
C. metapsilosis species were found in biological products other than blood; C. parapsilosis sensu 
stricto species were found in all biological samples. All 8 environment strains (6 from air and 2 
from food) were identified as C. parapsilosis sensu stricto. 
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Table 1. Distribution of 
Site of 
isolation 
No. of
C. parapsilosis 
stricto
Urine 
Respiratory tract 
Central venous catheter 
Blood 
Mucosal surface 
Peritoneal fluid 
Bile fluid 
Spinal fluid 
Hospital environment 
Unknown 
Total (%) 160 (91.4%)
 aTotal number of isolates is higher than the sum of 
molecular analysis of six isolates showed that they corresponded to distinct 
 
                   
Figure 1. Distinction of C. parapsilosis 
restriction profile. a) Amplification of a 716 bp
confirmation of C. parapsilosis group (lane 1, 2, 4, 5 and 6); smaller 
misidentified C. parapsilosis species (lane 3). b) Representative
1), C. orthopsilosis (lane 2), and C. parapsilosis
 
 
 
 
C. parapsilosis, C. orthopsilosis and C. metapsilosis. 
 
sensu 
 
No. of 
C. orthopsilosis 
No. of 
C. metapsilosis 
9 4 0 
2 0 1 
6 0 0 
60 0 0 
65 0 4 
1 0 0 
2 0 0 
1 0 0 
8 0 0 
6 0 0 
 4 (2.3%) 5 (2.9%) 
C. parapsilosis sensu stricto, C. orthopsilosis and C. metapsilosis
Candida species.   
sensu stricto, C. orthopsilosis and C. metapsilosis according to 
 SADH gene fragment from genomic DNA of isolates provided genetic 
SADH gene fragments amplifications correspond to 
 SADH gene restriction profile for C. metapsilosis
 (lane 3) type strains. Lane M, 100-bp DNA ladder. 
No. of 
isolates 
13 
3 
6 
64 
71 
1 
2 
1 
8 
6 
175
a
 (100%) 
, since the 
 
SADH gene 
 (lane 
 GENETIC HOMOGENETY OF 
 
Based on the major DNA fragments (ranging from 200 bp to approximately 2 kb) the RAPD 
profiles were defined. From the 160 
profiles (Fig. 2a). The isolates were identified as RAPD type 
isolates, 3.8 %) and A3 (3 isolates, 
These results were corroborated by mtDNA RE analysis. A representative example of the 
major type (which corresponds to RAPD type 
 
                         
Figure 2. C. parapsilosis genotypes. a) 
in this study. Lanes: 1, RAPD type 
endonuclease pattern of HinfI-digested DNA. The 
ladder. 
 
 
 
 
 
 
C. PARAPSILOSIS ISOLATES 
C. parapsilosis isolates RAPD analysis generated 
A1 (151 isolates, 
1.8 %). All the environmental isolates belong to type 
A1) is represented in Fig. 2b. 
 
RAPD profiles generated by primer RPO2 among C. parapsilosis
A1, 2, RAPD type A2, 3, RAPD type A3 and M, 100-bp DNA ladder.
pattern corresponds to RAPD profile type A1. Lane M, 1
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3 unique 
94.4 %), A2 (6 
A1.  
 isolates included 
 b) Restriction 
-kbp DNA 
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ANTIFUNGAL SUSCEPTIBILITY PROFILES OF C. PARAPSILOSIS, C. ORTHOPILOSIS AND                  
C. METAPSILOSIS 
 
The susceptibility profiles of C. parapsilosis, C. orthopsilosis and C. metapsilosis concerning 
azoles and AMB are detailed in Table 2. The vast majority of the C. parapsilosis sensu stricto 
isolates (94.4%) were susceptible to FLC; 8 isolates (5%) were susceptible-dose dependent to 
FLC, and a single (0.6%) isolate was resistant to FLC. No FLC-resistant or FLC-susceptible-dose 
dependent strains were detected among the C. orthopsilosis and C. metapsilosis isolates; the 
highest MIC was 4 µg.ml-1. A single isolate of C. parapsilosis sensu stricto (the same that was 
resistant to FLC) was resistant to VRC and PSC. All isolates of C. orthopsilosis and C. metapsilosis 
were susceptible to VRC and PSC. AMB MIC values were equal to or less than 1 µg.ml-1 for all 
isolates tested, with the exception of two C. parapsilosis sensu stricto isolates, which were 
resistant. AMB MIC values for C. orthopsilosis and C. metapsilosis were lower than AMB MIC 
values for C. parapsilosis sensu stricto.  
 
Table 2.  Antifungal  susceptibility  profile  of  Candida  parapsilosis,  C.  orthopsilosis  and                              
C. metapsilosis isolates to different azoles and amphotericin B. 
Species  
(no. of isolates) 
Antifungal 
MIC (µg.ml
-1
) 
range 
No. S 
(%) 
No. S-DD 
(%) 
C. parapsilosis 
sensu stricto 
(160) 
FLC 
VRC 
PSC 
AMB 
0.125 - 64 
≤0.015 - 8 
≤0.03 - 2 
0.06 - 2 
94.4 
99.4 
99.4 
98.8 
5 
0 
NE 
NE 
 
C. orthopsilosis 
(4) 
FLC 
VRC 
PSC 
AMB 
0.5 - 1 
≤0.015 - 0.03 
≤0.03 
0.5 
100 
100 
100 
100 
0 
0 
NE 
NE 
 
C. metapsilosis 
(5) 
FLC 
VRC 
PSC 
AMB 
1 - 4 
≤0.015 - 0.125 
<0.03 - 0.125 
0.125 - 1 
100 
100 
100 
100 
0 
0 
NE 
NE 
                S, susceptible; S-DD, susceptible-dose dependent; NE, not established. 
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The susceptibility pattern to echinocandins (CSF and ANF) is detailed in Table 3. A high 
number of C. parapsilosis sensu stricto isolates was nonsusceptible to CSF (38%); as a wide range 
of MIC values (4 to 32 µg.ml-1) was found. All C. orthopsilosis and C. metapsilosis isolates were 
susceptible to CSF. Similar findings were registered for ANF: all C. orthopsilosis and                        
C. metapsilosis isolates were susceptible to ANF, while 29% of the C. parapsilosis sensu stricto 
isolates were nonsusceptible to ANF; ANF MIC values (4 to 16 µg.ml-1) were lower than those of 
CSF. For C. parapsilosis sensu stricto, the standard MIC50 and MIC90 values of both 
echinocandins were 2 and 4 µg.ml-1, respectively. For C. orthopsilosis, the standard MIC50 of CSF 
was 2 µg.ml-1 and that of ANF was 1 µg.ml-1. For C. metapsilosis, the standard MIC50 value of 
both echinocandins was 1 µg.ml-1. The MIC90 was not calculated because the number of              
C. orthopsilosis and C. metapsilosis isolates was less than 10. 
 
Table 3.  Antifungal  susceptibility  profile of C.  parapsilosis,  C. orthopsilosis and          
C. metapsilosis to echinocandins. 
Species 
(no. of isolates) 
Antifungal Phenotype
a MIC 
Range (µg.ml
-1
) 
C. parapsilosis 
sensu stricto 
(160) 
CSF S (62%) 
NS (38%) 
0.06 – 2 
4 – 32 
 ANF S (71%) 
NS (29%) 
0,125 – 2 
4 – 16 
    
C. orthopsilosis 
(4) 
CSF 
ANF 
S (100%) 
S (100%) 
1 – 2 
1 
    
C. metapsilosis 
(5) 
CSF 
ANF 
S (100%) 
S (100%) 
1 – 2 
0.5 – 1 
              aS, susceptible (MIC ≤2 µg.ml-1); NS, nonsusceptible. 
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IN VITRO INDUCTION OF ANTIFUNGAL RESISTANCE 
 
DEVELOPMENT OF IN VITRO RESISTANCE 
Table 4 shows fluconazole, voriconazole and posaconazole MIC values before and after 
induction with different azoles, for all tested strains (ATCC 22019, BC014, BC011, BC190 and 
BC237). After exposure to therapeutic blood concentrations of the different azoles, distinct 
patterns of resistance were observed. Following 15 days of antifungal exposure, only the 
fluconazole susceptibility phenotype changed. This finding was observed with most strains 
exposed to fluconazole and with a few strains exposed to voriconazole; following posaconazole 
exposure, only minor MIC variations were registered after this period of time. Fluconazole and 
voriconazole increased MIC values to themselves and to each other, changing the susceptibility 
phenotype to resistant after 30 days, but not to posaconazole, which maintained the susceptible 
phenotype. Posaconazole induced resistance to all azoles only at the very end of incubation time 
(30 days). Therefore, the activity of fluconazole was the most impaired and it was the faster 
inducer of resistance.  
In a different strategy to compare the ability of the same azole drug to induce resistance, 
incubation with two- and four-fold MIC values was assayed. A representative example (type 
strain ATCC 22019) of the development of resistance in such instances is detailed in Fig. 3. The 
lower concentration of fluconazole was sufficient to induce resistance to itself and to 
voriconazole (at day 30th) but not to posaconazole; the exposure of the yeast cells to the lower 
concentration of voriconazole only changed the fluconazole phenotype (susceptible strain 
changed to susceptible-dose dependent; at day 30th); only minor variations of MIC  values were 
observed with the other tested azoles. Posaconazole had the minor effect on the MIC values of 
all azoles in such experimental conditions.  
Incubation with these three azoles, independently on the tested concentration, did not 
induce resistance to AMB or to CSF. 
Regarding the control assay, where the same strains were successively incubated without 
antifungals, the MIC values of all antifungals (FLC, VRC, PSC, AMB and CSF) tested remained 
constant throughout the duration of the study. 
Concerning the BC041 strain incubated with anidulafungin, the MIC values for CSF, ANF and 
MCF changed from 0,25 µg.ml-1 , 1 µg.ml-1 and 0,5 µg.ml-1 to 8 µg.ml-1, 16  µg.ml-1 and 8 µg.ml-1, 
respectively at the end of the incubation time. Fluconazole and AMB MIC values did not change 
after incubation with anidulafungin. In parell, the incubation throughout the 30 days without 
antifungal did not change the initial MIC values of all three echinocandins. 
  
                                                    
Figure 3. Variation of fluconazole (FLC), voriconazole (VRC) and posaconazole (PSC) MIC values for 
parapsilosis ATCC 22019 type strain cultured in the presence of two
PSC (c) for 30 days. MIC of FLC;
 STABILITY OF INDUCED RESISTANCE
Regarding the stability of the 
subcultured in drug-free medium for 30 days; the resistance pattern remained stable and no 
decrease greater than one single dilution was observed in MIC values of antifungals tested. 
These results are detailed in Fig. 4 for a representative example (type strain ATCC 22019). 
The stability of echinocandin resistance acquired by BC041NS strain was also assessed. No 
decrease greater than one dilution was observed in MIC values of the 3 echinocandins tested 
(data not shown). 
 
- and four-fold MIC values of FLC (a), VR
  MIC of VRC;   MIC of PSC.  
 
 
in vitro developed resistance, such resistant organisms were 
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Figure 4. Variation of fluconazole (FLC), voriconazole (VRC) and posaconazole (PSC) MIC values for 
parapsilosis ATCC 22019 type strain after induction with FLC (a), VRC (b) and PSC (c) 
antifungal for 30 days.  MIC of FLC;
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Figure 5. Population analysis (a representative example) of 
resistant induced strains following 30 days of exposure to azoles (BC014R
percentage of resistant cells (y-axis, log
indicated concentration of fluconazole (a), voriconazole (b) and posaconazole (c) 
of drug. 
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MOLECULAR IDENTIFICATION OF 
Although C. parapsilosis
testing was also performed in order to confirm identity. The 
polymorphism indicated that all 
since, as described by Tavanti et al. 
was obtained (Fig. 7). 
 
Figure 7. SADH gene restriction profile for 
BCB2 and BCB3) and patient C (BCC1, BC
 
Regarding genotyping results, RAPD analysis (Fig. 
patient shared identical profiles and were thus considered to belong to the same initial strain. 
Moreover, all strains exhibited the same profile (RAPD type 
For patient B and patient C, 
RAPD analysis revealed that these strains were similar to blood strains (data not shown).
 
                              
Figure 8. RAPD profiles produced for 
patient A (BCA1, BCA2 and BCA3), patient B (BC
bp DNA ladder. 
RESISTANCE 
ISOLATES 
 isolates were identified by conventional methods, molecular 
SADH
the clinical isolates were in fact C. parapsilosis
[84], a typical restriction profile of SADH
 
C. parapsilosis strains from patient A (BCA1, BCA2 and BC
C2, BCC3 and BCC4). Lane M, 100-bp DNA ladder. 
8) showed that isolates from the same 
A1).  
C. parapsilosis strains were also isolated from other 
 
C. parapsilosis strains with the primer RPO2, isolated from blood cultures of 
B1, BCB2 and BCB3) and patient C (BCC1, BCC2, BCC3
RESULTS 
87 
 gene restriction 
 sensu stricto, 
 gene of two bands 
A3), patient B (BCB1, 
body sites; 
 
 and BCC4). Lane M, 100-
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SUSCEPTIBILITY PROFILES 
The isolates from the three different fungaemia episodes were tested for antifungal 
susceptibility to four azoles (Table 5). Overall, throughout time the initial susceptible isolates  
became progressively less susceptible to azoles, especially to fluconazole, itraconazole and 
voriconazole. In the first case (patient A), the last isolate (BCA3), recovered after 14 days of FLC 
exposure, was resistant to all four azoles, with high MIC values. In the second case (patient B), 
although only a slightly increase in MIC values of all azoles was registered, the last isolate (BCB3), 
which had been exposed to FLC for 8 days, changed the susceptibility phenotype from 
susceptible to susceptible-dose dependent, only for FLC. Regarding the third patient (patient C), 
the isolate BCC4 also became susceptible-dose dependent to FLC and VRC after 9 days of 
exposure to FLC.  
 
Table 5.  In vitro  antifungal  susceptibility [MIC value (µg.ml
-1
) and phenotype] of 
C.parapsilosis blood culture isolates from patient A, patient B and patient C to diferent 
azoles. 
 MIC/Phenotype 
Isolate Fluconazole Itraconazole Voriconazole Posaconazole 
BCA1 0.25/S ≤ 0.015/S ≤ 0.015/S 0.06/S 
BCA2 1/S 0.06/S ≤ 0.015/S 0.06/S 
BCA3 > 64/R > 4/R > 8/R >16/R 
 
BCB1 
 
4/S 
 
0.125/S 
 
0.125/S 
 
≤ 0.03/S 
BCB2 16/S-DD 0.5/S-DD 0.5/S 0.06/S 
BCB3 32/S-DD 0.5/S-DD 0.5/S 0.06/S 
 
BCC1 
 
8/S 
 
0.125/S 
 
0.25/S 
 
≤ 0.03/S 
BCC2 8/S 0.25/S-DD 0.25/S ≤ 0.03/S 
BCC3 8/S 0.25/S-DD 0.25/S ≤ 0.03/S 
BCC4 32/S-DD 0.5/S-DD 1/S ≤ 0.03/S 
 
The susceptibility phenotypes acquired in vivo were confirmed to be stable in vitro, since 
after sub-culturing the last isolates from the three cases (BCA3, BCB3 and BCC4) in drug-free 
medium, only slight variations were seen (maximum one dilution) in MIC values of all azoles, 
maintaining the resistant and susceptible-dose dependent phenotypes (data not shown). Such 
findings are similar to what happened with in vitro induced resistant strains. 
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ANTIFUNGAL RESISTANCE MECHANISMS 
 
EFFECT OF EFFLUX BLOCKERS ON MIC VALUES OF AZOLES 
After incubation with ibuprofen and verapamil, two ATP-binding cassette efflux pumps 
blockers, a decrease of MIC values of no more than one single dilution was registered, while the 
resistance pattern remained stable; such results were obtained with all strains studied. Results 
obtained with BC014 resistant strains, a representative example, are represented in Table 6. 
Regarding the control strain C. albicans 95-68, displaying overexpression of CDR1 and CDR2 
genes, in the presence of verapamil and ibuprofen the MIC values of fluconazole, voriconazole 
and posaconazole decreased drastically; as expected for control strain C. albicans 2-76, with low 
levels of resistance genes expression, the MIC values of the three antifungals did not change. 
In the presence of FK506 no synergistic effect was detected for all C. parapsilosis strains 
tested using the agar diffusion method. In Fig. 9, a representative example of this assay with 
BC014RPSC strain is shown. In control plates (no fluconazole added to the medium) neither FK506 
nor its solvent was able to inhibit Candida growth, which demonstrates that such compound 
does not exhibit antifungal activity. Regarding BC014RPSC no synergistic effect was observed at 
any FK506 concentration tested. As expected for C. albicans 95-68, with overexpression of CDR1 
and CDR2 genes (ATP-dependent efflux pumps), a clear synergistic effect was observed. 
 
RH-6G STAINING 
The steady state regarding Rh-6G fluorescence of the susceptible phenotype (strains 
incubated in drug-free medium) and of the resistant phenotypes obtained after 30 days of 
antifungal exposure (in vitro induction studies) were compared. Similar intensity of fluorescence 
was obtained with induced resistant strains and susceptible strains (Fig. 10a depicts a 
representative example for BC014S and BC014RFLC strains). The fluorescence intensity did not 
increase in the presence of the efflux blocker verapamil (data not shown).  
The final strain (BCA3) and the initial strain (BCA1) from in vivo induction (case report A) were 
also compared by flow cytometric analysis and similar results were obtained (data not shown). 
Candida albicans strain 95-68, with overexpression of CDR1 and CDR2 resistance genes 
(ATP-dependent efflux pumps), behaved as expected, showing an increase in Rh-6G staining 
when incubated with verapamil (Fig. 10b), whereas C. albicans strain 2-76 showing low levels of 
efflux genes expression did not (data not shown), which validates the assays.  
R
ES
U
LT
S 
 9
0 
 
 
Ta
b
le
 6
. M
IC
 v
al
u
e 
(µ
g.
m
l-1
) 
an
d
 p
h
e
n
o
ty
p
e 
d
is
p
la
ye
d
 b
y 
C
a
n
d
id
a
 p
a
ra
p
si
lo
si
s 
af
te
r 
in
d
u
ct
io
n
 w
it
h
 f
lu
co
n
az
o
le
 (
B
C
0
1
4
R
FL
C
 s
tr
ai
n
),
 v
o
ri
co
n
az
o
le
 (
B
C
0
1
4
R
V
R
C
 s
tr
ai
n
) 
an
d
 p
o
sa
co
n
az
o
le
 
(B
C
0
1
4
R
P
SC
 s
tr
ai
n
) 
an
d
 o
f 
C
. 
a
lb
ic
a
n
s 
9
5
-6
8
 a
n
d
 C
. 
a
lb
ic
a
n
s 
2
-7
6
 s
tr
ai
n
s,
 d
et
er
m
in
ed
 in
 t
h
e 
ab
se
n
ce
 a
n
d
 t
h
e 
p
re
se
n
ce
 o
f 
th
e 
ef
fl
u
x 
m
o
d
u
la
to
rs
 v
er
ap
am
il 
(V
er
a)
 1
0
0
 µ
M
 a
n
d
 ib
u
p
ro
fe
n
 
(I
b
u
) 
1
0
0
 m
g.
l-1
. 
M
IC
/P
h
e
n
o
ty
p
e
 
St
ra
in
s 
Fl
u
co
n
az
o
le
 
Fl
u
co
n
az
o
le
 
+ 
V
e
ra
 
Fl
u
co
n
az
o
le
 
+ 
Ib
u
 
V
o
ri
co
n
az
o
le
 
V
o
ri
co
n
az
o
le
 
+ 
V
e
ra
 
V
o
ri
co
n
az
o
le
 
+ 
Ib
u
 
P
o
sa
co
n
az
o
le
 
P
o
sa
co
n
az
o
le
   
 
+ 
V
e
ra
 
P
o
sa
co
n
az
o
le
 
+ 
Ib
u
 
B
C
0
1
4
R
FL
C
 
1
2
8
/R
 
6
4
/R
 
1
2
8
/R
 
4
/R
 
2
/S
-D
D
 
4
/R
 
0
.5
/S
 
0
.2
5
/S
 
0
.5
/S
 
B
C
0
1
4
R
V
R
C
 
1
2
8
/R
 
6
4
/R
 
1
2
8
/R
 
4
/R
 
2
/S
-D
D
 
4
/R
 
0
.5
/S
 
0
.2
5
/S
 
0
.5
/S
 
B
C
0
1
4
R
P
SC
 
1
2
8
/R
 
1
2
8
/R
 
1
2
8
/R
 
1
6
/R
 
1
6
/R
 
1
6
/R
 
3
2
/S
 
3
2
/S
 
3
2
/S
 
C
. 
a
lb
ic
a
n
s 
9
5
-6
8 
>5
1
2
/R
 
1
2
8
/R
 
1
6
/S
-D
D
 
6
4
/R
 
1
6
/R
 
0
.5
/S
 
>1
6
/R
 
8
/R
 
0
.5
/S
 
C
. 
a
lb
ic
a
n
s 
2
-7
6 
0
.5
/S
 
0
.5
/S
 
0
.5
/S
 
0
.1
2
5
/S
 
0
.1
2
5
/S
 
0
.1
2
5
/S
 
0
.0
6
/S
 
0
.0
6
/S
 
0
.0
6
/S
 
   
   
  
      
 Figure 9. Disk diffusion assays with 
(BC014RPSC) in the presence of FK506. 
efflux pumps) and BC014RPSC strain 
dilutions of FK506 (0.1, 1.0, 10 and 100 mg.ml
µg.ml
-1
) (right panel) or in its absence (left panel).
 
 
        
Figure 10. Flow cytometric histograms
analysis at FL1 (515 nm) of BC014S strain incubated in drug
cytometric analysis at FL1 (515 nm) of resistant 
efflux pumps) without (A) and with (B) the efflux blocker verapamil. af, autofluorescence.
 
 
 
 
 
Candida albicans 95-78 control strain and C. parapsilosis 
C. albicans 95-78 control strain (with overexpression of genes that codify to 
were grown on YEPD agar medium with paper disks 
-1
) and DMSO (S-solvent), in the presence of fluconazole (FLC 128 
 
 of yeast cells after Rh-6G staining (efflux pumps substrate
-free medium (A) and of BC014R
Candida albicans 95-68 strain (overexpression of genes that codify to 
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). (a) Flow cytometric 
FLC strain (B). (b) Flow 
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GENE SEQUENCING ANALYSIS 
To determine whether resistance was associated with mutations in the target genes, 
genomic DNA extraction was performed and several genes were amplified and sequenced.  
No sequence alterations were detected in ERG11 gene when comparing the susceptible 
strain (BCA1) and the resistant strain (BCA3) from the in vivo case. 
Regarding the sequence of MRR1 gene in BC014RFLC and BC014RVRC, a single nucleotide 
exchange was detected in both strains, when comparing with the MRR1 sequence of the 
susceptible strain (BC014S). Regarding  BC014RFLC strain, a substitution of G1747A in BC014RFLC 
strain, results in an amino acid exchange G583R (glycine to arginine). In BC014RVRC strain, a 
different mutation was found, A2619C, which results in the substitution of a lysine by an 
asparagine (K873N). 
To determine whether the overexpression of the transcription factors NDT80 and UPC2  is 
associated with point mutations, the genes were sequenced both in BC014RPSC and BC014S 
strains. No difference in the nucleotide sequence was detected between the susceptible 
(BC014S) and the BC014RPSC strains. 
MIC values concerning echinocandins for the six nonsusceptible clinical strains are 
represented in Table 7. No sequence alterations were observed in HS1 region of the FKS1 gene 
for all strains, independently of the susceptibility phenotype for each echinocandin. Additionally, 
no sequence alterations were detected between the susceptible strain (BC041S) and the 
nonsusceptible strain (BC041NS) obtained from the in vitro induction assay. 
 
Table 7. MIC value (µg.ml
-1
) and susceptibility phenotype 
displayed by C. parapsilosis strains to echinocandins. 
 MIC/Phenotype
a 
Strain CSF ANF MCF 
BC011 4/NS 1/S 2/S 
BC017 4/NS 8/NS 2/S 
BC022 4/NS 8/NS 8/NS 
BC043 8/NS 2/S 2/S 
BC101 4/NS 4/NS 4/NS 
BC132 4/NS 2/S 2/S 
                                                                                         aS, susceptible (MIC ≤2 µg.ml-1); NS, nonsusceptible. 
 
 
 
 MICROARRAYS (1) WITH IN VITRO
 
TRANSCRIPTIONAL PROFILING
In order to identify genes that are differentially regulated in 
we performed transcriptional profiling experiments using genomic microarrays.
Microarray analysis identified differential expression (FC >2, p <
regulated and 533 down-regulated), 210 (138 up
(341 up-regulated and 257 down
respectively (Fig. 11a; the data is available in Tab
distribution of genes with differential expression in  
were the strains with similar expression gene profiles.
 
Figure 11. Distribution of genes with differential 
BC014RFLC and BC014RVRC strains (b)
 
GENE ONTOLOGY ANALYSIS
Gene Ontology (GO) analysis was used to identify similarities and differences between the 
resistant strains obtained after exposition to the different antifungals. GO terms assigned to 
both process and function analyses were used, and the process analysis 
results. The large number of genes affected makes it difficult to identify overrepresented 
categories. Figure 12 represents the processes overrepresented in 
the up-regulated genes are associated with RN
10% are associated with translation
 INDUCED STRAINS 
 
C. parapsilosis 
0.05) of 1128 (595 up
-regulated and 72 down-
-regulated) genes in BC014RFLC, BC014RVRC and BC014R
les S1-S3). Figure 1
BC014RFLC and BC014R
 
expression in BC014RFLC, BC014RVRC  and BC014R
.  
 
provided more relevant 
BC014RFLC
A metabolic process and ribosome biogenesis and 
. GO terms overrepresented in BC014RVRC
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-
regulated) and 598 
PSC strains 
1b represents the 
VRC strains, which 
 
PSC strains (a) and in 
 strain; up to 13% of 
 and BC014RPSC are 
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detailed in Table 8 (and Table S4). In BC014RVRC GO term associated with response to chemical 
stimulus is overrepresented, while in the BC014RPSC strain the GO terms associated with sterol 
biosynthesis, response to chemical stimulus and response to drugs are overrepresented. 
 
Figure 12. Selected process GO terms overrepresented in BC014RFLC strain. The full list is available in Table S1. 
 
Table 8. GO terms overrepresented in BC014RVRC and BC014RPSC strains. 
Cluster 
frequency
a
 
Background 
frequency
b
 
Corrected       p-
value 
GO term 
BC014RVRC    
   31/155 504/5085 0.0322 Response to chemical stimulus 
BC014RPSC    
   19/409 32/5085 1.17E-10 Sterol biosynthesis 
   70/409 504/5085 0.0014 Response to chemical stimulus 
   50/409 310/5085 0.0007 Response to drugs 
 aCluster frequency: fraction of genes that are differentially regulated with homologs identified in C. albicans 
assigned to GO term. 
bBackground frequency: fraction of entire dataset with homologs identified in C. albicans assigned to GO term. 
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GENE EXPRESSION PROFILE OF BC014RFLC AND BC014RVRC STRAINS 
Because BC014RFLC and BC014RVRC strains displayed a similar resistance profile, the genes 
that were differentially regulated in both strains were identified (Fig. 11b: 130 genes, 
representing 62% of total genes in BC014RVRC). Figure 13 shows the gene distribution into 5 
clusters distinguished by the level of gene expression (all members of the clusters are listed in 
Table S5, following the same order depicted in Fig. 13). Clusters 1, 2 and 3 contain genes with 
increased expression in BC014RFLC and BC014RVRC strains; cluster 3 showed the greatest change 
in gene expression (Table 9 describes the genes contained in these 3 clusters which included its 
description and FC value).  
Cluster 2 contains MDR1 and CPAG_03790 genes, both members of the major facilitator 
superfamily (MFS) of multidrug transporters. Expression of a third member of the MFS family 
(CPAG_01932) was also increased, albeit in a lesser extent (cluster 1, Fig. 13, Table 9). Expression 
of MDR1 is up-regulated by 19.43- and 40.22-fold in the BC014RFLC and BC014RVRC strains, 
respectively (confirmed by RT-qPCR; Fig.16). In C. albicans, expression of MDR1 is regulated by 
the transcription factor MRR1 [214]. Interestingly, expression of MRR1 is also up-regulated in     
C. parapsilosis BC014RFLC and BC014RVRC strains (Cluster 1; Fig. 13 and Table 9); this finding was 
confirmed by RT-qPCR (Fig.16). 
The expression of aldo-keto reductases and other genes associated with oxidative stress 
response is also regulated by Mrr1p transcription factor in C. albicans [214]. We observed a 
similar response in C. parapsilosis. Expression of several putative aldo-keto reductases and 
NADPH oxidoreductases (orthologs of orf19.3442, OYE32) is increased in both BC014RFLC and 
BC014RVRC strains (Clusters 1 and 2, Fig. 13, Table 9). Cluster 3 contains the stress response gene 
GRP2, which is up-regulated 107.63- and 207.94-fold in BC014RFLC and BC014RVRC strains, 
respectively (confirmed by RT-qPCR; Fig.16); the second member of cluster 3, CPAG_02538 gene, 
has a high sequence identity to GRP2, and therefore is likely to encode for a protein in the same 
family.  
Genes in cluster 4 are differentially regulated in the BC014RFLC and BC014RVRC strains, and 
are unlikely to play a role in azole resistance. Genes in cluster 5 are down-regulated in both 
strains. These include several genes linked to ergosterol synthesis (named below). 
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Figure 13. Cluster analysis of 130 genes that are differentially expressed in both BC014R
cluster is represented by a different number, and the members of each cluster are listed in Table S5. The genes 
identified as C. albicans orthologs are shown. Genes with decreased and increased expression are marked in yellow 
and blue, respectively. Genes with unchanged
side of the figure shows the distribution of the differentially expressed genes based on their logFC levels. The X axis 
represents the logFC levels in the heat
“value” or differential expression level. 
 
FLC and BC014R
 expression are marked in black. The histogram in the upper and left 
map. The Y (labeled as count) axis shows how many genes have a specific 
 
 
VRC strains. Each 
R
ES
U
LT
S 
9
7 
 
Ta
b
le
 9
. G
e
n
es
 w
it
h
 in
cr
ea
se
d
 e
xp
re
ss
io
n
 in
 B
C
0
1
4
R
FL
C
 a
n
d
 B
C
0
1
4
R
V
R
C
 s
tr
ai
n
s 
fr
o
m
 F
ig
. 1
3
. 
C
P
A
G
 
ID
a
 
C
. 
a
lb
ic
a
n
s 
h
o
m
o
lo
gb
 
G
e
n
e
 n
am
e
c  
D
e
sc
ri
p
ti
o
n
c  
B
C
0
1
4
R
FL
C
d
 
B
C
0
1
4
R
V
R
C
d
 
C
lu
st
e
r 
1
 
 
 
 
 
C
P
A
G
_0
0
1
6
8
 
o
rf
1
9
.7
3
0
6
 
 
A
ld
o
-k
et
o
 r
ed
u
ct
as
e 
fa
m
ily
 
5
.6
2
 
8
.5
1
 
C
P
A
G
_0
0
9
7
1
 
o
rf
1
9
.2
4
4
6
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
5
.7
8
 
7
.7
3
 
C
P
A
G
_0
2
1
9
2
 
o
rf
1
9
.6
0
0
0
* 
 
M
u
lt
id
ru
g 
tr
an
sp
o
rt
er
 o
f 
A
TP
-b
in
d
in
g 
ca
ss
et
te
 (
A
B
C
) 
su
p
er
fa
m
ily
 
5
.9
4
 
9
.5
8
 
cp
ar
4
4
1
7
 
o
rf
1
9
.6
9
4
3
* 
 
U
n
ch
ar
ac
te
ri
ze
d
 
4
.6
9
 
7
.1
1
 
C
P
A
G
_0
2
8
7
5
 
o
rf
1
9
.7
3
7
2
 
M
R
R
1
 
R
eg
u
la
to
r 
o
f 
M
D
R
1
 t
ra
n
sc
ri
p
ti
o
n
 
5
.2
4
 
5
.7
0
 
C
P
A
G
_0
1
1
7
4
 
o
rf
1
9
.3
4
5
 
 
 
9
.1
9
 
9
.0
0
 
C
P
A
G
_0
4
6
7
1
 
 
 
 
9
.7
1
 
6
.8
2
 
C
P
A
G
_0
4
7
3
0
 
o
rf
1
9
.6
5
8
6
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
6
.7
7
 
1
0
.9
3
 
C
P
A
G
_0
2
7
5
2
 
o
rf
1
9
.5
5
1
7
* 
 
A
lc
o
h
o
l d
eh
yd
ro
ge
n
as
es
 
6
.8
2
 
8
.5
7
 
C
P
A
G
_0
1
9
3
2
 
o
rf
1
9
.5
6
0
4
* 
 
M
em
b
er
 o
f 
th
e 
M
D
R
 f
am
ily
 o
f 
m
aj
o
r 
fa
ci
lit
at
o
r 
tr
an
sp
o
rt
er
 s
u
p
er
fa
m
ily
 
7
.4
1
 
5
.0
6
 
C
P
A
G
_0
1
1
7
3
 
o
rf
1
9
.5
8
6
0
* 
 
U
n
ch
ar
ac
te
ri
ze
d
 
6
.5
4
 
4
.6
3
 
C
P
A
G
_0
1
3
1
7
 
o
rf
1
9
.5
8
0
6
 
A
LD
5
 
A
ld
e
h
yd
e 
d
e
h
yd
ro
ge
n
as
e
 
3
.1
2
 
4
.7
2
 
C
P
A
G
_0
3
0
3
9
 
o
rf
1
9
.6
3
4
8
 
 
N
o
t 
es
se
n
ti
al
 f
o
r 
vi
ab
ili
ty
 
3
.1
6
 
4
.5
0
 
C
P
A
G
_0
3
0
4
0
 
o
rf
1
9
.6
3
4
9
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
3
.6
3
 
3
.9
2
 
C
P
A
G
_0
0
5
3
6
 
o
rf
1
9
.9
0
9
 
S
T
P
4
 
P
u
ta
ti
ve
 t
ra
n
sc
ri
p
ti
o
n
 f
ac
to
r 
3
.3
4
 
4
.6
6
 
R
ES
U
LT
S 
 9
8 
 
C
P
A
G
 
ID
a
 
C
. 
a
lb
ic
a
n
s 
h
o
m
o
lo
gb
 
G
e
n
e
 n
am
e
c  
D
e
sc
ri
p
ti
o
n
c  
B
C
0
1
4
R
FL
C
d
 
B
C
0
1
4
R
V
R
C
d
 
C
P
A
G
_0
1
9
0
8
 
o
rf
1
9
.4
9
0
7
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
3
.5
1
 
3
.6
8
 
C
P
A
G
_0
3
6
6
5
 
o
rf
1
9
.1
0
2
7
 
P
D
R
1
6
 
P
h
o
sp
h
at
id
yl
in
o
si
to
l t
ra
n
sf
e
r 
p
ro
te
in
 
5
.1
7
 
3
.6
8
 
C
P
A
G
_0
4
2
6
3
 
o
rf
1
9
.7
2
3
5
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
3
.9
2
 
3
.7
6
 
C
P
A
G
_0
4
7
6
1
 
o
rf
1
9
.7
1
6
6
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.9
7
 
6
.7
7
 
C
P
A
G
_0
3
2
1
5
 
o
rf
1
9
.4
6
0
9
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
3
.4
8
 
5
.1
3
 
C
P
A
G
_0
5
1
7
6
 
o
rf
1
9
.3
1
3
1
 
O
Y
E
3
2
 
N
A
D
(P
)H
 o
xi
d
o
re
d
u
ct
as
e
 
2
.6
9
 
8
.7
5
 
C
P
A
G
_0
3
2
8
4
 
o
rf
1
9
.4
8
8
6
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
3
.7
6
 
7
.4
6
 
C
P
A
G
_0
2
1
8
3
 
o
rf
1
9
.6
6
7
1
 
LA
P
4
 
Si
m
ila
r 
to
 a
m
in
o
p
e
p
ti
d
as
e 
I 
2
.5
5
 
3
.1
2
 
C
P
A
G
_0
0
2
3
4
 
o
rf
1
9
.3
6
6
1
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.6
0
 
2
.8
9
 
C
P
A
G
_0
0
9
0
5
 
o
rf
1
9
.3
0
4
5
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.6
8
 
2
.5
5
 
C
P
A
G
_0
3
6
3
1
 
o
rf
1
9
.6
8
3
8
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.2
5
 
3
.1
4
 
C
P
A
G
_0
0
6
6
8
 
o
rf
1
9
.2
7
2
6
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.1
3
 
2
.6
2
 
C
P
A
G
_0
2
7
1
0
 
o
rf
1
9
.3
4
4
2
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
1
.9
0
 
2
.9
1
 
C
P
A
G
_0
3
8
8
8
 
o
rf
1
9
.1
6
6
3
 
M
N
T
2
 
A
lp
h
a-
1
,2
-m
an
n
o
sy
l t
ra
n
sf
er
as
e
 
2
.4
4
 
2
.1
6
 
C
P
A
G
_0
3
1
4
8
 
o
rf
1
9
.4
5
9
2
 
H
S
X
1
1
 
U
D
P
-g
lu
co
se
:c
er
am
id
e 
gl
u
co
sy
lt
ra
n
sf
er
as
e
 
2
.2
5
 
1
.9
9
 
C
P
A
G
_0
2
0
4
4
 
o
rf
1
9
.1
1
3
9
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.1
0
 
2
.4
1
 
C
P
A
G
_0
0
1
2
3
 
o
rf
1
9
.5
6
1
1
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
1
.9
9
 
2
.1
7
 
C
P
A
G
_0
0
5
6
3
 
 
 
 
1
.9
3
 
2
.3
6
 
C
P
A
G
_0
4
3
2
3
 
o
rf
1
9
.6
5
9
4
 
P
LB
3
 
Se
cr
et
e
d
 p
h
o
sp
h
o
lip
as
e 
B
 
3
.8
9
 
2
.5
3
 
R
ES
U
LT
S 
9
9 
 
C
P
A
G
 
ID
a
 
C
. 
a
lb
ic
a
n
s 
h
o
m
o
lo
gb
 
G
e
n
e
 n
am
e
c  
D
e
sc
ri
p
ti
o
n
c  
B
C
0
1
4
R
FL
C
d
 
B
C
0
1
4
R
V
R
C
d
 
C
P
A
G
_0
5
2
9
6
 
o
rf
1
9
.1
2
4
0
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.8
3
 
2
.6
6
 
cp
ar
7
4
4
 
o
rf
1
9
.7
3
7
2
* 
 
Zn
-f
in
ge
r 
tr
an
sc
ri
p
ti
o
n
 f
ac
to
r,
 r
el
at
ed
 t
o
 
M
rr
1
 (
p
ar
ti
al
) 
3
.4
6
 
2
.0
0
 
C
P
A
G
_0
2
6
3
9
 
o
rf
1
9
.1
8
3
9
 
R
P
A
1
9
0
 
U
n
ch
ar
ac
te
ri
ze
d
 
5
.1
3
 
2
.1
6
 
C
P
A
G
_0
2
9
2
7
 
o
rf
1
9
.4
3
9
3
 
C
IT
1
 
C
it
ra
te
 s
yn
th
as
e
 
3
.1
6
 
2
.6
8
 
C
P
A
G
_0
3
9
8
1
 
o
rf
1
9
.4
6
8
8
 
D
A
G
7
 
U
n
ch
ar
ac
te
ri
ze
d
 
3
.5
6
 
2
.8
5
 
C
P
A
G
_0
5
6
4
5
 
o
rf
1
9
.4
3
7
7
 
K
R
E
1
 
P
re
d
ic
te
d
 G
P
I-
an
ch
o
r,
 r
o
le
 in
 1
,6
-b
et
a-
D
-
gl
u
ca
n
 b
io
sy
n
th
es
is
 
3
.7
6
 
2
.1
7
 
C
P
A
G
_0
4
4
5
8
 
o
rf
1
9
.2
8
2
9
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.7
9
 
2
.1
6
 
C
P
A
G
_0
3
6
1
5
 
o
rf
1
9
.7
5
6
 
S
A
P
7
 
Se
cr
et
e
d
 a
sp
ar
ty
l p
ro
te
in
as
e
 
2
.5
5
 
2
.1
6
 
C
P
A
G
_0
0
6
6
9
 
o
rf
1
9
.2
7
2
4
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.1
0
 
2
.2
6
 
C
P
A
G
_0
0
7
3
0
 
o
rf
1
9
.6
5
5
* 
 
H
ig
h
-a
ff
in
it
y 
p
h
o
sp
h
at
e 
tr
an
sp
o
rt
er
s 
2
.5
1
 
2
.1
7
 
C
P
A
G
_0
2
1
5
2
 
o
rf
1
9
.9
3
2
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
2
.5
5
 
3
.4
3
 
C
P
A
G
_0
4
0
5
6
 
o
rf
1
9
.1
4
3
0
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
1
.8
8
 
3
.3
9
 
C
P
A
G
_0
4
2
9
4
 
o
rf
1
9
.4
7
6
5
 
P
A
G
6
 
P
u
ta
ti
ve
 G
P
I-
an
ch
o
re
d
 c
el
l-
w
al
l p
ro
te
in
 
2
.2
5
 
2
.0
7
 
C
P
A
G
_0
3
8
6
8
 
o
rf
1
9
.5
3
8
3
 
P
M
A
1
 
P
la
sm
a 
m
em
b
ra
n
e 
H
(+
)-
A
TP
as
e;
 
fl
u
co
n
az
o
le
 in
d
u
ce
d
 
2
.1
9
 
2
.0
7
 
C
lu
st
e
r 
2
 
 
 
 
 
 
C
P
A
G
_0
2
1
2
2
 
o
rf
1
9
.3
5
4
4
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
3
2
.2
2
 
3
5
.0
2
 
C
P
A
G
_0
3
9
6
3
 
o
rf
1
9
.5
6
0
4
 
M
D
R
1
 
M
em
b
er
 o
f 
th
e 
M
D
R
 f
am
ily
 o
f 
m
aj
o
r 
fa
ci
lit
at
o
r 
tr
an
sp
o
rt
er
 s
u
p
er
fa
m
ily
 
1
9
.4
3
 
4
0
.2
2
 
R
ES
U
LT
S 
 1
00
 
 
C
P
A
G
 
ID
a
 
C
. 
a
lb
ic
a
n
s 
h
o
m
o
lo
gb
 
G
e
n
e
 n
am
e
c  
D
e
sc
ri
p
ti
o
n
c  
B
C
0
1
4
R
FL
C
d
 
B
C
0
1
4
R
V
R
C
d
 
C
P
A
G
_0
0
5
0
6
 
o
rf
1
9
.5
5
1
7
 
 
A
lc
o
h
o
l d
eh
yd
ro
ge
n
as
es
 
2
2
.6
3
 
2
9
.4
5
 
C
P
A
G
_0
0
9
7
8
 
o
rf
1
9
.3
2
0
 
 
U
n
ch
ar
ac
te
ri
ze
d
 
1
8
.3
8
 
2
4
.4
2
 
C
P
A
G
_0
0
4
7
8
 
o
rf
1
9
.2
8
1
2
* 
 
M
em
b
er
 o
f 
o
rf
1
9
.3
0
8
 f
am
ily
 
1
1
.7
1
 
2
1
.8
6
 
C
P
A
G
_0
3
7
9
0
 
o
rf
1
9
.5
6
0
4
* 
 
M
em
b
er
 o
f 
th
e 
M
D
R
 f
am
ily
 o
f 
m
aj
o
r 
fa
ci
lit
at
o
r 
tr
an
sp
o
rt
er
 s
u
p
er
fa
m
ily
 
2
1
.7
0
 
9
.5
8
 
C
P
A
G
_0
3
9
9
4
 
o
rf
1
9
.2
6
9
3
* 
 
G
ST
2
/U
R
E2
 f
am
ily
 
6
.1
9
 
3
0
.9
1
 
C
P
A
G
_0
3
6
3
6
 
o
rf
1
9
.7
7
1
 
LP
G
2
0
 
A
ld
o
-k
et
o
 r
ed
u
ct
as
e 
fa
m
ily
 
6
.5
0
 
2
2
.6
3
 
C
P
A
G
_0
4
3
2
2
 
o
rf
1
9
.6
5
9
4
 
 
Se
cr
et
e
d
 p
h
o
sp
h
o
lip
as
e 
B
 
3
.9
2
 
1
5
.8
9
 
C
lu
st
e
r 
3
 
 
 
 
 
 
C
P
A
G
_0
2
1
8
2
 
o
rf
1
9
.4
3
0
9
 
G
R
P
2
 
Si
m
ila
r 
to
 S
. c
er
ev
is
ia
e 
G
re
2
p
 
(m
et
h
yl
gl
yo
xa
l r
ed
u
ct
as
e)
 
1
0
7
.6
3
 
2
0
7
.9
4
 
C
P
A
G
_0
2
5
3
8
 
o
rf
1
9
.4
3
0
9
* 
 
Si
m
ila
r 
to
 S
. c
er
ev
is
ia
e 
G
re
2
p
 
(m
et
h
yl
gl
yo
xa
l r
ed
u
ct
as
e)
 
7
1
.5
1
 
1
4
8
.0
6
 
a
C
P
A
G
 ID
 f
ro
m
 g
en
o
m
e 
an
n
o
ta
ti
o
n
 o
f 
C
. 
p
a
ra
p
si
lo
si
s 
[7
5
].
 W
h
er
e 
n
o
 C
P
A
G
 g
en
e 
h
as
 b
ee
n
 a
n
n
o
ta
te
d
, t
h
e 
cp
ar
 a
n
n
o
ta
ti
o
n
 is
 u
se
d
   
   
   
   
   
   
   
   
   
   
   
   
 (
se
e 
h
tt
p
:/
/c
go
b
.u
cd
.ie
).
 G
en
es
 a
re
 li
st
ed
 in
 t
h
e 
o
rd
e
r 
sh
o
w
n
 in
 F
ig
. 1
3
. 
b
C
. 
a
lb
ic
a
n
s 
o
rt
h
o
lo
gs
 a
re
 id
e
n
ti
fi
ed
 w
h
er
e 
p
o
ss
ib
le
, f
ro
m
 h
tt
p
:/
/c
go
b
.u
cd
.ie
. G
en
es
 w
it
h
 *
 a
re
 h
o
m
o
lo
gs
 b
u
t 
n
o
t 
o
rt
h
o
lo
gs
. 
c C
. 
a
lb
ic
a
n
s 
ge
n
e 
n
am
es
 a
n
d
 d
es
cr
ip
ti
o
n
s 
ar
e 
ta
ke
n
 f
ro
m
 t
h
e 
C
an
d
id
a 
G
en
o
m
e 
D
at
ab
as
e.
 
d
A
ve
ra
ge
 F
C
 in
 g
en
e 
ex
p
re
ss
io
n
. 
 
 GENE EXPRESSION PROFILE OF 
The specific genes which showed the greatest change in gene expression profile of 
BC014RPSC strain are depicted in Table 
We observed an increased expression of the transcription factors 
BC014RPSC, confirmed by RT
C. albicans [139, 215] as transcription factors t
biosynthesis genes. 
Expression of SOD4 gene was also up
confirmed by RT-qPCR; Fig.16). 
 
 ERGOSTEROL BIOSYNTHESIS 
Several genes displayed in the 
ergosterol biosynthesis. Figure 14 represents a simplified ergosterol pathway which depicts the 
genes involved in the process; the regulation level of such genes in 
BC014RPSC strains is shown in Table 11. 
Figure 14. Simplified ergosterol metabolic pathway, as described for 
Genes up-regulated or down-regulated in BC014R
BC014RPSC  STRAIN 
10 (full list is available in Table S3).  
NDT80
-qPCR (Fig. 16). Ndt80p and Upc2p were recently identified in 
hat bind to the promoter regions of ergosterol 
-regulated (2.68-fold) in the BC014R
 
GENES 
expression profiles of the three resistant strains are
BC014R
 
S. cerevisiae (http://www.yeastgenome.org/). 
FLC, BC014RVRC and BC014RPSC strains are indicated in the 
RESULTS 
101 
 and UPC2 in 
            
PSC strain (also 
 linked to 
FLC, BC014RVRC and 
 
Table 11. 
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Table 11.   Genes   from   ergosterol  biosynthesis   process  up-
regulated (+) or down-regulated (-) in BC014RFLC, BC014RVRC and 
BC014RPSC strains. 
 
Gene 
name
a 
BC014FLC
b 
BC014VRC
b 
BC014PSC
b 
ERG13   +3.69 
HMG1   +2.66 
ERG10   +2.91 
ERG9   +2.52 
ERG1 -2.60 -2.28  
ERG7   +2.15 
ERG11 -2.69 -2.01 +2.89 
ERG25 -2.24  +5.52 
ERG24   +4.10 
ERG27   +2.20 
ERG6   +5.24 
ERG2 -2.01  +6.52 
ERG5   +2.10 
ERG3 -4.86  +3.24 
ERG4   +4.14 
 aC. albicans gene names are taken from the Candida Genome Database. 
 bAverage FC in gene expression. 
 
The expression of ERG1 and ERG11 is reduced in BC014RFLC (2.60- and 2.69-fold 
respectively) and in BC014RVRC (2.28- and 2.01-fold respectively). Additionally, the expression of 
ERG2, ERG3 and ERG25 is reduced in BC014RFLC (2.01-, 4.86- and -2.24-fold respectively). The 
expression of ERG11 gene was confirmed for both strains by RT-qPCR (Fig.16).  
In contrast, BC014RPSC strain displayed an over-expression of thirteen genes directly linked 
to ergosterol biosynthesis (Table 11, Fig. 14). The expression of ERG11 and ERG6 genes was 
confirmed by RT-qPCR (Fig.16). 
 
 ANTIFUNGAL TRANSPORTER GENES 
The C. parapsilosis genome encodes at least 14 members of the ABC transporter family 
[75]. The expression of one of these transporters, CPAG_0151, is up-regulated (2.30-fold) in the 
BC014RPSC strain (Table 10). Expression of CPAG_02192, another ABC transporter, is up-regulated 
both in BC014RFLC and BC014RVRC strains (Table 9). Expression of CPAG_03665, an ortholog of     
C. albicans PDR16, is up-regulated 5.17-, 3.68- and 2.93-fold in BC014RFLC, BC014RVRC and 
BC014RPSC strains respectively (Table 9 and Table 10).  
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BC014RFLC and BC014RVRC strains displayed a decreased expression of CPAG_03819 (Fig. 13 
and Table S5); this gene is an ortholog of C. albicans orf19.3902, and its reduced expression is 
correlated with over-expression of CDR1 and CDR2 in C. albicans azole resistant isolates [216]. 
The expression of CPAG_02274 (SNQ2) was down-regulated in BC014RFLC and BC014RVRC strains 
(Fig. 13 and Table S5), while the expression of the other ABC transporter family members 
remained unchanged. 
 
COPPER TRANSPORT AND IRON MOBOLIZATION RELATED GENES 
The expression levels of several genes involved in copper and iron transportation were 
found to be changed in all three azole resistant C. parapsilosis strains: CTR1 (copper transporter; 
4.53-fold) and FRE10 (ferric reductase; 2.08-fold) are up-regulated while CRP1 (copper 
transporter; 30.70-fold) is down-regulated in BC014RFLC strain; FTR1 (iron membrane permease; 
2.25-fold) is down-regulated in BC014RVRC strain; CTR1 (6.32-fold) is up-regulated while CRP1 
(28.25-fold) is down-regulated in BC014RPSC strain (Tables S1-S3).  
Expression of the two genes FLC1 and FLC2 involved in heme uptake [217] is increased 2.28- 
and 2.03-fold, respectively, in the BC014RPSC strain (Table 10).  
 
MICROARRAYS (1) WITH IN VIVO INDUCED STRAIN  
Despite the low quality of the array that compared the susceptible strain (BCA1) with the 
resistant strain (BCA3) from the in vivo case, relevant data could be extracted. Microarray analysis 
revealed 198 genes (150 up-regulated and 48 down-regulated) differently expressed (all genes 
are listed in Table S6). GO analysis of processes is represented in Fig. 15; up to 27% of the up-
regulated genes are associated with membrane transport. The total number of genes displaying 
expression changes is much lower than the number revealed by microarray analysis of BC014S 
versus BC014RFLC strains. Moreover, the processes showing up- and down-regulation in the in 
vivo resistant strain are quite different comparing to the in vitro induced resistant strains. 
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Figure 15. Selected process GO terms overrepresented (up
in Table S6. 
 
GENE EXPRESSION 
The expression level of certain genes involved in azole resistance mechanisms and 
that were found altered in microarray analysis of BC014R
was assessed by RT-qPCR. Results are presented in Fig. 1
expression results obtained with microarray assays, already mentioned throughout the 
Regarding the in vivo strains, the expression of 
BCA3 strain was quantified (Fig. 17).  The e
 
 
- and down-regulated) in BCA3 strain. The full list is available 
FLC, BC014RVRC and BC014R
6. These results confirm the gene 
ERG11, ERG6, NDT80 and 
xpression level for resistant strain is higher.
 
others 
PSC strains 
text.  
UPC2 genes for 
 
 Figure 16. RT-qPCR analysis of genes implicated in antifungal resistance (
response (GRP2) and metabolism (
bars represents BC014RFLC (a), BC014R
the large variance in gene expression levels. The expression level shown f
gene expression relative to the susceptible strain and is expressed as average with standard deviation of five 
independent experiments.  Each mean value was normalized to the amplification efficiency and to the amou
TUB4 (endogenous reference gene). All genes displayed similar levels of expression to microarrray results.
                                  
Figure 17. RT-qPCR analysis of ERG11, ERG6, NDT80 and UPC2
strain (BCA1) and the blue ligth bar represent
represents the variation in gene expression relative to the susceptible strain and is expressed as average 
standard deviation of five independent experiments. The mean value was normalized to the amplification efficiency 
and to the amount of TUB4 (endogenous reference gene). 
microarrray results.  
 
ERG5, ERG11, MDR1
ALD5, RPL82). Blue dark bars represent the susceptible strain (BC014S); blue ligth
VRC (b) and BC0114RPSC (c) resistant strains. The y axe scale is logarithimic due to 
or each gene represents the variation in 
 
 genes. The blue dark bar represents the susceptible 
s the resistant strain (BCA3). The expression level shown for the gene 
All genes displayed similar levels of expression to 
RESULTS 
107 
, MRR1, NTD80), stress 
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SUSCEPTIBILITY TO PHYSICAL AND CHEMICAL AGENTS 
 
ANTIFUNGAL ACTIVITY OF PHYSICAL AGENTS 
The effect of heating at 60ºC, microwave and ultraviolet irradiation against C. parapsilosis 
strains is shown in Fig. 18. Graphics were obtained after plotting the number of CFUs obtained 
after a specific time of treatment.  After 5 min of exposure at 60ºC the number of CFUs 
decreased 3 log for clinical and environmental strains. After 45 min the number decreased 5 log 
for clinical strains and 4 log for environmental strains. Regarding microwave irradiation 
treatment, after 20 and 40 s of exposure, the reduction is scarse independently the strains 
origin, however, after 60 s and 90 s the reduction was 3 log for clinical strains and 5 log for 
environmental strains. When exposed to ultraviolet irradiation there was a reduction of 1 log 
after 2 min for clinical strains and 3 min for environmental strains. With the maximum time of 
exposure (10 min) the reduction among clinical strains was higher than the reduction of 
environmental strains (7 and 4 log, respectively).     
 
ANTIFUNGAL ACTIVITY OF CHEMICAL AGENTS  
The results of in vitro susceptibility of C. parapsilosis strains to chemical agents (pure 
compounds) are shown in Table 12; for each chemical agent MIC and MLC values range is 
represented. No significant differences were found regarding the antifungal effect of chemical 
agents against clinical and environmental strains. The concentrations of 0.06% of chlorhexidine, 
10% of ethanol, 2.5% of sodium hypochlorite, 0.06% of hydrogen peroxide, 0.1% of potassium 
permanganate and 1% of acid boric, inhibited all C. parapsilosis strains growth, independently of 
its endogenous or exogenous origin. Due to the proximity between MIC and MLC values (only 
one or two dilutions apart) all chemical seems to have a fungicidal effect upon C. parapsilosis.  
 
Table 12.  MIC  and  MLC values range for chemical agents (pure 
compounds) against all 16 C. parapsilosis strains. 
Chemical agent MIC range (%) MLC range (%) 
Chlorhexidine 0.004-0.06 0.008-0.06 
Ethanol  5-10 5-10 
Sodium hypochlorite  0.625-2.5 0.625-2.5 
Hydrogen peroxide  0.03 0.06 
Potassium permanganate  <0.0008-0.1 0.0015-0.1 
Acid Boric  0.125-0.25 0.25-1 
  
                        
Figure 18. Effect of heating at 60º
clinical ( ) and environmental (
number of CFUs for all strains.  
 
Figure 19 depicts the result of the time
C. parapsilosis strains. No differences 
Handscrub, Aniosgel 85 NPC and Solution Dakin 
Considering the MLC values achieved
(chlorhexidine 0.4%) and Angiosgel 85 NPC (
solution concentration is higher than 
Hydrogen Peroxide 3% and Acid Boric 3%
concentration is higher than MLC values it 
 
C (a), microwave irradiation (b) and ultraviolet irradiation (c) upon the survival
) C. parapsilosis strains. Each point represents the geometric mean
-kill assays with commercial solutions
were found between clinical and environmental strains
revealed to be the most active compounds. 
 with the pure coumponds, the results
ethanol 70%) solutions were expected, since the 
MLC values. Conversely, the results obtained with 
 were quite different; despite
could not kill all cells at least in 30 min; 
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 of the 
 for all 16        
. 
 
 with Handscrub 
 the solution 
Solution Dakin 
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(0.5% sodium hypochlorite) and
concentration than MLC values (the highes
 
Figure 19. Effect of different commercial solutions upon the reduction of 
time.  Growth inhibition was determined comparing the test plates with control plates unexposed to solutions 
(contact time 0). a, Hanscrub; b, Aniosgel 85 NPC; c, Solution Dakin; d, Hydrogen Peroxide; e, Potassium 
Permanganate; and f, Acid Boric. 
 
 
 
 
 
 
 Potassium Permanganate 0.01% were efficient even 
t value from MLC range).  
C. parapsilosis CFUs according to the contact 
at a lower 
 
 IP STAINING  
The cell membrane lesion resulting from the activity of physical and chemical agents 
(commercial solutions) was characterized by flow cytometry. Regarding physical agents, both 
heating at 60ºC and microwave irradiation caused evident cell membrane
Fig. 20). Regarding chemical agents, only after Hydrogen Peroxide exposure an increase in PI 
stain was observed during time (Fig. 21).
 
 
Table
C. parapsilosis
means)
Treatment with
Heating at 60
Microwave irradiation (90 s)
Ultraviolet irradiation (10 min)
Control live cells 
Dead live cells 
 
 
Figure 20. Propidium iodide staining of 
Histogram obtained by flow cytometric analysis at FL3 (650 nm). af, 
dead cells; and C, treated cells with microwave irradiation for 90 s.
 
 
 lesion (Table 13 and 
 
 13.  Propidium iodide (PI)  staining (%) of one                      
   strain   tested   (values   represent  geometric 
, following treatments with physical agents. 
 PI staining (%) 
ºC (45 min) 89.75±7.12 
 90.54±12.36 
 14.53±2.54 
 1.50±0.45 
 81.38±14.87 
 
one C. parapsilosis strain after treatment with microwave irradiation
autofluorescence; A, control live cells; B, control 
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Figure 21. Propidium iodide staining (%) of one 
Peroxide 3%. 0, control live cells; d, control dead cells.
 
 
EFFICACY OF HYDROGEN PEROXIDE 
In order to evaluate the antimicrobial efficacy of 
system against C. parapsilosis, in vitro
was observed following exposure; such results were obtained both with ATCC and clinical 
strains. For other fungi tested the reduction was also 
in Publication section). 
The MIC value obtained when testing 
peroxide and <0.2 ppm of sylver cations (Table 14). The results concerning other species tested 
are detailed in Table 14. 
The microbicidal activity of 
22 represents the percentage of PI staining cells of 
5 min with the disinfectant; this cell population was significantly stained, meaning that  dead 
was due to membrane lesion induced by exposure to the disinfectant. 
 
 
 
 
 
 
 
C. parapsilosis strain after exposed (at different times) to Hydrogen 
 
DRY-MIST SYSTEM 
hydrogen peroxide/sylver cations dry
 studies were performed. A reduction in growth of 
5 log; for bacteria was 7 log
C. parapsilosis ATCC 22019 was 0.02% of hydrogen 
disinfectant solution was confirmed by flow cytometry. Figure 
C. parapsilosis untreated and treated during 
 
-mist 
5 log 
 (manuscript VII 
 Table 14. Results of susceptibility testing of 
fungal species. For each strain the dilution and the respective concentration of the 
that inhibited growth corresponding to the MIC value
 
Strain 
A. baumannii 
E. coli 
S. aureus 
P. aeruginosa 
E. faecalis 
C. krusei 
C. parapsilosis 
C. albicans 
A. fumigatus 
P. marneffei 
M. tuberculosis 
 
 
 
                           
Figure 22. (a) Histogram obtained by flow cytometric analysis at FL3 (650 nm) of 
propidium iodide, following 5 min of treatment with 
control dead cells; and C, cells treated with 
cells (A) and of cells treated with disinfectant 
 
 
 
disinfectant solution against selected bacterial and 
 is represented.
 
Dilution 
Concentration (hydrogen peroxide % and 
sylver cations ppm)
1:128 0.04 and <0.4 
1:128 0.04 and <0.4 
1:128 0.04 and <0.4 
1:128 0.04 and <0.4 
1:128 0.04 and <0.4 
1:512 0.01 and <0.1 
1:256 0.02 and <0.2 
1:256 0.02 and <0.2 
1:256  0.02 and <0.2 
1:256 0.02 and <0.2 
1:280 0.02 and <0.2 
C. parapsilosis 
disinfectant solution. af, autofluorescence; A, control live cells; B, 
disinfectant solution. (b) Optical microscopy photograph
solution (C).  
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cells stained with 
 of control live 
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VIRULENCE ATTRIBUTES 
 
GROWTH OF STRAINS 
Resistant strain (BC014RPSC
growth capacity at 37ºC.  BC014R
its total growth yield after 24 h to 48 h was higher; nonetheless, the two strains displayed almost 
overlapping growth curves in the lag phase (Fig. 
 
Figure 23. Growth curves of BC014S and BC01
YEPD broth. The growth rate (X) is represent
 
IDENTIFICATION OF COLONY PHENOTYPES
For the susceptible strain BC014S two phenotypes (smooth and crepe) were identified (Fig. 
24a). For the resistant strain BC014R
identified (Fig. 24a). Cells from each phenotype were photographed (Fig. 
BC014RPSC we identified other cell
here smooth phenotype, and myceliated
colonies. Under microscopy, it was evident that the cell morp
considerably (Fig. 25). Whilst the crepe and concentric phenotypes correspond to mostly 
pseudohyphae, cells from the smooth phenotype are small and yeast
of BC014RPSC colonies cells have a pseudohyp
 
 
) was compared to its parent susceptible strain (
PSC strain had a prominent log phase compared to BC014S and 
23). 
 
4RPSC strains. The growth curves were obtained from cultures at 37
s for each strain.  
 
PSC two phenotypes (smooth and concentric) w
25). Moreover, for 
-phase forms, namely white-opaque (Fig. 2
-unmyceliated (Fig. 24c), giving rise to sectored 
hology of the phenotypes varies 
-shaped. In opaque section 
hal form.  
BC014S) for 
ºC in 
ere also 
4b), considered 
  
       
Figure 24. Colony morphotypes of BC014S and BC014R
BC014S strain (up) and from BC014R
unmyceliated form in BC014RPSC strain.
 
To address the frequency of switching, single nonsectored colonies from each morphology 
type were disaggregated, and cells from the individual colonies were plated. In each case, we 
determined the fraction of new colonies (excluding mixed colony types) that resembled the 
parental colony morphology as well as the fraction of spontaneous variants. Figure 26 
summarizes the switching results. Regarding smooth and crepe phenotypes, the majority of the 
new colonies exhibited the same colony morphology seen in the parent colony. The same was 
not observed for the concentric phenotype of BC014R
 
Figure 26. Switching in BC014S (a) and BC014R
emanating from a single non-sectored colony of the indicated morphology are shown in vertical columns. Top bar 
from left to right: (a) smooth and crepe; (b) smooth and concentric. The results 
plates. 
PSC strains. (a) Representative colonies of phenotypes from 
PSC strain (down). (b) White-opaque form in BC014RPSC
 
PSC. 
 
PSC strains (b). The proportion (in percentage) of colony variants 
represent the average results from ten 
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 strain. (c) Myceliated-
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Figure 25. Cells from different colony morphotypes of BC014S and BC014R
magnification (40 X). (a) Smooth phenotype of BC014S strain. (b) Crepe phenotype of BC014S strain. (c) Smooth 
phenotype of BC014RPSC strain. (d) Concentric phenotype of BC014R
BC014RPSC strain. 
 
PSC strains, photographed under the same 
PSC strain. (e) Cells from opaque colonies 
 
of 
 AGAR INVASION 
The effect of phenotype upon agar invasion ability by 
determined. The colonies were photographed and
(Fig. 27). The mass remaining after washi
agar. The crepe phenotype of BC014S strain is the greatest invader, leaving a larger mass of cells 
after washing in the agar; then the concentric phenotype of BC014R
phenotype of both strains, which invades in a much lesser extent.
 
Figure 27.  Agar invasion by the morphotypes of BC014S (a) and BC014R
from stationary-phase cultures of the four phe
30 days. Colonies were photographed before and after removing cells on the surface by washing under running water.
 
 
PSEUDOHYPHAL DEVELOPMENT
Experiments were carried out to assess
paseudohyphae in vitro. Figure 2
producing more numerous and longer pseudohyphal filaments in rich serum
the susceptible parent strain (BC014S)
 
BC014S and BC014R
 then washed off the plate with running water 
ng is an indication of the amount of invasion of the 
PSC and at last the smooth 
 
PSC (b) strains. Equal volumes and cell numbers 
notypes were spotted onto YEPD agar plates and incubated at 30
 
 the capacity of each strain to produce 
8 shows that resistant strain (BC014RPSC
-
.  
RESULTS 
117 
PSC strains was 
 
ºC for 
 
) was capable of 
based medium than 
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Figure 28. Pseudohyphal development
magnification (40 X. Cells were induced to form pseudohyphae by 24 h incubation at 37
containing 10% fetal calf medium. The photographs are representative of the 
 
ADHERENCE 
Flow cytometric results regarding adherence are shown in Fig. 2
strain was higher than BC014S strain. Similar results were obtained with the classic methodology 
(data not shown). 
 
Figure 29.  Adhesion ability (%) displayed by BC014S and BC014R
cytometric assay. Each result is representative of three experiments.
 
 
 of BC014S (a) and BC014RPSC (b) strains photographed under the same 
ºC in RPMI 1640 medium 
whole-mounted microscopic plates.
9. Adherence of BC014R
 
PSC strains to polisterene beads assessed by flow 
 
 
PSC 
 BIOFILM FORMATION 
We determined the ability of the BC014S and BC014R
strain produced more biofilm when compared with BC014R
assays showed similar results.
 
  
Figure 30. Biofilm formation by BC014S and BC014R
the metabolic activity by a XTT assay (b). The values 
three independent biofilms. 
 
ENZYMES EXPRESSION 
Coagulase production was assessed by the
strains. Both strains were coagulase negative (data not shown).
Catalase production for BC014S and BC014R
the presence of hydrogen peroxide 
growth observed for BC014S strain, therefore BC014R
stress.  
 
PSC strains to form biofilm. BC014S 
PSC (Fig. 30). Both the CV and XTT 
 
PSC strains.  The biofilm mass was measured 
represent the mean ± standard deviation 
 classical tube test for BC014S and BC014R
 
PSC strains was assessed by growth inhibition in 
25 mM (Fig. 31). BC014RPSC strain growth is higher that the 
PSC strain supports better the oxidative 
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by CV assay (a) and 
absorvance values, from 
PSC 
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Figure 31. Growth inhibition of BC014S and BC014R
result is representative of three experiments.
 
MICROARRAYS (2): TRANSCRIPTION 
The microarrays platform was used to elucidate the antifungal resistance mechanisms, as 
already described (Antifungal Resistance Mechanisms section
attributes was also extracted from the microarray results. 
Microarray analysis identified 598 genes 
differential expression (FC >2, p 
S3 and the confirmation of expression of certain genes by RT
(Antifungal Resistance Mechanisms section
Groups of genes (filamentous growth, lipid 
pathogenesis, response to stress, interaction with host, pseudohyphal growth, cell budding, cell 
adhesion, biofilm formation and protein catabolic process) associated with fungal virulence were 
found to be overrepresented in the resistant strain. Table 1
available in Table S4). 
 
 
 
 
 
 
 
 
 
 
PSC strains in the presence of hydrogen peroxide 25 mM.
 
PROFILING 
). Information regarding virulence 
 
(341 up-regulated and 257 down
<0.05) in BC014RPSC strain. The full gene list is available in Table 
-qPCR was previously mentioned 
).  
metabolic process, hyphal growth, 
5 details such findings (full list is 
 Each 
-regulated) with 
RESULTS 
121 
 
Table 15. GO terms overrepresend in BC014RPSC strain.  
Cluster 
frequency
a
 
Background 
frequency
a
 
p-value GO term 
50/409  310/5085  7.20E-4  Response to drug 
56/409  393/5058  8.57E-3  Filamentous growth 
70/409 504/5085  1.45E-3  Response to chemical stimulus 
31/409  177/5085  1.93E-2  Pathogenesis 
57/409  413/5085  1.88E-2  Growth 
aCluster frequency: fraction of genes that are differentially regulated with homologs identified in C. albicans 
assigned to GO term; Background frequency: fraction of entire dataset with homologs identified in C. 
albicans assigned to GO term. 
 
CHITIN CONTENT  
 
CFW RESISTANCE 
Susceptible profiles of C. parapsilosis strains included in this study are represented in Table 
16. These strains were screened against CFW to determine its sensitivity to this cell-wall-
damaging agent (Fig. 32). Increased resistance to CFW is indicative of a reduction in cell-wall 
chitin content. Overall, C. parapsilosis strains displayed different sensitivity levels to CFW, 
meaning different amounts in chitin. The sensitivity to CFW is unrelated to the antifungal 
susceptible profile to echinocandins. In vitro induction of echinocandin resistance with 
anidulafungin increased cells chitin content (BC041S versus BC041NS).  
 
Table 16.  MIC  value  (µg.ml
-1
)  and  susceptibility 
phenotype   displayed  by   C. parapsilosis  strains  to 
echinocandins. 
 MIC/Phenotype
a 
Strain CSF ANF MCF 
BC011 4/NS 1/S 2/S 
BC017 4/NS 8/NS 2/S 
BC022 4/NS 8/NS 8/NS 
BC002 2/S 1/S 0.5/S 
BC021 0.5/S 2/S 1/S 
BC034 2/S 0.5/S 0.5/S 
                                                                            aS, susceptible (MIC ≤2 µg.ml-1); NS, nonsusceptible. 
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Figure 32. Sensitivity of Candida parapsilosis
YEPD overnight; serial dilutions corresponding to 10
caspofungin (CSF) 4 µg.ml
-1
  or CFW 50 µg.ml
are echinocandin susceptible strains and
16); BC041S and BC041NS are strains from 
 
FLOW CYTOMETRY 
The results obtained by flow cytometry are detailed in Fig. 
discrepancy in chitin content of control strains, 
content levels measured by a classic methodology 
C. parapsilosis strains tested exhibited different chitin contents, as demonstrated previously 
with CFW. Interestingly, the strain with higher chitin level is nonsusceptible
induced nonsusceptible strain (BC041NS) exhibite
results were consistent with epifluorescence microscopy observations (representative images 
are represented in Fig. 33b). Overall, t
allow establishing a relation between chitin levels and NS phenotype to echinocandins.
 
 
 
 
 strains to Calcofluor White (CFW). C. parapsilosis strains were grown in 
6
-10
2
 yeast cells were spotted in solid medium containing 
-1
 and plates were incubated at 30ºC for 3 days. BC002, BC021 and BC034 
  BC011, BC017 and BC022 are echinocandin nonsusceptible strains
the in vitro induction assay. 
33a. This method revealed the 
SC5314 and Δchs3, which have different chitin 
as already described 
 and the 
d higher chitin level than the parent strain
he quantification of chitin content of all
 
 (see Table 
[146].                                 
in vitro 
. The 
 strains did not 
 
  
Figure 33. Cell wall chitin content of 
with 2.5 µg.ml
-1
 CFW and fluorescence emitted was quantified. (b) Epifluorescence microscopy results. Cells were 
photographed after 25 µg.ml
-1
 CFW staining. 
strains;; BC002, BC021 and BC034 are ec
echinocandin nonsusceptible strains (see Table 16); BC041S and BC041NS are strains from the 
  
Other species (C. glabrata
neoformans) were also evaluated in this study (
paradoxical effect of CFS against 
Publications section. The comparison between species revealed that 
and C. albicans strains showed higher CFW staining, and therefore higher chitin content in the 
cell wall comparing to C. glabrata
chitin level exhibited a paradoxical 
 
Candida parapsilosis strains. (a) Flow cytometry results. Yeast cells were stained 
SC5314 (wild type strain) and  Δchs3 (chitinase deleted strain) are control 
hinocandin susceptible strains and  BC011, BC017 and BC022 are 
, C. tropicalis, C. albicans, C. krusei
Fig. 34). In vitro antifungal susceptibility and 
these clinical isolates can be consulted in 
C. parapsilosis
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Figure 34. Cell wall chitin content of Candida
stained with 2.5 µg.ml
-1
 CFW and fluorescence emitted was quantified by flow cytometry. 
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INCIDENCE AND DISTRIBUTION OF C. PARAPSILOSIS, C. ORTHOPSILOSIS AND                             
C. METAPSILOSIS  
Three distinct species within the C. parapsilosis groups (I, II and III) were previously 
recognized on a molecular basis. Subsequent studies focusing on the level of heterozygosity and 
on the linear and circular forms of the mitochondrial genome of C. parapsilosis support the 
existence of these distinct species [14]. In 2005, after sequencing analysis of several genes, 
groups II and III were reclassified as two new distinct species from C. parapsilosis and were 
named C. orthopsilosis and C. metapsilosis, respectively [84].  
After molecular analysis of a large set of C. parapsilosis isolates (n=175) from a large 
university hospital (Hospital S. João), 91.4% were found to correspond to C. parapsilosis sensu 
stricto, while 2.3% and 2.9% corresponded to C. orthopsilosis and C. metapsilosis, respectively. 
Discrepancies between the results of biochemical identification and molecular analysis were 
found since six isolates (3.4%) corresponded to other distinct species. This fact highlights the 
relevance of complementing traditional biochemistry-based identification methods with         
DNA-based molecular assays such as PCR, since such tests provide a much higher discriminatory 
powers. These results improve the knowledge about the national distribution of C. parapsilosis 
sensu stricto, C. orthopsilosis, and C. metapsilosis. Lockhart et al. [87] had identified among 67 
Portuguese yeast isolates 1 C. orthopsilosis isolate and not a single C. metapsilosis isolate. In 
another study in a hospital in the centre of Portugal involving 50 isolates identified biochemically 
as C. parapsilosis, 5 (10%) were re-identified as C. metapsilosis and 6 (12%) as C. orthopsilosis 
[218]. The values found in our study are in accordance with data reported from international 
studies and including isolates from different parts of the world, namely, 91.3% C. parapsilosis 
sensu stricto isolates, 6.1% C. orthopsilosis isolates, and 1.8% C. metapsilosis isolates [87]. 
Similar prevalence rates were reported by other surveillance studies, namely, in Brazil, Spain, 
Italia and Taiwan [124, 162, 175, 177], the majority of isolates corresponding to C. parapsilosis 
sensu stricto and the minority to C. metapsilosis.  
Our study reinforces the assumption that C. parapsilosis sensu stricto is the predominant 
among clinical isolates, namely, isolates from patients with hematogenous infections. 
Interestingly, C. orthopsilosis and C. metapsilosis isolates were recovered from other biological 
products, like urine, respiratory tract samples, and mucosal surfaces. The higher prevalence of       
C. parapsilosis sensu stricto may be related to its ubiquitous nature, since it commonly inhabits 
different environmental sources. Such niches may represent potential routes for nosocomial 
transmission to patients [25, 26] and/or may be related with a wider set of virulence attributes, 
compared to the other two species [96, 106, 122]. In fact, the strains isolated from the hospital 
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air and patient food corresponded to C. parapsilosis sensu stricto, which supports the first 
assumption. Pertaining the last assumption, the literature describes C. parapsilosis sensu stricto 
as the most virulent species and C. metapsilosis as the least virulent within the C. parapsilosis 
groups [122, 126, 219]. 
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GENETIC HOMOGENETY OF C. PARAPSILOSIS ISOLATES 
Identification of Candida spp. from clinical specimens is important to facilitate optimal 
antifungal therapy and patient management [220, 221]. Molecular techniques are excellent tools 
for identification and strain typing of yeasts. In this study the genetic heterogeneity of                  
C. parapsilosis clinical isolates (n=160) were investigated.   RAPD analysis using a single primer, 
RPO2, was used to provide a screening of the genetic heterogeneity of the isolates. The RAPD 
profiles generated were stable. Only 3 RAPD types were recognized, RAPD type A1 being the 
most frequent. Not surprisingly, the environmental isolates were RAPD type A1. The genomic 
homogeneity among C. parapsilosis isolates observed by RAPD analysis in this study has been 
demonstrated previously by molecular techniques [78, 84, 86]. However, a recent investigation 
of the size polymorphisms in loci harboring microsatellite repeat sequences of C. parapsilosis 
group I isolates [92] demonstrated 30 different microsatellite genotypes from 42 isolates. Due to 
the low discriminatory power of RAPD analysis, in contrast with microsatellite analysis, this 
technique should not be used for C. parapsilosis outbreak and epidemiological investigations.  
The existing studies that also used RAPD analysis [33, 84, 86, 91] only described one single 
profile for C. parapsilosis isolates. According to their results, the advantage of this technique is 
the power to discriminate between the three C. parapsilosis groups (C. parapsilosis,                      
C. orthopsilosis and C. metapsilosis). Whenever RFLP analysis was also applied [33], more profiles 
were found for C. parapsilosis. Our study revealed two additional profiles (RAPD type A2 and 
RAPD type A3), probably due to the higher amount of isolates.  
Our typing results were reproduced by another technique, namely restriction endonuclease 
analysis of the mitochondrial DNA. REA for Candida species was first described by Scherer and 
Stevens [222] who considered this method to be an extremely valuable tool for epidemiological 
studies. Fujita et al. [223] described HinfI restriction patterns as exhibiting a superior 
discriminatory power among distinct Candida isolates compared to patterns obtained with other 
enzymes such as EcoRI or MspI. Additionally, Sancak et al. [224] established a correspondence of 
almost 100% between the results obtained with HinfI restriction endonuclease-based analysis 
and PCR methodologies. Recently, in a study, undertook by our group, involving 22 C. krusei 
isolates and using REA analysis [225], a long-lasting colonization by C. krusei was confirmed. 
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ANTIFUNGAL SUSCEPTIBILITY PROFILES OF C. PARAPSILOSIS, C. ORTHOPSILOSIS AND              
C. METAPSILOSIS 
We evaluated the in vitro activity of fluconazole, voriconazole, posaconazole, caspofungin, 
anidulafungin, and amphotericin B against C. parapsilosis sensu stricto, C. orthopsilosis, and        
C. metapsilosis. The definition of the susceptibility profiles provides information relevant to the 
development of recommendations for prophylactic, empirical, or targeted antifungal therapy 
[226-228], particularly at a national level. In this evaluation, statistical comparison of the 
antifungal susceptibility patterns of the three species were seriously compromised due to the 
reduced number of strains of C. orthopsilosis and C. metapsilosis tested.  
Although the MIC values of echinocandins were high for all three species, C. parapsilosis 
sensu stricto isolates were less susceptible to CSF and ANF than C. orthopsilosis and                      
C. metapsilosis isolates. Other studies corroborate our finding, demonstrating that all 
echinocandins (CSF, ANF and MCF) exhibit lower MIC values for C. metapsilosis and                      
C. orthopsilosis than for C. parapsilosis sensu stricto [124, 175, 229]. Not surprisingly, MIC values 
of CSF were higher than MIC values of ANF for all the three species. Previous studies by our team 
[19] had already reported high CSF MIC values for C. parapsilosis groups (for all C. parapsilosis 
isolates, the CSF MIC values were ≥ 2 µg.ml-1). It has repeatedly been shown that echinocandin 
MIC values are consistently higher for the C. parapsilosis groups than for C. albicans or                 
C. glabrata, when assessed by broth microdilution methods [19, 38, 228, 230-232], thus 
suggesting that the C. parapsilosis groups are less susceptible to this class of antifungal agents. 
Recently, new clinical breakpoints were appointed for these antifungals regarding                          
C. parapsilosis: S phenotype for a MIC value ≤ 2 µg.ml-1, S-DD for a MIC value 4 µg.ml-1 and R for 
a MIC value ≥ 8 µg.ml-1 [233]. The reduced susceptibility of C. parapsilosis groups to 
echinocandins has been related to a naturally occurring polymorphism at the edge of HS1 region 
of FSK1 gene [144, 234, 235]. van Asbeck et al. [148]  suggested that interspecies variation in CSF 
susceptibility resulted from the combination of structural differences in the cell wall 
components, from a reduced affinity for the glucan synthase protein complex or from variations 
in the regulatory network of this complex.  
Susceptibility phenotype was stablished according to the CLSI protocol [190, 191] described 
in Material and Methods section. However, Pfaller et al [236, 237] revised those clinical 
breakpoints considering MIC value ≥ 4 µg.ml-1 for fluconazole and  MIC value ≥ 2 µg.ml-1 for 
voriconazole and posaconazole the resistant breakpoints. Azole resistance was detected only 
amongst C. parapsilosis sensu stricto isolates but not C. orthopsilosis or C. metapsilosis isolates. 
In contrast, other studies reported higher MIC values to both FLC and VRC for C. metapsilosis 
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and C. orthopsilosis than those for C. parapsilosis sensu stricto [124, 175]. The differences in FLC 
susceptibility among the three species might reflect the distinct affinity of azoles for the key 
ergosterol-synthesizing enzyme, lanosterol 14α-demethylase, or other enzymes involved in this 
metabolic pathway [148].  
Interestingly in our study, two C. parapsilosis sensu stricto isolates were resistant to AMB, 
an uncommon finding.  
In summary, we detected a multiechinocandin-, multiazole-resistant phenotype of              
C. parapsilosis sensu stricto, as reported by Moudgal et al. [238] and Ghannoum et al. [239]. The 
development and subsequent nosocomial expansion of echinocandin- and azole-resistant            
C. parapsilosis sensu stricto strains may have important clinical implications. Continuous 
monitoring for the emergence of this multidrug-resistant phenotype of C. parapsilosis sensu 
stricto should represent an important component of the effective prevention of nosocomial 
infections. Although FLC showed good activity against C. parapsilosis sensu stricto,                         
C. orthopsilosis, and C. metapsilosis, local routine monitoring of the susceptibility profiles of 
these organisms may be highly advisable. The combination of decreased susceptibility to FLC and 
the ability to form extensive biofilm at the surface of central venous catheters and other medical 
indwelling devices may become problematic [25, 95, 100, 240, 241]. Recently, our group 
characterized the microorganisms that colonized central venous catheters in intensive care 
patients admitted in Hospital S. João during 12 months [241]; 104 (7%) of isolates correspond to 
Candida spp., however no antifungal resistance was detected among the low number (n=35) of 
tested isolates. In over 50% of the episodes of C. parapsilosis candidaemia, the source is a 
vascular catheter, and such infections usually develop in patients who had previously received 
antifungal treatment [18]. Thus, an optimal response to FLC or to any other antifungal may not 
be fully obtained. The administration of the antifungal should be coupled with the prompt 
removal of the catheter to ensure a successful response [234]. 
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IN VITRO ACQUISITION OF AZOLE RESISTANCE 
The acquisition of azole resistance, particularly after prolonged exposure, as it happens 
with prophylactic overuse, is a well-known phenomenon in fungi [242-245]. The widespread use 
of azole antifungals, especially fluconazole, resulted in a growing incidence of Candida species in 
which resistance is easily induced, such as C. glabrata [246], or species that show intrinsic 
resistance, such as C. krusei  [247]. Previous studies with C. albicans [136], C. dubliniensis [248] 
and C. tropicalis [249] demonstrated that resistance to fluconazole can be promoted following 
repeated in vitro exposure to the drug. The ability of a drug to induce in vitro resistance suggests 
that similar mechanisms may also occur in vivo, which may thus became problematic, for 
instance during prophylactic regimens. 
Although C. parapsilosis is not considered to be particularly prone to the development of 
antifungal resistance [36, 95, 147], several recent reports suggested that its decreased 
susceptibility to azoles and echinocandins might become a cause for clinical concern [148-151]. 
Scarce data is yet available regarding resistance amongst C. parapsilosis. Therefore in order to 
assess and characterize its in vitro acquisition of resistance to different antifungals, studies of 
induction were undertaken. The results stress several relevant characteristics of the in vitro 
acquisition of resistance by C. parapsilosis after prolonged exposure to antifungals.  
Following the incubation of C. parapsilosis with therapeutic fluconazole concentrations 
(aiming to reproduce in vivo antifungal therapy), azole resistance quickly developed; similar 
results were obtained with a lower concentration of the same antifungal, showing that of the 
three azoles tested, fluconazole is an easy and fast inducer of resistance. The two different 
approaches used for induction of resistance corroborate this conclusion. The resistant 
phenotype obtained was stable after exposure was stopped and population analysis clearly 
demonstrated the homogeneous nature of the population, excluding the possibility of a mixture 
of susceptible and resistant clones being present in the final cultures. Our findings stress the 
need to review therapeutic protocols. Both voriconazole and posaconazole can induce resistance 
at concentrations of 2 and 1 µg.ml-1, respectively, but at lower concentrations the susceptibility 
pattern did not change drastically. As expected, incubation with any of the three azoles did not 
induce resistance to AMB and CSF, as the azole targets are distinct and selective. Our data 
strongly suggest that the dynamics of in vitro development of azole resistance in C. parapsilosis 
is different from that described for C. tropicalis and C. albicans [194, 249, 250]. For C. albicans, 
the time required to develop fluconazole resistance is longer and such phenotype could be fully 
reverted to baseline when the antifungal exposure was stopped [194].  
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IN VITRO ACQUISITION OF ECHINOCANDIN RESISTANCE 
Following the incubation of C. parapsilosis with anidulafungin, a stable echinocandin 
resistance pattern quickly developed and cross-resistance between all three echinocandins was 
observed. Echinocandins are non-competitive inhibitors of the fungal 1,3-β-D-glucan synthase 
complex, which is responsible for the biosynthesis of the major structural component of the cell 
wall (glucan), by targeting the putative catalytic subunit Fks1 [251, 252]. Since they have a 
common target, it is understandable that the resistance mechanism developed affected all three 
compounds. Resistance to these antifungal drugs is more often associated with mutations in two 
highly conserved regions of Fks1p, known as hot spot 1 and hot spot 2 [144, 253]. However, 
other mechanisms could be involved (discussed below).  
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INDUCED AZOLE RESISTANCE MECHANISMS 
 
IN VITRO INDUCED 
The mechanisms of azole resistance due to antifungal exposure have been extensively 
investigated in clinical strains of C. albicans [137, 138, 141, 142, 254, 255]. Other studies have 
also elucidated the mechanisms of azole resistance in C. glabrata, C. krusei and C. tropicalis [256-
258]. However, very few studies have addressed the mechanisms of azole resistance by               
C. parapsilosis. Throughout our study, we shed some light on drug resistance mechanisms 
developed by C. parapsilosis after exposure to fluconazole, voriconazole and posaconazole.  
Candida albicans isolates that became resistant, in vitro and in vivo induced, showed an 
increase of mRNA specific for a CDR ATP-binding cassette transporter efflux pump [136, 194]. 
The in vitro induction of resistance in C. tropicalis has been associated with increased expression 
of CDR1 and MDR1 genes [249], coding for a specific fluconazole transporter. Distinct antifungal 
resistance mechanisms have been described among Candida spp., active efflux being the most 
relevant mechanism of azole resistance; its molecular base is relatively well known for                  
C. albicans [141]. Overexpression of these efflux proteins confers resistance to most azoles but 
in the same degree. Whereas, ketoconazole, fluconazole, itraconazole and voriconazole are 
transported readily, posaconazole is transported in a much lesser extent [259]. Apparently, this 
compound is not the ideal substrate for these transporters. Our study expectations were similar 
to studies involving C. albicans and C. tropicalis; therefore the presence of efflux pumps was 
phenotypically checked. If the resistance mechanism induced after antifungal exposure was 
overexpression of ATP-binding cassette efflux pumps, we would expect that in the presence of 
efflux blockers, like verapamil and ibuprofen, MIC values would decrease and that Rh-6G 
staining in resistant cells would be lower when compared with nonexposed cells. Moreover, a 
synergistic effect between azole and FK506 should be observed. According to our results, efflux 
seems to play a minor role in the induced resistance; however, the hypothesis of the existence 
of specific C. parapsilosis efflux pumps blocked by different modulators or evidenced with 
fluorescent substrates other than Rh-6G cannot be excluded.  However, the hypothesis that 
induced resistance in C. parapsilosis may be due to mutation in genes that codify enzymes 
involved in the ergosterol biosynthesis pathway gains considerable strength. This mutation is 
probably induced by the antifungal and does not result from selection of an initial resistant 
clone. This last assumption was supported by the results of population studies, as both the 
susceptible population (without antifungal exposure) as well as the resistant population 
obtained following induction, were shown to be homogeneous. The azoles bind in the vicinity of 
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the haeme group of lanosterol-14α-demethylase. Although there are silent mutations scattered 
throughout the gene, at least a dozen different mutations in the active region may create a 
lower affinity for azoles, resulting in a greater influence upon the antimicrobial activity of 
fluconazole and voriconazole than of posaconazole and itraconazole [25]. These two drugs are 
able to bind to an additional domain of the enzyme by means of their long side chain [260, 261], 
meaning that these two antifungals can still inhibit the target at a point when fluconazole and 
voriconazole are no longer active [262]. Accordingly, such mutations should result in a lower 
impact upon the susceptibility profile to posaconazole than to fluconazole or voriconazole. 
Because of the two different binding sites of posaconazole, the occurrence of large-spectrum 
cross-resistance is highly unlikely. Based upon phenotypic experiments (antifungal susceptibility 
in the presence of efflux pumps blockers and flow cytometric assay with Rh-6G), different 
assumptions support the occurrence of drug induced mutation: the rapidity of development of 
the resistant phenotype; the fact that the three azoles are affected, although in a different 
extent; the insignificant role of efflux; and the stability of resistance following prolonged 
absence of drug. Spontaneous mutations are very infrequent, occurring at frequencies of 10-6-
10-8 per gene. The constancy of the MIC values along time when strains were incubated in drug-
free medium strongly supports the unlikely occurrence of spontaneous mutation. Diminished 
sensitivity of the target is probably the main resistance mechanism to azoles in C. parapsilosis. 
Likewise, phenotypically stable resistance to azole antifungals in C. albicans can result from 
mutations in genes involved in the ergosterol synthesis pathway (including the target enzyme 
lanosterol-14α-demethylase) [260, 263-265].  
At this point, C. parapsilosis azole resistance mechanisms were not clarified. In the attempt 
to obtain additional information, the global constitutive changes in gene expression of resistant 
strains obtained after exposure to different azoles (BC014RFLC, BC014RVRC and BC014RPSC strains) 
were assessed using a microarray platform.  
Microarray analysis identified differential expression of 1128, 210 and 598 genes in 
BC014RFLC, BC014RVRC and BC014RPSC strains, respectively. Alterations in expression levels of a 
large number of genes have also been reported in azole resistant C. albicans strains [266-268]. 
Thus, it is clear that the presence of azoles induces a reformulation of the transcriptome of 
Candida species, possibly as a mechanism of adapting to stress response.  
Gene Ontology analysis clearly demonstrated that azoles impaired the expression of genes 
involved in multiple cellular processes, resulting in a pleiotropic effect upon gene expression.  
Expression of MDR1 and other members of the major facilitator superfamily of multidrug 
transporters are up-regulated in the BC014RFLC and BC014RVRC strains, whereas its expression in 
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BC014RPSC strain remained unchanged. Overexpression of MDR1 is also associated with 
resistance to fluconazole in clinical C. albicans isolates and with reduced susceptibility to 
voriconazole [214, 269]. Overexpression of MDR genes renders yeast cells less susceptible to 
voriconazole [269]. In C. albicans, expression of MDR1 is regulated by the transcription factors 
MRR1, CAP1 and MCM1 [214, 270, 271]. Mrr1p appears to play a central role in the 
development of drug resistance in C. albicans. Using a genome-wide gene expression analysis 
approach, Morschhäuser et al.  [214] identified mutations in the MRR1 gene in drug-resistant 
clinical isolates of C. albicans which resulted in up-regulation, and were associated with a co-
ordinate up-regulation of MDR1 [272, 273]. Interestingly, expression of MRR1 was also up-
regulated in C. parapsilosis BC014RFLC and BC014RVRC strains; we therefore determined the 
sequence of the MRR1 gene in such strains. A single nucleotide exchange was detected in both 
(but it was different from each other) when compared with the MRR1 sequence of the 
susceptible strain (BC014S). In C. albicans several mutations in the MRR1 gene in fluconazole 
resistant clinical isolates have been described [214, 272]; thus, it is likely that mutations 
described herein may also play a key role in MDR1 overexpression in C. parapsilosis. However, 
this hypothesis remains to be validated experimentally.  
Overexpression of MDR1 in C. albicans is also correlated with increased expression of aldo-
keto reductases and other genes associated with oxidative stress response, which may protect 
from cell damage caused by toxic molecules produced in the presence of azoles, and also 
contribute to antifungal drug resistance [274]. The expression of these genes is also regulated by 
Mrr1p transcription factor in C. albicans [214]. We observed a similar response in C. parapsilosis. 
Expression of several putative aldo-keto reductases and NADPH oxidoreductases is increased in 
both BC014RFLC and BC014RVRC strains. As a representative example, it is the case of stress 
response gene GRP2, whose up-regulation in C. albicans is correlated with increased expression 
of MDR1 [214] and is associated with the stepwise development of resistance to azoles [267, 
275]. However, GRP2 expression is not only triggered by azoles but it is also regulated positively 
by certain compounds like fluphenazine, benomyl [216] and farnesol [201].  
The comparison of the expression patterns of C. parapsilosis (BC014RFLC and BC014RVRC 
strains) with C. albicans azole resistant isolates [214, 272] reveals that the alterations in the 
transcriptome underlying azole resistance are similar in both species. We therefore suggest that 
resistance to fluconazole and voriconazole in C. parapsilosis, in particular in BC014RFLC and 
BC014RVRC strains, is conferred by the increased expression of MRR1 transcription factor, which 
results in a concomitant overexpression of MDR1 and possibly other members of MFS family, 
and of aldo-keto reductases. As described with C. albicans [214, 272], C. parapsilosis gain-of-
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function mutations in MRR1 results in overexpression. Mutations in MRR1 are unlikely to cause 
resistance to posaconazole, which is a poor substrate for Mdr1p [260, 276]. The decreased 
susceptibility to posaconazole observed with BC014RFLC and BC014RVRC strains is likely to involve 
another yet unidentified mechanism. We did observe the up-regulation of the transcription 
factor NDT80 in BC014RFLC, which may result in overexpression of the CDR1 drug efflux pump; 
however, this was not verified. In C. albicans Ndt80p modulates azole tolerance by controlling 
the expression of the gene CDR1 [215].  
Several genes linked to ergosterol synthesis, including ERG11 gene, are down-regulated in 
both BC014RFLC and BC014RVRC strains. Since azoles target the cytochrome P450 sterol 14α-
demethylase enzyme, encoded by ERG11 gene, the reduction in ergosterol metabolism is likely 
to be a direct consequence of fungal cell exposure to azoles during induction of resistance in 
vitro. The decreased expression of sterol genes we found in BC014RFLC and BC014RVRC strains is 
unlikely to be related to the azole resistance phenotypes; in contrast, we would expect resistant 
isolates to demonstrate an increased expression of sterol synthesis genes. However, we have 
not directly tested the role of the ergosterol pathway in these strains. 
Gene expression of BC014RPSC strain was substantially different from the other two azole-
resistant isolates analyzed in this study. Although 46 of the differentially expressed genes were 
shared with the other two resistant strains (BC014RFLC and BC014RVRC), none of them plays a 
known role in conferring drug resistance. BC014RPSC strain displayed an overexpression of 
thirteen genes directly linked to ergosterol biosynthesis, which strongly indicates that an 
increase in ergosterol content is the most probable cellular mechanism conferring reduced 
susceptibility pattern to all azoles in this strain. In C. albicans, exposure to ketoconazole, also 
increases the expression of genes involved in lipid, fatty acid, and sterol metabolism, including 
ERG11 [277]. We also observed increased expression of the transcription factors NDT80 and 
UPC2 in BC014RPSC. Ndt80p was recently identified in C. albicans [215] as one of transcription 
factors that binds to the promoters of ergosterol biosynthesis genes, including the azole target 
ERG11 gene. Like NDT80, the zinc cluster transcriptional factor UPC2 also mediates the up-
regulation of ergosterol biosynthesis genes in C. albicans [139], and gain-of-function mutations 
result in overexpression of ergosterol biosynthesis genes [140]. Using genome-wide gene 
expression profiling, Dunkel et al. [272] found that UPC2 and other genes involved in ergosterol 
biosynthesis are coordinately up-regulated with ERG11 in a fluconazole-resistant, clinical isolate 
compared with a matched susceptible isolate from the same patient. Expression of UPC2 gene is 
up-regulated in C. parapsilosis BC014RPSC. We therefore propose that, similarly to what happens 
with C. albicans, resistance to azoles in C. parapsilosis can be partly conferred via induction of 
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NDT80 or UPC2, resulting in increased ergosterol production. To determine whether the 
overexpression of the transcription factors NDT80 and UPC2 is associated with point mutations, 
the genes were sequenced both in BC014RPSC and BC014S strains. No difference in the nucleotide 
sequence was detected between the susceptible and the BC014RPSC strains. Expression of SOD4 
gene was also up-regulated in the BC014RPSC strain. Superoxide dismutases are enzymes that 
convert superoxide radicals into less damaging hydrogen peroxide and are required for the 
protection against oxidative stress and the establishment of full virulence [278].  
High-level of azole resistance in clinical isolates of C. albicans and C. glabrata is often 
associated with overexpression of plasma membrane efflux pumps [279-281]. There are two 
main families of efflux proteins, the ATP-binding cassette (ABC) pumps and the major facilitator 
superfamily (MFS) transporters [276]. Expression of the ABC transporters CDR1 and CDR2 is 
increased in some azole-resistant isolates of C. albicans [282]. CDR genes expression is regulated 
by the Tac1p transcription factor and its induction occurs independently from the MFS family 
expression levels [282, 283]. 
The C. parapsilosis genome encodes at least 14 members of the ABC transporter family 
[75]. The expression of one these transporters, CPAG_0151, is up-regulated in the BC014RPSC 
strain. This gene is a syntenic homolog of C. albicans CDR3 [205]. Expression of CPAG_02192, 
another ABC transporter, is up-regulated both in BC014RFLC and BC014RVRC strains. C. albicans 
ABC transporters most frequently involved in azole resistance are the Cdr1p and Cdr2p [137, 
280]. Interestingly, in C. parapsilosis the expression of CDR1 ortholog is not altered between 
susceptible and resistant strains and the CDR2 ortholog was not identified. However, expression 
of CPAG_03665, an ortholog of C. albicans PDR16, is up-regulated in BC014RFLC, BC014RVRC and 
BC014RPSC strains. PDR16 encodes a phosphatidylinositol transfer protein, which modifies the 
passive diffusion of hydrophobic drugs across the cell plasma membrane, thereby modulating 
multi-drug resistance in Saccharomyces cerevisiae [284]. PDR16 is co-expressed with CDR1 and 
CDR2 in azole resistant clinical isolates of C. albicans [285].  BC014RFLC and BC014RVRC strains 
displayed a reduced expression of CPAG_03819. This gene is an ortholog of C. albicans 
orf19.3902, and its reduced expression was correlated with over-expression of CDR1 and CDR2 
in C. albicans azole resistant isolates [216]. It is therefore possible that azole resistance in             
C. parapsilosis is also associated with increased expression of ABC transporters. Nevertheless, 
our results suggest that such transporters play minor role; the expression of CPAG_02274 
(SNQ2) was downregulated in BC014RFLC and BC014RVRC strains, while the expression of the 
other ABC transporter family members remained unchanged. 
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The expression levels of several genes involved in copper and iron transportation were 
found to be differently altered in all three azole resistant C. parapsilosis strains. Due to this 
variability among resistant strains, it is difficult to effectively evaluate the impact of gene 
expression changes on the overall transport of metals. However, it is clear that azoles interfere 
with transport of iron and copper, and consequently its metabolism and management by              
C. parapsilosis. Similar phenotypes have been described in drug resistant isolates of C. albicans 
[266, 268]. Copper is essential for enzymes involved in a multitude of biological processes, such 
as signaling of transcription, protein trafficking machinery, oxidative phosphorylation, iron 
mobilization, neuropeptide maturation, and ultimately normal cell development [286, 287]. The 
acquisition of iron is essential for growth, survival and virulence of C. albicans [288]. Moreover, 
recent studies suggest that iron depletion increases membrane fluidity, which in turn leads to 
enhanced passive diffusion of drugs, resulting in increased drug susceptibility [289]. Expression 
of two genes, FLC1 and FLC2, involved in heme uptake [217] is increased in the BC014RPSC strain. 
Heme is a nutritional iron source required for the activity of a variety of enzymes including 
cytochrome P450 enzymes and iron-sulfur clusters. Azoles inhibit the synthesis of ergosterol by 
binding to the heme cofactor located in the active site of lanosterol 14α-demethylase. Increasing 
heme transport may contribute to enhanced lanosterol 14α-demethylase production, and thus 
contribute to the azole resistant phenotype of BC014RPSC. 
Other resistance mechanisms apart from those already addressed (after phenotypic and 
genotypic studies), such as mutations in the target enzymes might be implicated; however they 
were not covered by transcriptome analysis. In fact, as already discussed, for all resistant strains 
obtained, a mutation in the target enzyme may correlate with the resistant profile observed. 
Azole drugs bind to the area surrounding the heme group of lanosterol-14α-demethylase. 
Fluconazole and voriconazole bind only to one single domain, while posaconazole, by means of 
its long side chain, attaches to two binding sites in the enzyme [260, 261]. Thus, a point 
mutation in one domain of the enzyme might explain resistance to fluconazole and voriconazole. 
Regarding acquisition of resistance to posaconazole, mutation in both domains of the enzyme 
would have to occur in order to explain azole cross-resistance. 
To our knowledge, our study is the first to use cDNA microarray analysis to investigate 
whole genome level gene expression in sets of azole-resistant versus susceptible C. parapsilosis 
strains. Microarray gives an overview of genes that are differently expressed, from which 
important information should be extracted and studied in more detail using other molecular 
tools, in order to comprehensively systematize the molecular mechanisms underlying                   
C. parapsilosis drug resistance.  
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In summary, the two different approaches undertaken to provide insight about azole 
resistance mechanisms in C. parapsilosis showed to be coherent; they did not attribute a major 
role to ATP-binding cassette transporter efflux pumps and both hypothesized the acquisition of a 
mutation during the induction assay, which was confirmed for BC014RFLC and BC014RVRC strains.  
 
IN VIVO INDUCED 
For the three in vivo cases reported here, there was a rapid decrease in azole susceptibility, 
the isolates exhibiting azole cross resistance in one case. In order to get on insight about the 
resistance mechanisms developed, phenotypic and genotypic studies were carried out with 
isolates from patient A (last isolate was resistant to all azoles tested). Antifungal susceptibility 
testing with an efflux blocker and flow cytometry with Rh-6G revealed the scarce role of         
ATP-dependent efflux pumps. Several studies support the opposite, that ATP-dependent efflux 
pumps play a major role in antifungal resistance. For instance, clinical resistant C. albicans 
isolates exhibited CDR1 and CDR2 overexpression in a study carried out by Ricardo et al. [290]. In 
other study [281], azole-resistant clinical C. glabrata isolates showed upregulation of CDR1 
compared to susceptible strains, while ERG11 expression was minimally changed. 
As already mentioned, regarding C. albicans, several studies described the presence of 
point mutations in the ERG11 gene, whereas some isolates contained more than one single 
mutation, as the fluconazole resistance mechanism [263-265]. Li et al. [260] sequenced the 
ERG11 genes from seven sequential C. albicans isolates from an AIDS patient and concluded that 
multiple mutations in ERG11 gene are required to confer simultaneously decreased susceptibility 
to several azoles, including posaconazole. According to our results, the ERG11 gene of the last    
C. parapsilosis isolate did not show alterations.  
Similar to in vitro strains, the gene expression profile for in vivo strains also was evaluated. 
The microarray quality was not very high, probably because we are working with strains 
obtained directly from the patient and not with in vitro strains obtained after successive 
subcultures in the presence of the antifungal in stable environmental conditions. Nevertheless, 
relevant information could be extracted. The genes involved in lipid metabolism process were 
increased, which included ERG genes responsible for ergosterol biosynthesis. Azoles are 
responsible for the shortage of this lipid in yeast cell membrane. Through quantitative real-time 
PCR we could confirm the increase in ERG11 and ERG6 genes. Moreover, we could also observe 
a slight increase in transcription factors genes NDT80 and UPC2. Its role in increasing the 
expression of ERG genes was already discussed; however the search for point mutations was not 
performed. Constitutive ERG11 overexpression may contribute to fluconazole resistance in 
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clinical C. albicans isolates. Goldman et al. [264] found a few resistant C. albicans clinical isolates 
that showed increased mRNA expression of the ERG11 gene.  Morschhauser et al. [291] found 
ERG11 overexpression in many fluconazole-resistant C. albicans isolates compared with matched 
susceptible isolates. However, White et al. [254] had reported, from a collection of fluconazole-
resistant and -susceptible isolates, considerable variation in the levels of ERG11 mRNA 
expression; such expression did not seem to be related to azole resistance. 
In summary, and although the results were not conclusive, we can say that most probably 
the increase in membrane ergosterol content accounts for the cross-resistance profile observed 
in the in vivo induced resistant strain. 
Comparing the in vitro with the in vivo induction of azole resistance similarities and 
discrepancies can be appointed. In the in vitro assays, when the antifungal fluconazole was used 
to induce resistance, this phenotype developed very fast and ATP-dependent efflux pumps were 
not important for the resistance phenotype. The same happened in the in vivo case. 
Susceptibility against the different azoles is affected differentially by fluconazole. For instance, in 
the in vivo induced strain the susceptibility pattern to posaconazole was resistant while in the in 
vitro induced strains kept susceptible.  The major facilitators (like MDR1 efflux pump) seem to be 
important in the in vitro induced strain whilst in the in vivo induced strain are ERG genes, which 
enclose the in vivo case with the in vitro induction of resistance with posaconazole. In fact, in 
both cases a cross-resistance profile was achievied.  
According to our results, the in vitro induction of resistance model did not match exactly 
with the findings in an in vivo induction case. In the human body, the physiologic conditions 
interfere in the fitness of microorganisms; therefore different susceptibility phenotypes or 
virulence attributes can be expressed. The clinical outcome is dependent on factors that include 
host defenses, the virulence of the fungal pathogen, and drug efficacy/toxicity, as well as drug 
interactions [292, 293]. Additional factors, such as age, gender, underlying disease status, and 
concomitant therapies, can account for the drug efficacy, but host genetics probably play 
important roles in both drug efficacy and toxicity [294]. Meletiadis et al. [295] accomplished all 
the human factors that might be implicated in antifungal therapy, which are not taken 
accounted in the in vitro studies. Notably that the strain used in the in vitro assays was not the 
same isolate from the in vivo case; even if it was the same strain, the different environmental 
conditions could leed to different phenotypes for the same genotype. 
The findings from the in vitro induction assay and from the in vivo induction case of 
resistance characterized in this study demonstrated that different azole resistance mechanisms 
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can be developed by C. parapsilosis and that they are quite similar to the findings with                 
C. albicans. It should be viewed as examples and not as definitive rules.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
143 
 
ECHINOCANDIN RESISTANCE MECHANISMS 
Echinocandins inhibit β-1,3-D-glucan synthase, which catalyzes the biosynthesis of  β-1,3-D-
glucan, the major glucan component of Candida cell walls [296, 297]. Glucan synthase is an 
enzyme complex with at least two subunits, Fksp and Rho1p. Fksp, encoded by three related 
genes, FKS1, FKS2, and FKS3, contains the active site, which catalyzes the transfer of sugar 
moieties from activated donor molecules to specific acceptor molecules forming glycosidic 
bonds [298-300]. The inhibition of glucan synthase by echinocandin drugs disrupts the structure 
of the growing cell wall, resulting in osmotic instability and the death of susceptible yeast cells 
[301, 302]. 
 Echinocandin resistance in species such as C. albicans, C. tropicalis, and C. krusei has been 
associated with aminoacid substitutions in Fks1p [144]. Likewise, it is now understood that 
aminoacid substitutions in Fks1p and Fks2p are responsible for clinical echinocandin resistance 
in C. glabrata [303-307]. Our group recently described the acquisition of resistance by                 
C. glabrata after anidulafungin treatment [308].  The resistant isolate exhibited a Ser663Pro 
mutation in HS1 region of FKS2 gene.  
Pfaller et al. [233] evaluated several isolates from candidiasis cases, refractory to 
echinocandins, with FKS mutations and corresponding to MIC values in the susceptible category 
using the breakpoint ≤2 µg.ml-1. In these cases there was a relationship between high or 
increasing echinocandin MIC values and a poor clinical outcome. News species specific cutoffs 
were proposed. Regarding C. parapsilosis, the values ≤2   µg.ml-1, 4 µg.ml-1 and ≥8 µg.ml-1 were 
established for susceptible, susceptible-dose dependent and resistant phenotypes, respectively. 
The clinical C. parapsilosis strains studied exhibited high echinocandin MIC values, being 
considered as nonsusceptible, at least for one antifungal, according to the older breakpoints 
[190, 191]. However, at present some of them are considered susceptible. After sequencing the 
portion HS1 from FKS1 gene, no differences in the corresponding amino acid sequences were 
observed when compared to GenBank nucleotide sequence database. In fact C. parapsilosis 
strains are predisposed to exhibit high MIC values of echinocandins. A naturally occurring amino 
acid polymorphism in the highly conserved Fks1p HS1 region of C. parapsilosis, relatively to 
other Candida species, has been suggested to be responsible for the reduced echinocandin 
susceptibility of these species [144, 234, 235]. C. parapsilosis clinical isolates exhibited different 
MIC values concerning the three echinocandins tested, which stressed the need to check 
whether mutations accounted for the differences in the antifungal susceptibility profile of           
C. parapsilosis isolates; this hypothesis was not confirmed. Ghannoum et al. [239] study 
corroborates our results; they showed that C. parapsilosis isolates which were susceptible to 
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anidulafungin but not to caspofungin and micafungin did not exhibit mutations in 493-bp region 
of FKS1 gene. 
Regarding the in vitro induction assay, the resistant strain obtained exhibited MIC value      
≥8 µg.ml-1 for all three echinocandins.  The pattern of decreased enzyme sensitivity to inhibition 
extends across all three of the echinocandins. In contrast to our expectation, no mutation in the 
HS1 region of FKS1 gene was found when compared the sequences for the induced and the 
parent strains.  
In summary, none of our C. parapsilosis strains had characteristic mutations or exbhited 
polymorphism on HS1 region of FKS1 gene. 
This study has some limitations. The entire sequence of FKS1 gene should have been 
checked and the sequencing of other genes, like FKS2 and FKS3, addressed. However, for other 
Candida species, namely C. dubliniensis and C. krusei, mutations outside the hot-spot regions did 
not confer echinocandin nonsusceptibility [233].  
The existence of other echinocandin resistance mechanisms should not be excluded, like 
for instance, the expression level of FKS gene, that codifies the echinocandins target enzyme 
(similarly to what happens with azole resistance mechanism). As well as the role of chitin cell 
wall content (discussed below). 
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SUSCEPTIBILITY TO PHYSICAL AND CHEMICAL AGENTS 
It is a crude reality the fact that candidaemia can also be exogenous in origin in the hospital 
setting and that acquisition of yeasts by indirect contact is important in the context of hospital 
infections. Regarding C. parapsilosis, the carriage on the skin and hands of health care  personal 
and its consequent direct and indirect transmission have been identified as responsible for 
outbreaks of catheter-related C. parapsilosis infections in Intensive Care Units [309, 310]. 
Contamination of medical devices and surfaces from the patient´s own colonization or from 
hands of the health care workers is of at most importance concerning nosocomial infections 
[311].  
Therefore it is important to take appropriate prophylactic measures to avoid dissemination 
and transmission of C. parapsilosis and other Candida species. Russell et al. [312] noted a 
general lack of information about the antifungal activity of chemical germicides relevant for 
hospital settings. Much of the available data has been generated using test protocols that bear 
little resemblance to the field situation [313]. We assessed the effectiveness of chemical and 
physical agents against C. parapsilosis, in particular addressing the concentration and the 
exposure time required to inactivate this species.  
Different studies demonstrated the relative resistance of C. parapsilosis to certain 
categories of germicides. Traoré et al. [186] demonstrated that the reduction of C. parapsilosis 
by hydrogen peroxide is low comparing to C. albicans and C. tropicalis. Silverman et al. [185] 
took into account the range of exposure times and potential dilutions recommended by 
manufacturers of different commercial antiseptics for washing skin against different Candida 
species. The study demonstrated that some products failed to kill some Candida species, even at 
undiluted concentration. In our study the chemical agents were tested independently, for 
determination of the lethal concentration, which is important to develop products that combine 
different substances, improving the effectiveness against C. parapsilosis. Furthermore, it 
included environmental strains, collected from air and hospital food. In addition, it also provides 
information about the potential of physical agents to disinfect hospital environment.   
Chemical agents are very important for surface, medical devices and hand cleaning. 
According to the results obtained, chlorhexidine revealed to be effective at a very low 
concentration (approximately 0.06%), considering that commercial disinfectants contain 1% 
chlorhexidine. Ethanol and sodium hypochlorite were also effective at low concentrations (10% 
and 2.5%, respectively). Hydrogen peroxide (0.06%), potassium permanganate (0.1%) and acid 
boric (1%) was equally effective.   
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When commercial solutions were tested some discrepancies with pure compound testing 
were observed. Surprinsingly some solutions (Hydrogen Peroxide 3% and Acid Boric 3%) were 
not effective as expected, despite its concentration was higher than the MLC value determined. 
This can be due to the differences in both methodologies, especially in cell concentration and 
contact time. Probably for commercial solutions the time needed to kill cells is higher than 30 
min. 
Physical agents are very important to disinfect surface and medical devices and moreover 
to sterilize water and food, which may be very relevant, especially with immunocompromised 
patients. We can conclude that a short microwave irradiation time is sufficient to inactivate 
yeast cells present in water or food, being the easier and faster methodology to apply in hospital 
for food or water. Cell membrane lesion was observed with microwave irradiation and heating at 
60ºC treatments by flow cytometry. The same was not observed for UV irradiation, which needs 
further studies.  
Overall, little is known about the mechanism of antifungal effects of chemical agents. 
Potential targets include cell membranes, metabolic pathways and enzymes driving those 
pathways and DNA integrity or replication and gene expression. The results from the cytometric 
studies indicate that the effect of heating at 60ºC and microwave irradiation results in a lethal 
primary membrane lesion, which is an irreversible phenomenon. For chemical agents 
(commercial solutions), only for Hydrogen Peroxide physical membrane damage appears to be 
the primary cause of the antifungal effect, since as the percentage of death increased, PI staining 
also increased after Hydrogen Peroxide exposure. Indeed, Hydrogen Peroxide provokes 
oxidation that leads to membrane rupture. Regarding the other chemical agents, further studies 
should be addressed involving other fluorescence substractes in order to put in evidence the 
mechanism of action.  
Generally, the sensitivity of C. parapsilosis clinical and C. parapsilosis environmental strains 
to the chemical and physical agents did not vary much; however differences were found 
regarding ultraviolet irradiation and heating at 60ºC, since the reduction among environmental 
strains was lower than the reduction among clinical strains, which means that this type of strains 
are more tolerant to these treatments. 
With this study we look forward to establish effective measures and protocols for hospital 
surface disinfection and hand washing. We hope to provide a valuable contribution to the 
reduction of the incidence of candidaemia by C. parapsilosis, by limiting its presence in 
environmental niches.  
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It is widely recognized that routine cleaning of high-touch surfaces does not completely kill 
microbial pathogens. Therefore, improved disinfecting methods addressing air and surface 
decontamination are needed. Preliminary studies suggest that hydrogen peroxide disinfection 
(vapor and aerosol) is a promising technology for environmental decontamination of the hospital 
settings [314]. In our study, we used the new GlosairTM 400® system which provides aerosolised 
hydrogen peroxide/silver cations dry-mist. The antimicrobial efficacy of this technology was 
assessed both in situ and in vitro (manuscript VII in Publications section); susceptibility testing of 
several microorganisms to the disinfectant solution (GlosairTM 400® Cartridge) was also 
performed. Regarding the antimicrobial activity against C. parapsilosis, the dry-mist system 
resulted in a 5 log reduction of growth. According to the susceptibility testing results, the 
disinfectant solution exhibited a potent antimicrobial activity even following dilution. Despite 
this classic approach does not mimic “real life” situation, in vitro susceptibility testing is very 
helpful to optimize novel disinfection cycles and disinfectant concentrations, as could be the 
case with shorter duration cycles, an interesting option for the disinfection of high turnover 
facilities like operation theatres.  
The antimicrobial properties of the product are the result of the oxidative action of 
hydrogen peroxide on the lipid membrane, which results in modification in ribosomes and DNA, 
and the effect of sylver cations, which reverse membrane polarity and inhibit protein synthesis 
and cytoplasmic enzyme activity [315]. Flow cytometry technology is considered a very reliable 
methodology to evaluate the mechanism of action of antimicrobial drugs. Our results confirmed 
the cell membrane lesion in a short period of time by the hydrogen peroxide/sylver cations mist, 
meaning its microbicidal effect. 
Thus, our results strongly support the use of the hydrogen peroxide/silver cations dry-mist 
system as an excellent alternative to manual disinfection of hospital facilities due to its broad 
microbicidal activity and high efficacy. 
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VIRULENCE ATTRIBUTES 
AZOLE RESISTANT AND SUSCEPTIBLE STRAINS 
Overall, antifungal drug resistance and fungal virulence are critical issues for the host-
parasite relationship during a fungal infection. There is a growing concern about the rise of 
antifungal drug resistance, but scarce knowledge is yet available regarding the biological 
behaviour and pathogenicity of drug-resistant fungal strains. Due to the growing medical 
importance of C. parapsilosis, we decided to study the virulence attributes of two strains with 
opposite susceptibility profiles; the resistant strain derived from prolonged exposure to the 
antifungal in vitro and the susceptible parent strain. We compared both phenotypic and 
genotypic attributes of virulence. 
Our findings have extended the observations of Lott el al. [77] and Enger et al. [83] that 
phenotypic switching occurs in C. parapsilosis. Additionally, the results demonstrated that 
switching is unrelated with the antifungal susceptibility profile since it occurrs in both strains, 
although in different extense. We identified for each strain two phenotypes: smooth and crepe 
for the susceptible strain and smooth and concentric for the resistant strain. The phenotypes 
were similar to those described by Laffey et al. [109], who also found that the majority of            
C. parapsilosis isolates switched between at least two different morphologies. Interestingly, we 
identified only in the resistant strain the white-opaque transition and the sectoring 
phenomenon. It is the first time that white-opaque transition is described for C. parapsilosis 
species. For C. albicans it was described that white and opaque cells harbor identical genomes 
yet they differ in cellular morphologies, gene expression profiles, mating abilities, and virulence 
properties [316-322]. Regarding virulence, the opaque phase is considered less virulent.  
Phenotypic switching has been associated with promoted adherence of C. albicans to 
mammalian cells. In the well-studied white-opaque transition, C. albicans cells expressing the 
white phenotype display increased adhesion to  buccal epithelia than cells expressing the 
opaque phenotype [323]. Vargas et al. [324] showed that in a different C. albicans switching 
system with four phenotypes, there is a hierarchy of adhesion to buccal epithelia and stratum 
corneum from pigs; the phenotype o-smooth is the most adhesive, followed by irregular wrinkle, 
revertant smooth and star. Our results demonstrated that C. parapsilosis resistant strain 
exhibited increased adherence, also being the strain displaying higher frequency of smooth 
phenotype. Potential in vivo inducible virulence factors of C. parapsilosis are considered to 
include adherence and slime production, an attribute of special importance for adhesion to 
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plastic and therefore for catheter-related candidaemia [76] or infection of other medical 
indwelling devices. 
The propensity for biofilm formation has recently been shown to have an impact upon both 
pathogenicity and drug resistance [325]. Angiolella et al. [326] observed a marked increase in 
the propensity for biofilm formation by C. albicans when the fungus acquired antifungal drug 
resistance following exposure to the drug in vitro. In contrast, for C. parapsilosis species, our 
results demonstrated that the resistant strain produces less biofilm. We believe that this is 
related with phenotypic switching rather than the antifungal resistant trait itself. Laffey et al. 
[109] found that the concentric phenotype formed the greatest amount of biofilm, whilst the 
smooth phenotype formed less biofilm. Despite the resistant strain displaying the concentric 
phenotype, the frequency of the smooth phenotype is much higher. 
Regarding C. albicans there is substancial agreement that both adherence properties and 
the capacity to switch from yeast to mycelium - which are possibly interrelated - play a 
substantial role in host tissue invasion [327]. Filamentation in C. parapsilosis strains studied 
occurred in more extension in the resistant strain. The higher filamentation should relate with 
higher biofilm production, since most biofilm is composed of filamentous cells. However, this 
was not observed due the frequency of the smooth phenotype; this is the phenotype that 
predominantly grows as budding yeasts and produces less biofilm and does not invade agar. 
Nevertheless, we believe that filamentation and biofilm formation in C. parapsilosis are closely 
correlated like in C. albicans. 
 According to Laffey et al. [109] the smooth phenotype grows more rapidly. Indeed, the cell 
number for the resistant C. parapsilosis strain is higher, at all points of the growth curve.  
Although secreted enzymes are putative virulence factors for all yeast species, the patterns 
of expression vary considerably across species. Herein, we studied two enzymes, coagulase and 
catalase, the last being more active in the resistant strain. Studies with secreted aspartyl 
proteases (SAPs) and phospholipases could have also been addressed. However, its importance 
as virulence factors for C. parapsilosis is somehow controversial. Although SAPs may play a role 
in C. albicans adhesion [328], they are not important for the primary mode of invasion (through 
the gut mucosa) since knockout strains do not display attenuated virulence [116]. However, 
SAPs may be important for pathogenesis at other sites or stages of infection. Regarding                
C. parapsilosis, De Bernardis et al. [96] found an inverse relationship with invasiveness. Kuhn`s 
findings also did not support the concept that SAP expression is a critical virulence factor for       
C. parapsilosis [95].  Phospholipases are important virulence factors for C. albicans [115]. Kuhn 
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et al [95] did not find correlation between phospholipase activity and the site of infection or 
other virulence factors in C. parapsilosis. 
The assumption that antifungal drug resistance clearly influences fungal virulence was not 
fully and definitively confirmed; the differences observed could be linked to the presence of the 
different phenotypes. Nevertheless, several studies described similar findings for C. albicans. 
Previous studies described the correlation between expression of multiple virulence factors with 
antifungal resistance for C. albicans [326]. 
The definitive analysis of the role of virulence attributes would require further genetic 
analysis and studies in animal models, examining the behavior of knockout mutants of                 
C. parapsilosis. 
A first step was taken by us with microarray analysis, which revealed that several groups of 
genes associated with fungal virulence were overrepresented in the resistant strain.  Genes that 
regulate adherence to plastic and biofilm development in C. albicans are often also involved in 
cell adherence and invasion. EFG1 is a well characterized gene, which apart from being required 
for filamentation and biofilm development [329, 330], is also necessary for adherence and 
invasion of reconstructed human epithelia [331]. Members of the ALS adhesin family are also 
required for adhesion to human cells [332, 333] and are expressed differentially in biofilms 
[334]. C. parapsilosis microarray analysis showed that EFG1 and ALS1 genes were both up-
regulated in resistant strain. This finding correlates closely with the adherence assay results but 
not with biofilm development, which possible results from phenotypic switching in resistant 
strain. Anyway, this first genetic approach supports the correlation between azole resistance 
and a promoted expression of virulence attributes. 
 
ECHINOCANDIN NONSUSCEPTIBLE AND SUSCEPTIBLE STRAINS  
Chitin is an essential part of the carbohydrate skeleton of the fungal cell wall and is a 
molecule that is not represented in humans or other vertebrates. Complex regulatory 
mechanisms enable chitin to be positioned at specific sites throughout the cell cycle to maintain 
the overall strength of the wall, also enabling rapid and life-saving modifications to be made 
under cell wall stress conditions. Chitin has also recently emerged as a significant player in the 
activation and attenuation of immune responses to fungi and other chitin-containing parasites 
[213]. Recently, the increase in the production of chitin has been related to reduced efficacy of 
echinocandins: treatment of C. albicans in vitro with sub-MIC caspofungin activates chitin 
synthesis, and reciprocally cells that have higher cell wall chitin are less susceptible to 
caspofungin [335, 336].  
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With the aim to study the chitin role and its contribution to decreased susceptibility to 
echinocandins by C. parapsilosis, the cell wall chitin content was compared between susceptible 
and nonsusceptible strains both by CFW resistance test and a novel flow cytometric protocol. 
This last revealed a higher discriminatory power than the classic methodology. Additionally, a 
nonsusceptible strain generated in vitro following exposure to anidulafungin was studied. In fact, 
for some nonsusceptible clinical strains and for the nonsusceptible in vitro induced strain, the 
cell wall chitin content was higher than for the susceptible strains. However this was not a 
constant pattern since other susceptible strains also had high chitin levels. Overall the results did 
not allow to correlated echinocandin nonsusceptibility to cell wall chitin content; nonetheless 
this is a hypothesis that cannot be excluded in future echinocandin resistance mechanism 
studies. It was shown that C. parapsilosis displays high levels of chitin when compared to other 
Candida species. The possibility that it can rise in the presence of the antifungal or that it can 
contribute to the intrinsic lower susceptibility to echinocandins displayed by C. parapsilosis 
deserves to be confirmed. In fact, our group already evaluated by flow cytometry the chitin level 
in different Candida species in the absence and the presence of caspofungin, independently the 
susceptibility phenotype. We observed that caspofungin triggered the level of chitin, including in 
C. parapsilosis, after caspofungin exposure for a short period of time. The same effect could 
occur during induction of resistance by echinocandins as is the case of BC041NS nonsusceptible 
strain obtained after cultured for 30 days the BC041S susceptible strain in the presence of 
anidulafungin.  
Elevated chitin content appears to represent an adaptive growth response in the presence 
of echinocandins, in an attempt to maintain cell wall integrity and subsequent cell growth. This 
may occur either by selection of a sub-population of naturally occurring chitin-rich cells, and/or 
by induction of cell wall compensatory mechanisms that activate chitin synthesis. This increase 
in chitin content happens also whenever Candida strains display a paradoxical growth at high 
levels of drugs, despite exhibiting a normal susceptibility pattern in presence of a lower minimal 
inhibitory concentration value [337]. van Asbeck et al. [148] demonstrated that occurrence of 
the paradoxical effect with caspofungin is higher in C. parapsilosis than with C. albicans. The 
paradoxical growth effect described was observed with one single C. parapsilosis strain tested 
for chitin level. 
Studies concerning the role of individual chitin synthase genes should also be addressed in 
the future.  Munro et al. [146] described that treatment of C. albicans with low levels of 
echinocandins stimulated chitin synthase (CHS) gene expression, increased Chs activity, elevated 
chitin content and reduced efficacy of these drugs. Elevation of chitin synthesis was mediated 
DISCUSSION 
152 
 
via the PKC, HOG, and Ca(2+)-calcineurin signalling pathways. Stimulation of Chs2p and Chs8p by 
activators of these pathways enabled cells to survive otherwise lethal concentrations of 
echinocandins, even in the absence of Chs3p and the normally essential Chs1p, which regulate 
the synthesis of the chitinous septal ring and primary septum of the fungus. Under such 
conditions, a novel proximal offset septum was synthesized, which restored the capacity for cell 
division, sustained the viability of the cell, and abrogated morphological and growth defects 
associated with echinocandin treatment and the Chs mutations. 
Another limitation of our study is the fact that it should have included more C. parapsilosis 
strains and although the strains had no mutation in the HS1 region of FKS1 gene, as previous 
discussed, mutations in other locations should have been looked for.  
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MOLECULAR DISTINCTION BETWEEN C. PARAPSILOSIS, C. ORTHOPSILOSIS AND C. METAPSILOSIS 
• In a Portuguese university hospital, C. parapsilosis sensu stricto was predominant among 
clinical isolates, whilst the incidence of C. orthopsilosis and C. metapsilosis was low, 
especially regarding isolates from blood cultures.  
 
GENOTYPING OF C. PARAPSILOSIS 
• C. parapsilosis isolates (clinical and environmental) were genomic homogeneous.  
 
ANTIFUNGAL SUSCEPTIBILITY TESTING 
• C. parapsilosis groups displayed low susceptibility against echinocandins. 
• C. parapsilosis groups displayed high susceptibility against amphotericin B. 
• Azoles resistance was detected only among C. parapsilosis sensu stricto isolates. 
• A multi-echinocandin and multi-azole resistant phenotype was observed among               
C. parapsilosis sensu stricto isolates. 
• The differences in antifungal susceptibility described for different species (C. parapsilosis 
sensu stricto, C. orthopsilosis and C. metapsilosis) were not sufficiently distinct to 
warrant discrimination of the species in the clinical laboratory. 
 
IN VITRO INDUCTION OF ANTIFUNGAL RESISTANCE 
• The development of in vitro azole resistance in C. parapsilosis after growth in the 
presence of azole antifungals was rapid and stable. 
• In vitro induction assays of resistance revealed that fluconazole was the fastest inducer 
while posaconazole was the slowest. 
• The development of echinocandins resistance in C. parapsilosis after growth in the 
presence of anidulafungin was stable. 
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IN VIVO INDUCTION OF AZOLE ANTIFUNGAL RESISTANCE 
• Fluconazole rapidly induced a decreased susceptibility to itself and other azoles; the 
resistant phenotype acquired was stable. 
• Post-treatment isolates with reduced susceptibility were genetically identical to 
susceptible pre-treatment isolates, confirming the acquisition of azole resistance. 
 
ANTIFUNGAL RESISTANCE MECHANISMS (IN VITRO AND IN VIVO ACQUIRED) 
• ATP-dependent efflux pumps played a minor role in azole resistance in C. parapsilosis. 
• Azoles impaired the expression of genes involved in multiple cellular processes, resulting 
in a pleiotropic effect upon gene expression. 
• Resistance displayed by C. parapsilosis strains was associated with increased expression 
of MDR1p and other drug efflux pumps members, namely MFS and with ergosterol 
production.  
• MDR1 overexpression was correlated with increased expression of the MRR1 
transcription factor caused by single gain-of-function mutations. 
• Overexpression in ergosterol production was not associated with mutations in 
transcription factors NDT80 and UPC2. 
• Cross-resistance between different azoles occurred due to increase in lipid metabolism. 
• Different findings were obtained for in vitro and in vivo induced resistance with 
fluconazole. 
• Similar mechanisms confer resistance to azole drugs in C. parapsilosis and C. albicans. 
 
SUSCEPTIBILITY TO PHYSICAL AND CHEMICAL AGENTS 
• Heating at 60ºC, microwave irradiation, chlorexidine, ethanol and sodium hipochlorite 
seem to be very effective against C. parapsilosis in a short period of time.  
CONCLUSIONS 
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• The hydrogen peroxide/silver cations dry-mist system was a good microbicidal effect, 
namely against C. parapsilosis. 
 
VIRULENCE ATTRIBUTES 
• A relationship between virulence and resistance for C. parapsilosis could not be 
established, although some attributes were enhanced for resistant strain (growth 
capacity, phenotypes diversity, pseudohyphal development, adherence and catalase 
expression). 
• Microarray analysis evidenced that some especially groups of genes correlated with 
pathogenecity were found to be overexpressed in C. parapsilosis resistant strain. 
• Nonsusceptibility to echinocandins exhibited by C. parasilosis clinical isolates was not 
associated with mutation in HS1 region of the FKS1 gene. 
• Cell wall chitin levels differed within C. parapsilosis species although it was not possible 
to establish a relation between chitin levels and echinocandins high MIC values 
displayed by C. parapsilosis isolates.  
• Long time in vitro exposure to anidulafungin increase cell wall chitin levels. 
• An association between a paradoxical growth effect and a high chitin content was 
established. 
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FUTURE PERSPECTIVES 
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FUTURE PERSPECTIVES 
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The results of the different topics addressed in our study provide a useful insight into 
several aspects of C. parapsilosis, such as epidemiology, virulence and drug susceptibility, 
leading to further research. Some aspects that should be taken into consideration for future 
investigations are: 
 
1. To evaluate the impact of point mutations in the transcription factor MRR1 upon                
C. parapsilosis azole resistance; to achieve this goal, a double deleted C. parapsilosis 
strain for the mentioned transcription factor must be constructed and the susceptibility 
profile and gene expression evaluated. 
 
2. To continue the surveillance study in Portuguese university hospitals in order to 
characterize the susceptibility profile of C. parapsilosis clinical isolates; the resistant 
isolates identified should be screened for point mutations in transcription factors, 
MRR1, UPC2 and NDT80 and its role in azole resistance assessed. 
 
3. The followed up of in vivo infection cases by C. parapsilosis: the isolates from patients 
that developed candidaemia and are receiving azole treatment should be evaluated; the 
goal is to establish a parallelism with our in vitro findings regarding the resistance 
mechanisms developed following prolonged exposition to different classes of 
antifungals. 
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Table S1. Genes with differential expression in BC014RFLC. 
Table S2. Genes with differential expression in BC014RVRC. 
Table S3. Genes with differential expression in BC014RPSC. 
Table S4. GO terms overexpressed in BC014RVRC and BC014RPSC strains. 
Table S5. Genes differentially regulated in BC014RFLC and BC014RVRC strains. 
  
Supplementary Tables S1, S2, S3, S4 and S5 are available at Supplemental Material section of the 
manuscript “Transcriptional profiling of azole-resistant C. parapsilosis strains” (manuscript VI in 
Publications section) in the Antimicrobial Agents Chemotherapy journal internet homepage 
http://aac.asm.org/cgi/content/full/55/7/3546/DC1.   
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As espécies do género Candida representam uma importante causa de infeções 
nosocomiais. A espécie Candida parapsilosis é atualmente o segundo isolado mais frequente de 
hemoculturas na Europa e tem sido descrita como sendo responsável por uma grande variedade 
de manifestações clínicas, que ocorrem geralmente em indivíduos imunocomprometidos. 
A espécie C. parapsilosis representava anteriormente um complexo de três grupos 
geneticamente distintos (grupo I, II e III). Atualmente, estes grupos foram renomeados espécies 
distintas: C. parapsilosis sensu stricto, C. orthopsilosis, e C. metapsilosis. 
Apesar de ser considerada um membro da população microbiana endógena em indivíduos 
saudáveis, C. parapsilosis é também isolada de diferentes fontes ambientais e das mãos do 
pessoal prestador de cuidados de saúde, sugerindo assim outras vias de transmissão nosocomial. 
Esta espécie apresenta várias características biológicas, algumas relacionadas com a sua 
virulência. C. parapsilosis forma biofilmes em dispositivos médicos implantados, o que aumenta 
a sua adesão a tais equipamentos, produz enzimas extracelulares, expressa diferentes fenótipos 
e é capaz de proliferar na presença de concentrações elevadas de glucose e lipidos. 
 De um modo geral, as estirpes de C. parapsilosis têm sido descritas como sendo suscetíveis 
aos antifúngicos; contudo, estirpes resistentes têm sido descritas, em particular aos azoles e às 
equinocandinas. Poucos estudos de vigilância da atividade destes agentes sobre isolados de 
hemoculturas de C. parapislosis têm sido conduzidos e os mecanismos de resistência aos 
antifúngicos são ainda desconhecidos. Acresce ainda que há pouca informação disponível acerca 
da eficácia de desinfetantes e antisépticos assim como de agentes físicos como radiação U.V. e 
micro-ondas, de uso corrente nos hospitais, sobre este patogéneo. 
Procedemos ao estudo de isolados de C. parapsilosis de doentes admitidos num hospital 
universitário Português e isolados ambientais do mesmo hospital. Descrevemos a incidência e a 
distribuição de C. parapsilosis sensu stricto, C. orthopsilosis e C. metapsilosis entre os 175 
isolados clínicos e ambientais previamente identificados como C. parapsilosis por métodos 
convencionais. Adicionalmente, avaliamos a suscetibilidade in vitro dos isolados ao fluconazole, 
voriconazole, posaconazole, anfotericina B, caspofungina e anidulafungina. Dos 175 isolados 
estudados, 160 (91.4%) foram identificados como C. parapsilosis sensu stricto, 4 (2.3%) como      
C. orthopsilosis, e 5 (2.9%) como  C. metapsilosis. Seis isolados correspondem a outras espécies 
de Candida que não pertencem ao grupo da C. parapsilosis. A avaliação do perfil de 
suscetibilidade demonstrou que apenas 9 (5.6%) isolados de C. parapsiosis sensu stricto eram 
resistentes ou suscetível-dose dependente ao fluconazole, e apenas um isolado apresentava um 
fenótipo multi-azolerresistente; 2 (1.3%) isolados de C. parapsilosis sensu stricto eram 
resistentes à anfotericina B. Todos os isolados de C. orthopsilsois e C. metapsilosis eram 
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suscetíveis aos azoles e à anfotericina B. Um número elevado de estirpes de C. parapsilosis sensu 
stricto era não-suscetível às equinocandinas. 
Com o objetivo de explorar a diversidade genética entre os isolados de C. parapsilosis (um 
total de 160 isolados clínicos e ambientais) obtidos dos doentes e do ambiente hospitalar, duas 
técnicas moleculares distintas foram aplicadas: random amplified polymorphic DNA analysis e 
mithocondrial DNA restriction endonuclease analysis. Os resultados obtidos vão de encontro a 
outros estudos que referem que a diversidade genética para C. parapsilosis é mínima, tendo sido 
encontrado um perfil maioritário.  
No sentido de caracterizar o desenvolvimento da resistência antifúngica em                          
C. parapsilosis, 4 estirpes clínicas suscetíveis e uma estirpe da American Type Culture Collection 
foram cultivadas repetidamente na presença de fluconazole, voriconazole e posaconazole em 
diferentes concentrações. Os isolados desenvolveram diferentes graus de resistência aos azoles 
de acordo com o antifúngico utilizado. O fluconazole foi o indutor mais rápido e o posaconazole 
foi o mais lento. O fluconazole e o voriconazole induzem resistência a eles próprios e um ao 
outro, mas não ao posaconazole. O posaconazole induz resistência a todos os azoles. A 
resistência desenvolvida é estável; esse facto foi confirmado após cultivo em meio sem 
antifúngico. Os isolados resistentes aos azoles revelaram uma população homogénea. O efeito 
dos bloqueadores das bombas de efluxo (verapamil e ibuprofeno) é mínimo na resistência após 
avaliação por microdiluição e citometria de fluxo.  
Relativamente à classe de antifúngicos equinocandinas, a indução da resistência foi 
igualmente realizada com uma estirpe clínica de C. parapsilosis com a anidulafungina. A 
resistência desenvolvida é estável e não está associada a mutações na região HS1 do gene FKS1. 
A associação a níveis elevados de quitina na parede celular não está confirmada. 
Para esclarecer os mecanismos moleculares de resistência aos azoles, hipotéticas 
alterações no perfil de expressão de genes da C. parapsilosis associadas à aquisição 
experimental de resistência aos azoles foram analisadas. As estirpes resistentes obtidas após 
exposição do fluconazole e do voriconazole demonstraram um aumento de expressão do fator 
de transcrição MRR1, do transportador MDR1, e de diversas redutases e oxidoredutases. 
Curiosamente, e semelhante ao que está descrito para C. albicans, a sobrexpressão de MRR1 e 
de MDR1 está relacionada com mutações pontuais no gene MRR1 nas estirpes resistentes.          
A estirpe resistente obtida após exposição ao posaconazole tem a expressão de dois fatores de 
transcrição (UPC2 e NDT80) e de 13 genes envolvidos na biossíntese do ergosterol aumentada. 
Este estudo é o primeiro que aborda a base molecular dos mecanismos de resistência aos azoles 
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em C. parapsilosis; os resultados sugerem que de modo semelhante a C. albicans, a tolerância 
aos azoles envolve a ativação de bombas de efluxo e/ou o aumento da síntese do ergosterol. 
Na tentativa de estabelecer um paralelismo entre a indução de resistência in vitro e in vivo, 
três doentes com infeções sistémicas por C. parapsilosis tratadas com fluconazole foram 
acompanhados; os isolados foram recolhidos antes, durante e/ou após tratamento. O teste de 
suscetibilidade aos antifúngicos demonstrou um aumento na concentração mínima inibitória de 
vários azoles para os isolados obtidos após tratamento com fluconazole. A tipagem molecular 
dos isolados demonstrou que os isolados pós-tratamento com reduzida suscetibilidade eram 
geneticamente idênticos aos isolados pré-tratamento suscetíveis, sugerindo a aquisição in vivo 
da resistência aos azoles. Os fenótipos de suscetibilidade apresentados pelos isolados eram 
estáveis in vitro. O papel do efluxo ativo dos antifúngicos na resistência foi avaliado por 
citometria de fluxo; a marcação nos isolados pós-tratamento e nos isolados pré-tratamento é 
semelhante. Uma análise mais profunda nas alterações a nível de expressão de genes foi 
realizada recorrendo a tecnologia de microarrays. Verificou-se que a expressão de genes 
envolvidos no metabolismo lipídico estava aumentada. 
O potencial de diferentes agentes físicos (aquecimento a 60ºC, micro-ondas e radiação UV) 
e agentes químicos (clorohexidina, etanol, hipoclorito de sódio, peróxido de hidrogénio, 
permanganato de potássio e ácido bórico) de uso corrente para inativar C. parapsilosis foi  
avaliado. Para os agentes químicos, a atividade antifúngica foi determinada recorrendo ao 
método da microdiluição e a ensaios do time-kill. Relativamente aos agentes físicos, a cinética de 
sobrevivência das células durante o tratamento foi determinada. Adicionalmente, a ocorrência 
de lesão de membrana provocada por cada tratamento foi avaliada por citometria de fluxo com 
iodeto de propídeo. As concentrações 0.06% de clorohexidina, 10% de etanol, 2.5% de 
hipoclorito de sódio, 0.06% de peróxido de hidrogénio, 0.1% de permanganato de potássio e 1% 
de ácido bórico são capazes de matar todas as células das estirpes de C. parapsilosis estudadas. 
Relativamente aos agentes físicos, após aquecimento a 60ºC durante 5 min, radiação micro-
ondas durante 60 s e radiação UV durante 10 min, foi confirmada uma redução de pelo menos 3 
log no crescimento de C. parapsilosis. A marcação com iodeto de propídeo demonstrou que o 
aquecimento a 60ºC e a radição micro-ondas, assim como o peróxido de hidrogéneo provocam 
lesões primárias graves na membrana. Adicionalmente, estudamos a atividade antimicrobiana 
de um novo sistema de desinfeção hospitalar; envolvendo a produção de um aerossol de 
peróxido de hidrogénio com catiões de prata. A atividade in vitro sobre suspensões de bactérias, 
leveduras e fungos filamentosos foi avaliada. A citometria de fluxo foi utilizada para confirmar a 
lesão de membrana das células microbianas após exposição ao desinfetante. Uma redução no 
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crescimento de pelo menos 5 log foi observada in vitro com todos os micro-organismos 
testados, sendo a solução desinfetante bastante ativa mesmo em baixa concentração. A 
citometria de fluxo evidenciou a ocorrência de lesão primária de membrana. 
Com o objetivo de estudar a relação entre a resistência aos antifúngicos e os atributos de 
virulência, comparamos, pela primeira vez, o perfil de expressão de genes da estirpe resistente 
com a estirpe suscetível de C. parapsilosis através da análise de microarrays. Alguns grupos 
especiais de genes relacionados com patogenicidade estavam sobrexpressos na estirpe 
resistente: filamentação, metabolismo de lípidos, formação de hifas, patogénese, resposta ao 
stress, interação com o hospedeiro, gemulação, adesão celular, formação de biofilme e 
catabolismo de proteínas. Diversos estudos fenotípicos foram realizados, nomeadamente 
avaliação da capacidade de adesão, diversidade fenotípica, capacidade de crescimento, 
desenvolvimento de pseudohifas e expressão da catalase, cujos resultados corroboram os 
achados anteriores.  
O conteúdo em quitina da parede celular (considerado atributo de virulência) dos isolados 
clínicos de C. parapsilosis com diferentes perfis de suscetibilidade às equinocandinas foi avaliado 
por microscopia de epifluorescência e por citometria de fluxo. Apesar do papel conhecido da 
quitina na tolerância aos antifúngicos, nenhuma relação entre o conteúdo em quitina e a 
resistência aos antifúngicos foi estabelecida; todavia parece existir uma possível relação com o 
efeito de crescimento paradoxal na presença de caspofungina. A citometria de fluxo representou 
uma eficiente e rápida abordagem para quantificar o conteúdo em quitina das células 
leveduriformes; através da marcação com calcofluor white desenvolvemos um protocolo 
citométrico que avalia o conteúdo em quitina das leveduras. 
Esforços consideráveis são ainda necessários para elucidar acerca das fontes de                     
C. parapsilosis no ambiente hospitalar, a relação entre isolados clínicos e ambientais, seus 
atributos de virulência e perfil de suscetibilidade, no sentido de reduzir a morbilidade e 
mortalidade e os custos inerentes. 
Em suma, realizamos um estudo compreensivo acerca da génese da infeção sistémica por                 
C. parapsilosis, uma espécie frequentemente isolada entre isolados clínicos hospitalares, 
nomeadamente no Hospital de S. João, um grande hospital universitário do Norte do país. 
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Candida species play a relevant role as agents of nosocomial infections. Candida 
parapsilosis is nowadays the second most common isolate from blood cultures in Europe and 
has been reported to be responsible for a broad variety of clinical manifestations that generally 
occur in individuals with impaired immunity. 
C. parapsilosis was previously made up of a complex of three genetically distinct groups 
(groups I, II, and III). Recently, the C. parapsilosis groups have been renamed as distinct species: 
C. parapsilosis sensu stricto, C. orthopsilosis, and C. metapsilosis. 
Although being sometimes considered a member of the indigenous flora in healthy 
individuals, C. parapsilosis has also been isolated from different environmental sources and from 
the hands of health care workers, thus suggesting potential routes for nosocomial transmission. 
This species displays many interesting biological characteristics, some of them presumed to 
be related to its virulence. C. parapsilosis tends to form biofilms on implanted medical devices, is 
capable of slime production and adhesion to indwelling devices, production of extracellular 
enzymes, expression of phenotype switching; it is also able to proliferate in the presence of high 
glucose and lipids concentration.  
Overall C. parapsilosis has been described to be susceptible to antifungal drugs, however 
resistant strains have been reported, in particular to azoles and echinocandins. Few prospective 
surveillance studies regarding the activity of these agents against C. parapsilosis bloodstream 
isolates are available and the antifungal resistance mechanisms expressed by C. parapsilosis are 
not yet described. Additionally, there is very limited information about the effectiveness of 
disinfectants and antiseptics as well as physical agents, e.g. U.V. and microwave radiation, 
current used in hospital, against this pathogen. 
We studied C. parapsilosis isolates from patients admitted at a Portuguese university 
hospital and environmental isolates isolated from the same hospital. The incidence and 
distribution of C. parapsilosis sensu stricto, C. orthopsilosis, and  C. metapsilosis among 175 
clinical and environmental isolates previously identified by conventional methods as                    
C. parapsilosis were established. Furthermore, the in vitro susceptibility patterns to fluconazole, 
voriconazole, posaconazole, amphotericin B, caspofungin and anidulafungin were assessed.        
Of the 175 isolates tested, 160 (91.4%) were identified as C. parapsilosis sensu stricto, 4 (2.3%) 
as C. orthopsilosis, and 5 (2.9%) as C. metapsilosis. Six isolates corresponded to Candida species 
other than the C. parapsilosis group. The susceptibility profile showed that only nine (5.6%)         
C. parapsilosis sensu stricto strains were resistant or susceptible-dose dependent to fluconazole, 
while a single strain displayed a multi-azole-resistant phenotype; two (1.3%) C. parapsilosis 
sensu stricto strains were amphotericin B resistant. All C. orthopsilosis and C. metapsilosis 
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isolates were susceptible to azoles and amphotericin B. A high number of C. parapsilosis sensu 
stricto strains were nonsusceptible to the echinocandins. 
In order to assess about genetic diversity among C. parapsilosis isolates recovered from 
patients and hospital environment (a total of 160 isolates) two different molecular techniques 
were applied: random amplified polymorphic DNA and mithocondrial DNA restriction 
endonuclease analysis.  Our results corroborate previous studies that showed that the genetic 
diversity for C. parapsilosis is scarce, being one genetic profile dominant. 
In order to characterize the development of antifungal resistance by C. parapsilosis, four 
azole-susceptible clinical strains and one type strain from the American Type Culture Collection 
were repeatedly cultured in the presence of fluconazole, voriconazole and posaconazole at 
different concentrations. The isolates developed variable degree of azole resistance according to 
the antifungal used. Fluconazole was the fastest inducer while posaconazole was the slowest. 
Fluconazole and voriconazole induced resistance to themselves and each other, but not to 
posaconazole. Posaconazole induced resistance to all three azoles. Developed resistance was 
stable; it could be confirmed after repeated subcultured in drug-free medium. Azole-resistant 
isolates revealed a homogeneous population structure; the role of azole transporter efflux 
pumps (ATP-dependent) was minor after evaluation by microdilution and flow cytometric assays 
with efflux pump blockers (verapamil and ibuprofen).  
Regarding the echinocandin antifungal class, induction of resistance was also performed 
with one clinical C. parapsilosis strain incubated with anidulafungin. The developed resistance 
was stable and was not associated with mutation in the HS1 region of the FKS1 gene. The 
correlation with high chitin level was not confirmed. 
To highlight the molecular azole resistance mechanisms, the changes in gene expression 
profile of C. parapsilosis associated with the acquisition of experimentally-induced resistance to 
azole antifungal drugs were also described. The resistant strains obtained after exposure to 
fluconazole and to voriconazole displayed increased expression of the transcription factor MRR1, 
of the major facilitator transporter MDR1, and of several reductases and oxidoreductases. 
Interestingly, and similarly to what has been described in C. albicans, up-regulation of the MRR1 
and MDR1 correlated with point mutations in MRR1 in the resistant strains. The resistant strain 
obtained after exposure to posaconazole displayed up-regulation of two transcription factors 
(UPC2 and NDT80) and increased expression of 13 genes involved in ergosterol biosynthesis. This 
was the first study addressing global molecular mechanisms underlying azole resistance by          
C. parapsilosis; the results suggest that similarly to C. albicans, tolerance to azoles involves the 
activation of efflux pumps and/or increased ergosterol synthesis. 
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In an attempt to compare in vitro and in vivo induction of resistance, isolates from three 
patients with C. parapsilosis fungaemia were serially recovered before, during and/or after 
treatment with fluconazole. A microbiological study was performed to characterize these 
isolates.  In vitro antifungal susceptibility testing showed the increase for several azoles of the 
minimal inhibitory concentration values in isolates recovered after fluconazole treatment. 
Molecular typing of isolates showed that the post-treatment isolates with reduced susceptibility 
were identical to susceptible pre-treatment isolates, confirming the in vivo acquisition of azole 
resistance. The susceptibility phenotypes displayed by isolates were confirmed to be stable in 
vitro. The role of active efflux of drugs in resistance was evaluated by flow cytometry; the 
staining profiles in post-treatment isolates and pre-treatment isolates were similar. A deep 
analysis into genomic changes by microarray technology showed that the expression of genes 
involved in lipid metabolism process was increased among the resistant isolate. 
The potential of different physical (heating at 60ºC, microwave and ultraviolet irradiation) 
and chemicals agents (chlorhexidine, ethanol, sodium hypochlorite, hydrogen peroxide, 
potassium permanganate and acid boric) to inactivate C. parapsilosis was determined. For 
chemical agents the antifungal activity was determined using the microdilution method and a 
time-kill assay. Regarding physical agents, the kinetics of survival of the cells during treatment 
were assessed.  Additionally, the membrane lesion provoked by each treatment was evaluated 
using a flow cytometric assay with propidium iodide. Concentrations of 0.06% of chlorhexidine, 
10% of ethanol, 2.5% of sodium hypochlorite, 0.06% of hydrogen peroxide, 0.1% of potassium 
permanganate and 1% of acid boric were able to kill all C. parapsilosis. Regarding physical 
agents, after heating at 60ºC for 5 min, microwave irradiation after 60 s and ultraviolet 
irradiation for 10 min, a reduction of at least 3 log in C. parapsilosis growth was achieved. 
Propidium iodide staining demonstrated that heating at 60ºC, microwave irradiation and 
hydrogen peroxide causes serious primary membrane lesions. We also report on the 
antimicrobial activity of a new disinfection system: aerosolized hydrogen peroxide in 
combination with silver cations dry-mist. The in vitro activity against suspensions of pathogenic 
bacteria, yeasts and moulds was assessed. Additionally, flow cytometry was used to confirm 
membrane lesion of microbial cells following exposure to the disinfectant. A growth reduction of 
at least 5 log was observed in vitro with all tested microorganisms, the disinfectant solution 
being highly active even at very low concentration; flow cytometry evidenced cell membrane 
lesion.  
In order to study the correlation between drug resistance and pathogenicity attributes, we 
compared, for the first time, large-scale gene expression profile between susceptible and 
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resistant strains using microarray analysis. Some particular groups of genes usually correlated 
with pathogenecity were found to be differentially expressed in the resistant strain: filamentous 
growth, lipid metabolic process, hyphal growth, pathogenesis, response to stress, interaction 
with host, pseudohyphal growth, cell budding, cell adhesion, biofilm formation and protein 
catabolic process. Several phenotypic studies, namely adherence ability, phenotype diversity, 
growth capacity, pseudohyphal development and catalase expression, corroborated such 
results. 
Cell wall chitin content, considered a virulence attribute, of C. parapsilosis clinical isolates 
with different echinocandin susceptibility profiles was evaluated by epifluorescence microscopy 
and flow cytometry. Despite the chitin role in drug tolerance, no relation between the chitin 
amount and antifungal resistance was established; although a possible relation with paradoxical 
growth effect of echinocandins could be established. Flow cytometry represents an efficient and 
fast approach in analysis of cell phenotypes; using calcofluor white staining, we developed a flow 
cytometric assay to quantitatively measure chitin content in yeasts.   
Considerable efforts are needed to provide elucidation regarding the sources of                   
C. parapsilosis in the hospital milieu, the relation between environmental isolates and the 
clinical isolates, its virulence attributes and its respective antifungal susceptibility profile, in 
order to reduce morbidity and mortality in a cost-effective manner. 
Herein we performed a comprehensive evaluation of many of such topics involved in the 
genesis of bloodstream infection by C. parapsilosis, which is a common isolate in hospitals in 
Portugal, namely in S. João Hospital, a large University Hospital in the North of country.  
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